<SEC-DOCUMENT>0001193805-25-000455.txt : 20250409
<SEC-HEADER>0001193805-25-000455.hdr.sgml : 20250409
<ACCEPTANCE-DATETIME>20250409172740
ACCESSION NUMBER:		0001193805-25-000455
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20250409
DATE AS OF CHANGE:		20250409

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUNIC, INC.
		CENTRAL INDEX KEY:			0001280776
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				562358443
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-275717
		FILM NUMBER:		25826005

	BUSINESS ADDRESS:	
		STREET 1:		1200 AVENUE OF THE AMERICAS
		STREET 2:		SUITE 200
		CITY:			NEW YORK
		STATE:			X1
		ZIP:			10036
		BUSINESS PHONE:		(332) 255-9818

	MAIL ADDRESS:	
		STREET 1:		1200 AVENUE OF THE AMERICAS
		STREET 2:		SUITE 200
		CITY:			NEW YORK
		STATE:			X1
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	VITAL THERAPIES INC
		DATE OF NAME CHANGE:	20040219
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>e664312_424b5-immunic.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 80%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 20%; font-size: 10pt"><B>Filed Pursuant to Rule 424(b)(5)&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 10pt"><B>Registration No. 333-275717</B></TD></TR>
  </TABLE>

<P STYLE="margin: 0pt">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 106.9pt 0pt 104.25pt; text-align: center">5,666,667 Shares of Common
Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 70px; width: 241px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Immunic, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">We are offering 5,666,667 shares of our common stock, par
value $0.0001 per share, at a price of $0.90 per share pursuant to this prospectus supplement and the accompanying prospectus.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Our common stock is listed
on the Nasdaq Global Select Market under the symbol &ldquo;IMUX&rdquo;. On April 8, 2025, the last reported sale price of our common
stock on the Nasdaq Global Select Market was $0.895 per share.<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Per Share</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Total</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; font-size: 10pt; font-weight: bold">Public offering price</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">0.90</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">5,100,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Placement agent fees (1)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.054</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">306,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Proceeds to us before expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.846</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">4,794,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 7%; text-align: right">(1)</TD><TD STYLE="width: 2%"></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">See &ldquo;Plan of Distribution&rdquo; beginning on page S-16 of this
prospectus supplement for additional information with respect to the compensation we will pay the Placement Agent.</P></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.4pt 0pt 5.45pt; text-align: justify"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-style: normal; font-weight: normal; text-decoration-style: double">We
anticipate delivery of the securities will take place on or about April 10, 2025, subject to the satisfaction of customary closing conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investing in our common stock involves a high degree of risk. Please
read the section titled &ldquo;Risk Factors&rdquo; beginning on page S-8 of this prospectus supplement, page 7 of the accompanying prospectus,
and in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Neither the Securities and Exchange Commission nor any state securities
commission has approved of anyone's investment in these securities or determined if this prospectus supplement is truthful or complete.
Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Titan Partners Group</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>a division of American Capital Partners</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus supplement is
April 9, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS SUPPLEMENT</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right; width: 5%"><FONT STYLE="font-size: 10pt"><B><U>Page</U></B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">ABOUT THIS PROSPECTUS SUPPLEMENT</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right">S-1</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right">S-2</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">PROSPECTUS SUPPLEMENT SUMMARY</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right">S-3</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">THE OFFERING</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right">S-7</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">RISK FACTORS</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right">S-8</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">USE OF PROCEEDS</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right">S-10</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">DIVIDEND POLICY</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right">S-10</TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">DILUTION</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right">S-11</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES FOR NON-U.S. HOLDERS OF OUR COMMON STOCK</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right">S-12</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-size: 10pt">DESCRIPTION OF SECURITIES WE ARE OFFERING</TD>
    <TD STYLE="font-size: 10pt; text-align: right">S-15</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">PLAN OF DISTRIBUTION</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right">S-16</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">LEGAL MATTERS</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right">S-19</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">EXPERTS</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right">S-19</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right">S-19</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">INFORMATION INCORPORATED BY REFERENCE</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: right">S-19</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS DATED MAY 31, 2024</B>&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Page</U></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
  <TR STYLE="font: 10pt Times New Roman; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in">ABOUT THIS PROSPECTUS</TD>
    <TD STYLE="width: 5%; text-align: right; padding-top: 0in">1</TD></TR>
  <TR STYLE="font: 10pt Times New Roman; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in">WHERE YOU CAN FIND MORE INFORMATION</TD>
    <TD STYLE="text-align: right; padding-top: 0in">2</TD></TR>
  <TR STYLE="font: 10pt Times New Roman; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</TD>
    <TD STYLE="text-align: right; padding-top: 0in">3</TD></TR>
  <TR STYLE="font: 10pt Times New Roman; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in">THE COMPANY</TD>
    <TD STYLE="text-align: right; padding-top: 0in">4</TD></TR>
  <TR STYLE="font: 10pt Times New Roman; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in">RISK FACTORS</TD>
    <TD STYLE="text-align: right; padding-top: 0in">7</TD></TR>
  <TR STYLE="font: 10pt Times New Roman; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in">USE OF PROCEEDS</TD>
    <TD STYLE="text-align: right; padding-top: 0in">7</TD></TR>
  <TR STYLE="font: 10pt Times New Roman; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in">DESCRIPTION OF CAPITAL STOCK WE MAY OFFER</TD>
    <TD STYLE="text-align: right; padding-top: 0in">8</TD></TR>
  <TR STYLE="font: 10pt Times New Roman; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in">DESCRIPTION OF DEBT SECURITIES WE MAY OFFER</TD>
    <TD STYLE="text-align: right; padding-top: 0in">11</TD></TR>
  <TR STYLE="font: 10pt Times New Roman; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in">DESCRIPTION OF WARRANTS WE MAY OFFER</TD>
    <TD STYLE="text-align: right; padding-top: 0in">19</TD></TR>
  <TR STYLE="font: 10pt Times New Roman; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in">DESCRIPTION OF UNITS WE MAY OFFER</TD>
    <TD STYLE="text-align: right; padding-top: 0in">21</TD></TR>
  <TR STYLE="font: 10pt Times New Roman; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in">GLOBAL SECURITIES</TD>
    <TD STYLE="text-align: right; padding-top: 0in">22</TD></TR>
  <TR STYLE="font: 10pt Times New Roman; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in">PLAN OF DISTRIBUTION</TD>
    <TD STYLE="text-align: right; padding-top: 0in">26</TD></TR>
  <TR STYLE="font: 10pt Times New Roman; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in">LEGAL MATTERS</TD>
    <TD STYLE="text-align: right; padding-top: 0in">27</TD></TR>
  <TR STYLE="font: 10pt Times New Roman; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in">EXPERTS</TD>
    <TD STYLE="text-align: right; padding-top: 0in">27</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ABOUT THIS PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">This document contains two parts. The first part
is this prospectus supplement, which describes the specific terms of this offering and also supplements and updates information contained
in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus.
The second part is the accompanying prospectus, which provides more general information, some of which may not apply to this offering.
Generally, when we refer only to the &ldquo;prospectus,&rdquo; we are referring to both parts combined. If the information contained in
this prospectus supplement differs or varies from the information contained in the accompanying prospectus, you should rely on the information
set forth in this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">You should rely only on the information contained or incorporated by
reference in this prospectus supplement, the accompanying prospectus and any free writing prospectuses we have authorized for use in connection
with this offering. We have not, and the placement agent has not, authorized anyone else to provide you with information that is in addition
to or different from that contained or incorporated by reference in this prospectus supplement and the accompanying prospectus, along
with the information contained in any permitted free writing prospectuses we have authorized for use in connection with this offering.
This prospectus supplement and the accompanying prospectus shall not constitute an offer to sell or the solicitation of an offer to buy
any securities other than the securities to which the prospectus supplement relates, or an offer of solicitation in any jurisdiction where
offers or sales are not permitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">The information contained in this prospectus supplement
and the accompanying prospectus is accurate only as of the date of this prospectus supplement or the date of the accompanying prospectus,
and the information in the documents incorporated by reference in this prospectus supplement and the accompanying prospectus is accurate
only as of the date of those respective documents, regardless of the time of delivery of this prospectus supplement and the accompanying
prospectus or of any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed
since those dates. It is important for you to read and consider all information contained or incorporated by reference in this prospectus
supplement and the accompanying prospectus when making your investment decision. You should read both this prospectus supplement and the
accompanying prospectus, as well as the documents incorporated by reference into this prospectus supplement and the accompanying prospectus
and the additional information described under &ldquo;Where You Can Find More Information&rdquo; in this prospectus supplement and in
the accompanying prospectus before investing in our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Unless the context indicates otherwise, all references
in this prospectus supplement to &ldquo;Immunic,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;the Company,&rdquo; &ldquo;our&rdquo;
and similar references refer to Immunic, Inc. and its consolidated subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">This prospectus supplement, the accompanying prospectus,
and the documents we have filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) that are incorporated herein by reference
contain &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933, as amended (the &ldquo;Securities
Act&rdquo;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). These forward-looking
statements are based on our current beliefs and assumptions concerning various future events and involve numerous risks and uncertainties
that could cause actual results to differ materially from expectations. Forward-looking statements include all statements that are not
historical facts and can be identified by such terms as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential,&rdquo;
&ldquo;might,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;should&rdquo; or similar expressions and the negatives of those
terms. These forward-looking statements include, among other things, statements about:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 18px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">the strategies, prospects, plans, expectations and objectives of management;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 18px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">our ability to regain or maintain compliance with Nasdaq listing standards;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 18px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">strategies with respect to our development programs;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 18px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">our estimates regarding expenses, capital requirements, projected cash requirements and needs for additional financing;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 18px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">possible sources of funding for future operations;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 18px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">our ability to protect intellectual property rights and our intellectual property position;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 18px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">future economic conditions or performance;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 18px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">proposed products or product candidates;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 18px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">our ability to retain key personnel;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 18px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">our ability to maintain effective internal control over financial reporting;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 18px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">our expectations related to the use of proceeds from this offering;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 18px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">the accuracy of our estimates regarding future expenses, future revenues, capital requirements and need for additional financing; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 18px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">beliefs and assumptions underlying any of the foregoing.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from
any future results, performance or achievements expressed or implied by any such forward-looking statements, including those described
in &ldquo;Risk Factors&rdquo; and elsewhere in this prospectus supplement, the accompanying prospectus, and in the documents incorporated
by reference into this prospectus supplement and the accompanying prospectus. Given these uncertainties, you should not place undue reliance
on these forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the
date of this prospectus supplement. You should read this prospectus supplement and the accompanying prospectus, and the documents incorporated
by reference herein and therein, and with the understanding that our actual future results may be materially different from what we expect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Moreover, neither we nor any other person assumes
responsibility for the accuracy and completeness of these statements. Except as required by law, we assume no obligation to update these
forward-looking statements publicly and actual results could differ materially from those anticipated in these forward-looking statements,
even if new information becomes available in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>





<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><I>&nbsp;</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><I>This summary highlights selected information
    contained elsewhere in, or incorporated by reference into, this prospectus supplement and the accompanying prospectus. Because it is only
    a summary, it does not contain all of the information that you should consider before investing in our common stock and it is qualified
    in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere in this prospectus supplement,
    the accompanying prospectus, any free writing prospectus that we have authorized for use in connection with this offering and the documents
    incorporated by reference in this prospectus supplement and the accompanying prospectus. You should read all such documents carefully
    and you should pay special attention to the information contained under the caption entitled &ldquo;Risk Factors&rdquo; in this prospectus
    supplement, in our Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K and in our other reports filed from time to time with
    the SEC, which are incorporated by reference into this prospectus supplement and the accompanying prospectus, before deciding to buy shares
    of our common stock.</I></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company Overview </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 22.5pt">We are a biotechnology company developing
a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. We are headquartered
in New York City with our main operations in Gr&auml;felfing near Munich, Germany. We had approximately 91 employees as of March 1, 2025.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 22.5pt">We are pursuing clinical development
of orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients
with serious chronic inflammatory and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase
3 and Phase 2 clinical development for patients with relapsing and progressive multiple sclerosis (&ldquo;MS&rdquo;), respectively, and
which has shown therapeutic activity in Phase 2 clinical trials in patients suffering from relapsing-remitting MS (&ldquo;RRMS&rdquo;),
progressive MS and moderate-to-severe ulcerative colitis (&ldquo;UC&rdquo;); the IMU-856 program, which is targeted to regenerate bowel
epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such
as celiac disease, inflammatory bowel disease (&ldquo;IBD&rdquo;), Graft-versus-Host- Disease (&quot;GvHD&quot;) and weight management;
and the IMU-381 program, which is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">The following table summarizes the potential indications,
    clinical targets and clinical development status of our three product candidates:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 328px; width: 654px"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt"></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid">


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 22.5pt">Our most advanced drug candidate, vidofludimus calcium (IMU-838), is
being tested in several ongoing MS trials as part of its overall clinical program in order to support potential approvals for patients
with MS in major markets. The Phase 3 ENSURE program of vidofludimus calcium in relapsing multiple sclerosis (&ldquo;RMS&rdquo;), comprising
twin studies evaluating efficacy, safety, and tolerability of vidofludimus calcium versus placebo, and the Phase 2 CALLIPER trial of vidofludimus
calcium in progressive multiple sclerosis (&ldquo;PMS&rdquo;), designed to corroborate vidofludimus calcium&rsquo;s neuroprotective potential,
are ongoing. On October 9, 2023, we announced positive interim data from the CALLIPER trial, showing biomarker evidence that vidofludimus
calcium&rsquo;s activity extends beyond the previously observed anti-inflammatory effects, thereby further reinforcing its neuroprotective
potential. Top-line data from the CALLIPER trial, for which the recruitment of 467 total patients was completed in August 2023, is expected
to be available in April 2025<FONT STYLE="text-decoration-style: double">. </FONT>Moreover, on October 22, 2024, we announced
a positive outcome of an interim analysis of the ENSURE program, with an unblinded Independent Data Monitoring Committee (<FONT STYLE="color: red"><STRIKE></STRIKE></FONT><FONT STYLE="text-decoration-style: double">&ldquo;</FONT>IDMC<FONT STYLE="color: red"><STRIKE></STRIKE></FONT><FONT STYLE="text-decoration-style: double">&rdquo;</FONT>)
confirming that the predetermined futility criteria have not been met and recommending that both ENSURE trials should continue without
changes, including no need for a potential increase of the sample size. Completion of the first of the ENSURE trials is currently anticipated
in the second quarter of 2026; and the completion of the second ENSURE trial in the second half of 2026. Although we currently believe
that each of these goals is achievable, they are each dependent on numerous factors, most of which are not under our direct control and
can be difficult to predict. We plan to periodically review this assessment and provide updates of material changes as appropriate.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 22.5pt">If approved, we believe that vidofludimus
calcium, with combined neuroprotective, anti-inflammatory, and antiviral effects as well as a favorable safety and tolerability profile,
has the potential to be a unique treatment option targeted to the complex pathophysiology of MS. Preclinical data showed that vidofludimus
calcium activates the neuroprotective transcription factor nuclear receptor-related 1 (&ldquo;Nurr1&rdquo;), which is associated with
direct neuroprotective properties and may enhance the potential benefit for patients. Additionally, vidofludimus calcium is a known inhibitor
of the enzyme dihydroorotate dehydrogenase (&ldquo;DHODH&rdquo;), which is a key enzyme in the metabolism of overactive immune cells and
virus-infected cells. This mechanism is associated with the anti- inflammatory and antiviral effects of vidofludimus calcium. We believe
that the combined mechanisms of vidofludimus calcium are unique in the MS space and support the therapeutic performance shown in our Phase
2 EMPhASIS trial in RRMS patients, in particular, via data illustrating the potential to reduce magnetic resonance imaging (&ldquo;MRI&rdquo;)
lesions, prevent relapses, reduce the rate of disability progression, and reduce levels of serum neurofilament light chain (&ldquo;NfL&rdquo;),
an important biomarker of neuronal damage. Vidofludimus calcium has shown a consistent pharmacokinetic, safety and tolerability profile
in clinical trials reported, to date, and has already been exposed to approximately 2,700 human subjects and patients in either of the
drug&rsquo;s formulations.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">IMU-856 is an orally available and systemically
    acting small molecule modulator that targets Sirtuin 6 (&ldquo;SIRT6&rdquo;), a protein which serves as a transcriptional regulator of
    intestinal barrier function and regeneration of bowel epithelium. Based on preclinical data, we believe this compound may represent a
    unique treatment approach, as the mechanism of action targets the restoration of the intestinal barrier function and bowel wall architecture
    in patients suffering from gastrointestinal diseases such as celiac disease, IBD, GvHD and other intestinal barrier function associated
    diseases. Based on preclinical investigations demonstrating no suppression of immune cells, IMU-856 may have the potential to maintain
    immune surveillance for patients during therapy, which would be an important advantage versus immunosuppressive medications and may allow
    the potential for combination with available treatments in gastroenterological diseases.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 22.5pt">Data from a Phase 1b clinical trial
in celiac disease patients during periods of gluten-free diet and gluten challenge demonstrated positive effects for IMU-856 over placebo
in four key dimensions of celiac disease pathophysiology: protection of the gut architecture, improvement of patients&rsquo; symptoms,
biomarker response, and enhancement of nutrient absorption. IMU-856 was also observed to be safe and well-tolerated in this trial. In
a post hoc analysis of this Phase 1b clinical trial, IMU-856 demonstrated a dose-dependent increase of endogenous glucagon-like peptide-1
(&ldquo;GLP-1&rdquo;) levels. IMU-856 also showed a dose-dependent reduction of body weight gain and food consumption in preclinical <I>in
vivo</I> testing. These two effects may indicate the potential for IMU-856 as an oral treatment option for weight management. Contingent
on financing, licensing or partnering, we are currently preparing clinical Phase 2 testing of IMU-856 in patients with ongoing active
celiac disease (&ldquo;OACD&rdquo;) despite gluten-free diet, while also considering further potential clinical applications in other
gastrointestinal disorders.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt"></P></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>


<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-top: Black 1pt solid; border-left: Black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">Immunic has selected IMU-381 as a development
    candidate to specifically address the needs of gastrointestinal diseases. IMU-381 is a next generation molecule with improved overall
    properties, supported by a series of chemical derivatives. IMU-381 is currently in preclinical testing.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">Additional research and development activities
    remain ongoing through preclinical research examining the potential to treat a broad set of neuroinflammatory, autoimmune and viral diseases
    with new molecules leveraging our chemical and pharmacological research platform as well as generated intellectual property in these areas.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">We expect to continue to lead most of our research
    and development activities from our Gr&auml;felfing, Germany location, where dedicated scientific, regulatory, clinical and medical teams
    conduct their activities. Due to these teams' key relationships with local and international service providers, we anticipate that this
    should result in more timely and cost-effective execution of our development programs. In addition, we are using our subsidiary in Melbourne,
    Australia to perform research and development activities in the Australasia region. We also conduct preclinical work in our laboratory
    in Martinsried, Germany and in Halle/Saale, Germany through a collaboration with the Fraunhofer Institute.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">Our business, operating results, financial condition
    and growth prospects are subject to significant risks and uncertainties, including delays in clinical trials, the failure of our clinical
    trials to meet their endpoints, failure to obtain regulatory approval and failure to obtain needed additional funding on acceptable terms,
    if at all, to complete the development and commercialization of our three development programs.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0pt"><B>Strategy </B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">We are focused on the development of new molecules
    that maximize the therapeutic benefits for patients by uniquely addressing biologically relevant immunological targets. We take advantage
    of our established research and development infrastructure and operations in Germany and Australia to more efficiently develop our product
    candidates in indications of high unmet need and where the product candidates have the potential to elevate the standard of care for the
    benefit of patients. Given the mechanisms of action and the data generated for our product candidates, to date, we continue to execute
    on the clinical development of our programs for established indications as well as explore additional indications where patients could
    potentially benefit from the unique profiles of each product candidate.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">We are currently focused on maximizing the potential
    of our development programs through the following strategic initiatives:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt"></P></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 10pt">Executing the ongoing Phase 3 ENSURE clinical trials of vidofludimus calcium in RMS.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 10pt">Completing the Phase 2 CALLIPER clinical trial of vidofludimus calcium in PMS.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 10pt">Executing the IMU-856 development program, including preparation of a Phase 2 clinical trial.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 10pt">Continuing preclinical research to complement the existing clinical activities, explore additional indications for potential future development and generating additional molecules for potential future development.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">Facilitating readiness for potential commercial launch of our product candidates through targeted
    and stage-appropriate pre-commercial activities.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&bull;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">Evaluating potential strategic collaborations for each product candidate in order to complement our existing research and development capabilities and to facilitate potential commercialization of these product candidates by taking advantage of the resources and capabilities of strategic collaborators in order to enhance the potential and value of each product candidate.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>Recent Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&bull;&#9;&#8239;&#8239;On January 8, 2024, we announced the first closing of a
three-tranched private placement of shares of common stock. The first tranche provided $80 million of gross proceeds to the Company from
the purchase of shares of common stock at a price of $1.43 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&bull;&#9;&#8239;&#8239;On March 20, 2024, we announced Notice of Allowance
from the United States Patent and Trademark Office (&ldquo;USPTO&rdquo;) for patent application 16/981,122, entitled, &ldquo;Calcium
salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferative agents,&rdquo; covering the composition-of-matter of a
specific polymorph of vidofludimus calcium and a related method of production of the material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&bull;&#9;&#8239;&#8239;On April 30, 2024, we announced that data from our
Phase 2 EMPhASIS trial of vidofludimus calcium in patients with RRMS has been published online on April 25, 2024 in Neurology&reg; Neuroimmunology
&amp; Neuroinflammation, an official journal of the American Academy of Neurology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&bull;&#9;&#8239;&#8239;On July 9, 2024, we announced that seasoned biopharmaceutical
executive, Jason Tardio, will be joining the company as Chief Operating Officer and President, effective July 12, 2024. On July 9, 2024,
we also reported that Werner Gladdines, former Vice President, Program Management &amp; Clinical Development Operations, has been promoted
to Chief Development Officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&bull;&#9;&#8239;&#8239;On July 24, 2024, we announced the appointment of
Simona Skerjanec, M.Pharm, MBA, a thought-leader in brain health with decades of experience in drug development and commercialization,
as a member of our Board of Directors, effective as of July 22, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&bull;&#9;&#8239;&#8239;On September 4, 2024, we announced enrollment of the
first patient in an investigator-sponsored Phase 2 clinical trial of vidofludimus calcium, entitled, &ldquo;Randomized Adaptive Assessment
of Post COVID Syndrome Treatments_Reducing Inflammatory Activity in Patients with Post COVID Syndrome (RAPID_REVIVE).&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&bull;&#9;&#8239;&#8239;At two MS R&amp;D Days, on September 10, 2024 in New
York City and on April 9, 2024 in San Francisco, management discussed the latest developments in the MS landscape, along with recent
mode of action, preclinical and clinical data supporting the combined neuroprotective, anti-inflammatory and antiviral profile of vidofludimus
calcium.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&bull;&#9;&#8239;&#8239;On September 18, 2024, we announced the presentation
of key data at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (&ldquo;ECTRIMS&rdquo;),
highlighting vidofludimus calcium&rsquo;s therapeutic potential in MS. The data was presented in an oral poster presentation and three
ePosters at this conference in Copenhagen, Denmark.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&bull;&#9;&#8239;&#8239;On October 22, 2024, we announced a positive outcome
of an interim analysis of our Phase 3 ENSURE program, investigating vidofludimus calcium for the treatment of RMS. An unblinded IDMC
confirmed that the predetermined futility criteria have not been met and recommended that both ENSURE trials should continue without
changes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&bull;&#9;&#8239;&#8239;On November 13, 2024, we announced that the data from
our Phase 1/1b clinical trial of IMU-856, has been published in the peer reviewed journal, The Lancet Gastroenterology &amp; Hepatology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&bull;&#9;&#8239;&#8239;On February 20, 2025, we announced that IMU-856
demonstrated a dose-dependent increase of endogenous GLP-1 levels in a post hoc analysis of patients from our Phase 1b clinical trial
in celiac disease. IMU-856 also showed a dose-dependent reduction of body weight gain and food consumption in preclinical <I>in vivo
</I>testing. These effects may indicate the potential for IMU-856 as an oral treatment option for weight management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>Corporate Information</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">Prior to April 12, 2019, we were a clinical-stage
    biotherapeutic company known as Vital Therapies, Inc. that had historically been focused on the development of a cell-based therapy targeting
    the treatment of acute forms of liver failure. Vital Therapies, Inc. was originally incorporated in the State of California in May of
    2003 as Vitagen Acquisition Corp., subsequently changed its name to Vital Therapies, Inc. in June 2003, and reincorporated in Delaware
    in January 2004. On April 12, 2019, we completed an exchange transaction with Immunic AG pursuant to which holders of ordinary shares
    of Immunic AG exchanged all of their shares for shares of our common stock, resulting in Immunic AG becoming our wholly owned subsidiary.
    Following the exchange, we changed our name to Immunic, Inc. and we became a clinical-stage biopharmaceutical company focused on the development
    of selective oral therapies in immunology with the goal of becoming a leader in treatments for chronic inflammatory and autoimmune diseases.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 22.5pt">Our corporate headquarters are located
at 1200 Avenue of the Americas, Suite 200, New York, New York 10036. We also have an office at Lochhamer Schlag 21, 82166 Gr&auml;felfing,
Germany. Our telephone number is (332) 255-9818. We maintain a website at www.imux.com. The information contained on, or that can be accessed
through, our website is not a part of this prospectus supplement. Investors should not rely on any such information in deciding whether
to purchase our common stock. We have included our website address in this prospectus supplement solely as an inactive textual reference.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">Our Annual Reports on Form 10-K, Quarterly Reports
    on Form 10-Q, Current Reports on Form 8-K and all amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of
    the Exchange Act are available free of charge through the investor relations page of our internet website as soon as reasonably practicable
    after we electronically file such material with, or furnish it to, the SEC.</P></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-top: Black 1pt solid; border-left: Black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>THE OFFERING</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; font-size: 10pt; text-align: center; border-left: Black 1pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Common stock offered </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; width: 40%; font-size: 10pt; text-indent: 0pt"><P STYLE="margin: 0pt; text-indent: 0pt">5,666,667 shares of common stock</P></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; font-size: 10pt; text-indent: 0.25in">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Common stock outstanding before this offering</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">90,150,869 shares of common stock.</P></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; font-size: 10pt; text-indent: 0.25in">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Common stock to be outstanding after this offering </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font-size: 10pt"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">95,817,536 shares of common stock, excluding shares issuable upon the
exercise of Placement Agent Warrants.</P></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; font-size: 10pt">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; font-size: 10pt"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><B>Public
                                            offering price per share of common stock</B></P></TD>
    <TD STYLE="border-right: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">$ 0.90
    per share. </FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; font-size: 10pt">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; font-size: 10pt"><B>Placement Agent Warrants</B></TD>
    <TD STYLE="border-right: Black 1pt solid; font-size: 10pt"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Upon the closing of this offering, we have agreed to issue to the placement
agent, or its respective designees, unregistered warrants to purchase a number of shares of common stock (the &ldquo;Placement Agent Warrants&rdquo;)
equal to an aggregate of 5% of the total number of shares of common stock sold in this offering as partial compensation for the placement
agent&rsquo;s services in connection with this offering. The Placement Agent Warrants will be exercisable at a per share exercise price
equal to 125% of the public offering price of the shares of common stock sold in this offering, or $1.125 per share. The Placement Agent
Warrants are exercisable commencing six (6) months after the date of this commencement of sales, and will be exercisable for a period
of five (5) years from the commencement of sales. The Placement Agent Warrants and the shares of common stock underlying the Placement
Agent Warrants are being offered pursuant to the exemptions from registration provided in Section 4(a)(2) under the Securities Act and
Regulation D promulgated thereunder, and are not being offered pursuant to this prospectus supplement and the accompanying prospectus.
See &ldquo;Plan of Distribution &mdash; Placement Agent Warrants&rdquo; on page S-16 of this prospectus supplement.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; font-size: 10pt">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Use of proceeds</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">We intend to use the net proceeds from this offering to fund our clinical trials and operations, and for other general corporate purposes. See the section titled &ldquo;Use of Proceeds&rdquo; in this prospectus supplement for additional information.</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; font-size: 10pt">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Risk factors </B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Investing in our common stock involves a high degree of risk and purchasers of shares of our common stock may lose their entire investment. See the section titled &ldquo;Risk Factors&rdquo; in this prospectus supplement and in the documents incorporated by reference into this prospectus supplement for a discussion of factors you should carefully consider before deciding to invest in our securities.</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; font-size: 10pt">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Nasdaq Global Select Market symbol</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"></FONT>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Our common stock is listed on the Nasdaq Global Select
Market under the symbol &ldquo;IMUX.&rdquo;</P>
<FONT STYLE="font-size: 10pt"></FONT></TD>
    </TR>
</TABLE>

<P STYLE="margin: 0"></P>


<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid"><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless otherwise stated, all information in this prospectus supplement
is as of December 31, 2024, and assumes no exercise of the Placement Agent Warrants.</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; width: 5%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD>&bull;</TD>
    <TD STYLE="border-right: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">16,136,045 shares of common stock issuable upon exercise
of outstanding options at a weighted average exercise price of $1.52 per share; and</P></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&bull;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">11,193,564 shares of common stock issuable upon exercise of
outstanding pre-funded warrants.</P></TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RISK FACTORS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><I>&nbsp;</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 24.45pt"><I>An investment in our securities involves a
high degree of risk. Prior to deciding whether to invest in our securities, you should carefully consider the specific risks discussed
in this prospectus supplement, the accompanying prospectus and in the documents incorporated by reference in this prospectus supplement
and the accompanying prospectus. The risks and uncertainties described herein and in our SEC filings are not the only ones facing us.
Additional risks and uncertainties not presently known to us, or that we currently see as immaterial, may also harm our business. If
any of the risks or uncertainties described in this prospectus supplement, the accompanying prospectus or in the documents incorporated
by reference in this prospectus supplement and the accompanying prospectus or any such additional risks and uncertainties actually occur,
our business, results of operations, cash flows, financial condition and prospects could be materially and adversely affected. In that
case, the trading price of our common stock could decline, and you might lose part or all of your investment.</I></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to this Offering </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Our management has broad discretion as to the use of the net
proceeds from this offering.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 24.45pt">We cannot specify with certainty the particular
uses of the net proceeds we will receive from this offering, and these uses may vary from our current plans. Our management will have
discretion in the application of the net proceeds, including to fund our clinical trials and operations and for general corporate purposes
as described in &ldquo;Use of Proceeds.&rdquo; Accordingly, you will have to rely upon the judgment of our management with respect to
the use of the net proceeds from this offering. Our management may spend a portion or all of the net proceeds from this offering in ways
that holders of our common stock may not desire or that may not yield a significant return or any return at all. Pending their use, we
may also invest the net proceeds from this offering in a manner that does not produce income or that loses value. The failure by our
management to apply these funds effectively could harm our business and cause the price of our common stock to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">If you purchase our shares in this offering, you may incur immediate
and substantial dilution in the book value of your shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 24.35pt">The offering price per share of
common stock in this offering exceed the net tangible book value per share of our common stock outstanding prior to this offering. Therefore,
if you purchase shares of common stock  in this offering, you may pay a price per share that exceeds our as adjusted
net tangible book value per share of common stock. Upon the sale of shares of our common stock at $0.90 per share, and after deducting
fees and estimated offering expenses payable by us, you will experience immediate dilution of $0.66 per share, representing the difference
between our as adjusted net tangible book value per share after giving effect to this offering, and the public offering price for shares
in this offering. To the extent outstanding options or other rights to purchase our common stock are exercised, you will experience further
dilution. In addition, to the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial
dilution.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 24.4pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We will require additional capital funding, the receipt of which
may impair the value of our common stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Our future capital requirements depend on many
factors, including our clinical trial, research, development, sales and marketing activities. We will need to raise additional capital
through public or private equity or debt offerings or through arrangements with strategic partners or other sources in order to continue
to develop our drug candidates. There can be no assurance that additional capital will be available when needed or on terms satisfactory
to us, if at all. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial
dilution and the new equity securities may have greater rights, preferences or privileges than our existing common stock. Further, we
have a significant number of stock options outstanding. The exercise of outstanding stock options may result in further dilution of your
investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: blue"><FONT STYLE="color: Black"><B>The
public offering price will be set by our board of directors and does not necessarily indicate the actual or market value of our common
stock.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: blue"><FONT STYLE="color: Black">Our
board of directors (or a committee thereof) will approve the public offering price and other terms of this offering after considering,
among other things: the number of shares authorized in our certificate of incorporation; the current market price of our common stock;
trading prices of our common stock over time; the volatility of our common stock; our current financial condition and the prospects for
our future cash flows; the availability of and likely cost of capital of other potential sources of capital; and market and economic
conditions at the time of the offering. The public offering price is not intended to bear any relationship to the book value of our assets
or our past operations, cash flows, losses, financial condition, net worth, or any other established criteria used to value securities.
The public offering price may not be indicative of the fair value of the common stock.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If securities or industry analysts issue an adverse opinion regarding
our common stock, the price and trading volume of our common stock could decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt">The trading market for our common stock is influenced by, among other
things, the research and reports that securities or industry analysts may publish about us, our business, our market or our competitors.
If any of the analysts who may cover us adversely change their recommendation regarding our common stock, or provide more favorable relative
recommendations about our competitors, the trading price of our common stock could decline. If any analyst who may cover us were to cease
coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could
cause the trading price of our common stock or trading volume to decline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin: 0pt">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>USE OF PROCEEDS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.45pt; text-indent: 24.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 24.4pt">We estimate that the net proceeds we
will receive from this offering will be approximately $4.6 million, after deducting fees and estimated offering expenses payable by us.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 24.45pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">We intend to use the net proceeds from this offering
to fund our clinical trials and operations and for other general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Our expected use of the net proceeds to us from
this offering represents our current intentions based upon our present plans and business condition. The amounts and timing of our actual
expenditures will depend on numerous factors, including the progress of our research and development efforts, the status of and results
from our current or future clinical trials, the timing of regulatory submissions and any unforeseen cash needs. Accordingly, our management
will have broad discretion in the application of any net proceeds from this offering.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">Until we use the net proceeds of this offering
for the purposes described above, we intend to invest any funds we receive in short-term, investment-grade, interest-bearing instruments
and U.S. government securities. We cannot predict whether these investments will yield a favorable return.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">We have never declared or paid any cash dividends
on our shares of common stock and do not anticipate paying any cash dividends in the foreseeable future. Payment of cash dividends, if
any, in the future will be at the discretion of our board of directors and will depend on then-existing conditions, including our financial
condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors
may deem relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DILUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt">If you invest
in our common stock in this offering, your interest will be diluted immediately to the extent of the difference between our as adjusted
net tangible book value per share after giving effect to this offering, and the public offering price for shares in this offering. Our
net tangible book value as of December 31, 2024 was approximately $18.4 million or $0.20 per share. Net tangible book value per share
is determined by dividing our tangible assets, less total liabilities, by the number of shares of our common stock outstanding as of December
31, 2024.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt">After giving
effect to the issuance and sale of shares of common stock in this offering at the public offering price of $0.90 per share, and after
deducting fees and estimated offering expenses payable by us, our as adjusted net tangible book value as of December 31, 2024, would have
been approximately $23.0 million, or $0.24 per share. This represents an immediate increase in net tangible book value of $0.04 per share
to existing stockholders and immediate dilution of $0.66 per share to investors purchasing our shares in this offering at the public offering
price. The dilution information described below is illustrative only and will be adjusted based on the actual public offering price and
other terms of this offering determined at pricing. The following table illustrates this dilution on a per share basis:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; font-size: 10pt">Public offering price per share</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">0.90</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Net tangible book value per share of as December 31, 2024</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.20</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"></TD><TD STYLE="font-size: 10pt; text-align: right"></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Increase in net tangible book value per share attributable to existing investors in this offering</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.04</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">As adjusted net tangible book value per share after giving effect to this offering</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.24</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Dilution per share to new investors in this offering</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">0.66</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 22.5pt">The foregoing table and calculations
are based on 90,150,869 shares outstanding as of December 31, 2024, and assumes no exercise by the placement agent of the Placement Agent
Warrants, and excludes as of such date:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">16,136,045 shares of common stock issuable upon exercise
of outstanding options at a weighted average exercise price of $1.52 per share; and</P></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">11,193,564 shares of common stock issuable upon exercise of outstanding
pre-funded warrants.</P></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">In addition, we may choose to raise additional
capital due to market conditions or strategic considerations even if we believe that we have sufficient funds for our current or future
operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance
of these securities could result in further dilution to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>MATERIAL U.S. FEDERAL
INCOME TAX CONSEQUENCES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>FOR NON-U.S. HOLDERS
OF OUR COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The following is a general
discussion of material U.S. federal income tax considerations and certain U.S. federal estate tax considerations relating to the acquisition,
ownership, and disposition of our common stock applicable to non-U.S. holders that purchase our common stock in this offering and hold
it as a &ldquo;capital asset&rdquo; within the meaning of Section 1221 of the Code (generally, property held for investment). For purposes
of this discussion, a &ldquo;non-U.S. holder&rdquo; means a beneficial owner of our common stock (other than an entity or arrangement
that is treated as a partnership for U.S. federal income tax purposes) that is not, for U.S. federal income tax purposes, any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">an individual who is a citizen or resident of the United States;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">a corporation (or entity treated as a corporation for United States federal income tax purposes) created or organized in or under the laws of the United States, any state thereof or the District of Columbia, or otherwise treated as a domestic corporation;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">an estate, the income of which is includable in gross income for U.S. federal income tax purposes regardless of its source; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">a trust if (i) a court within the United States is able to exercise primary supervision over the administration of the trust and one or more &ldquo;United States persons,&rdquo; as defined under the U.S. Internal Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;), (&ldquo;U.S. persons&rdquo;) have the authority to control all substantial decisions of the trust or (ii) such trust has made a valid election to be treated as a U.S. person for U.S. federal income tax purposes.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If a partnership (or other entity or arrangement
treated as a partnership for U.S. federal income tax purposes) holds our common stock, the tax treatment of a partner therein will generally
depend on the status of the partner and the activities of the partnership. Partners of a partnership holding our common stock should consult
their tax advisors as to the particular U.S. federal income tax consequences applicable to them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">This discussion is based on current provisions
of the Code, final, temporary and proposed Treasury regulations promulgated thereunder (the &ldquo;Treasury Regulations&rdquo;),
judicial decisions, published rulings and administrative pronouncements of the U.S. Internal Revenue Service (the &ldquo;IRS<FONT STYLE="text-decoration-style: double">&rdquo;)</FONT>,
all in effect as of the date of this prospectus supplement and all of which are subject to change or to differing interpretation,
possibly with retroactive effect. Any change could alter the tax consequences to non-U.S. holders described herein. There can be no
assurance that the IRS will not challenge one or more of the tax consequences described herein.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.45pt; text-indent: 0.5in">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">This discussion does not
address all aspects of U.S. federal income and estate taxation that may be relevant to a particular non-U.S. holder in light of that non-U.S.
holder&rsquo;s particular circumstances nor does it address any aspects of U.S. state or local or non-U.S. taxes, other U.S. federal tax,
the alternative minimum tax, or the tax on net investment income. This discussion also does not consider any specific facts or circumstances
that may apply to a non-U.S. holder and does not address the special tax rules applicable to particular non-U.S. holders, such as:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">banks, insurance companies and other financial institutions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">brokers or dealers or traders in securities;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">tax-exempt organizations;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">pension plans;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">persons who hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security or other integrated investment or who have elected to mark securities to market;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">controlled foreign corporations, passive foreign investment companies, and corporations that accumulate earnings to avoid U.S. federal income tax;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">non-U.S. governments; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">former citizens or long-term residents of the United States.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">THIS SUMMARY IS NOT INTENDED
TO CONSTITUTE A COMPLETE DESCRIPTION OF ALL TAX CONSEQUENCES FOR NON-U.S. HOLDERS RELATING TO THE OWNERSHIP AND DISPOSITION OF OUR COMMON
STOCK. PROSPECTIVE HOLDERS OF OUR COMMON STOCK SHOULD CONSULT WITH THEIR TAX ADVISORS REGARDING THE TAX CONSEQUENCES TO THEM (INCLUDING
THE APPLICATION AND EFFECT OF ANY STATE, LOCAL, NON-U.S. INCOME AND OTHER TAX LAWS) OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF OUR
COMMON STOCK.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Distributions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">As discussed under &ldquo;Dividend
Policy&rdquo; above, we do not expect to make distributions on our common stock in the foreseeable future. However, if we do make distributions
of cash or property on our common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent
paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts of distributions
not treated as dividends for U.S. federal income tax purposes will first constitute a tax-free return of capital of the non-U.S. holder&rsquo;s
investment and be applied against and reduce a non-U.S. holder&rsquo;s adjusted tax basis in its common stock, but not below zero. Any
remaining excess will be treated as capital gain and will be treated as described below under &ldquo;Gain on Sale or Other Disposition
of Common Stock.&rdquo; Because we may not know the extent to which a distribution is a dividend for U.S. federal income tax purposes
at the time it is made, for purposes of the withholding rules discussed below we or the applicable withholding agent may treat the entire
distribution as a dividend. Any such distributions will also be subject to the discussions below under the headings &ldquo;FATCA&rdquo;
and &ldquo;Backup Withholding, Information Reporting and Other Reporting Requirements.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Subject to the discussion
in the next two paragraphs, dividends paid to a non-U.S. holder generally will be subject to withholding of U.S. federal income tax at
a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&rsquo;s
country of residence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Dividends we pay to a
non-U.S. holder that are effectively connected with such non-U.S. holder&rsquo;s conduct of a trade or business within the United States
(and, if required by an applicable tax treaty, are attributable to a U.S. permanent establishment or a fixed base maintained by such non-U.S.
holder) will generally be exempt from the U.S. federal withholding tax described above, if the non-U.S. holder complies with applicable
certification and disclosure requirements (generally including provision of a valid IRS Form W-8ECI (or applicable successor form) certifying
that the dividends are effectively connected with the non-U.S. holder&rsquo;s conduct of a trade or business within the United States).
Instead, such dividends generally will be subject to U.S. federal income tax on a net income basis, at regular U.S. federal income tax
rates as would apply if such holder were a U.S. person (as defined in the Code). Any U.S. effectively connected income received by a non-U.S.
holder that is classified as a corporation for U.S. federal income tax purposes may also be subject to an additional &ldquo;branch profits
tax&rdquo; at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">A non-U.S. holder of our
common stock who claims the benefit of an applicable income tax treaty between the United States and such holder&rsquo;s country of residence
generally will be required to provide a properly executed IRS Form W-8BEN or W-8BEN-E (or successor form) and satisfy applicable certification
and other requirements. Non-U.S. holders are urged to consult their tax advisors regarding their entitlement to benefits under a relevant
income tax treaty and the specific methods available to them to satisfy these requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Gain on Sale or Other Disposition of Common
Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Subject to the discussion
below under the headings &ldquo;FATCA&rdquo; and &ldquo;Backup Withholding, Information Reporting and Other Reporting Requirements,&rdquo;
a non-U.S. holder generally will not be subject to U.S. federal income tax on any gain realized upon the sale or other disposition of
the non-U.S. holder&rsquo;s shares of our common stock unless:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">the gain is effectively connected with a trade or business carried on by the non-U.S. holder within the United States (and, if required by an applicable income tax treaty, is attributable to a U.S. permanent establishment or fixed base maintained by such non-U.S. holder);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">the non-U.S. holder is an individual and is present in the United States for 183 days or more in the taxable year of disposition and certain other conditions are met; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">we are or have been a &ldquo;U.S. real property holding corporation&rdquo; for U.S. federal income tax purposes at any time within the shorter of the five-year period preceding such disposition or such non-U.S. holder&rsquo;s holding period of our common stock, and, provided that our common stock is regularly traded on an established securities market within the meaning of applicable Treasury Regulations, the non-U.S. holder has held, directly, indirectly, or constructively, at any time during said period, more than 5% of our common stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Gain that is effectively
connected with the conduct of a trade or business in the United States generally will be subject to U.S. federal income tax on a net income
tax basis, at regular U.S. federal income tax rates that apply to U.S. persons. If the non-U.S. holder is a non-U.S. corporation, the
branch profits tax described above also may apply to such effectively connected gain. An individual non-U.S. holder who is subject to
U.S. federal income tax because the non-U.S. holder was present in the United States for 183 days or more during the year of sale or other
disposition of our common stock will be subject to a flat 30% tax (or such lower rate as may be specified by an applicable income tax
treaty) on the gain derived from such sale or other disposition, which may be offset by certain U.S.-source capital losses, if any. We
believe that we are not and we do not anticipate becoming a U.S. real property holding corporation for U.S. federal income tax purposes.
Non-U.S. holders should consult their tax advisors regarding potentially applicable income tax treaties that may provide for different
rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>FATCA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Withholding taxes may
be imposed under the so-called Foreign Account Tax Compliance Act (&ldquo;FATCA&rdquo;), on certain types of payments made to non-U.S.
financial institutions and certain other non-U.S. entities. Specifically, a 30% withholding tax may be imposed on dividends (including
deemed dividends) paid on our common stock, to a &ldquo;foreign financial institution&rdquo; or a &ldquo;non-financial foreign entity&rdquo;
(each as defined in the Code), unless (1) the foreign financial institution undertakes certain diligence and reporting obligations, (2)
the non-financial foreign entity either certifies it does not have any &ldquo;substantial United States owners&rdquo; (as defined in the
Code) or furnishes identifying information regarding each substantial U.S. owner, or (3) the foreign financial institution or non-financial
foreign entity otherwise qualifies for an exemption from these rules. Foreign financial institutions located in jurisdictions that have
an intergovernmental agreement with the United States governing FATCA may be subject to the reporting rules of that intergovernmental
agreement. Because we may not know the extent to which a distribution is a dividend for U.S. federal income tax purposes at the time it
is made, for purposes of these withholding rules we or the applicable withholding agent may treat the entire distribution as a dividend.
Although withholding under FATCA applies also to payments of gross proceeds from the sale or other disposition of stock on or after January
1, 2019, proposed Treasury Regulations would eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers generally may
rely on these proposed Treasury Regulations until final Treasury Regulations are issued. Under certain circumstances, a non-U.S. holder
will be eligible for refunds or credits of withholding taxes imposed under FATCA by timely filing a U.S. federal income tax return. Prospective
investors should consult their tax advisors regarding the potential application of these withholding provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Backup Withholding, Information Reporting
and Other Reporting Requirements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">We must report annually
to the IRS and to each non-U.S. holder the amount of any distributions paid to, and the tax withheld with respect to, each non-U.S. holder.
These reporting requirements apply regardless of whether withholding was reduced or eliminated by an applicable income tax treaty. Copies
of this information reporting may also be made available under the provisions of a specific income tax treaty or agreement with the tax
authorities in the country in which the non-U.S. holder resides or is established.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">A non-U.S. holder may
be subject to backup withholding for dividends on our common stock paid to such holder unless such holder certifies under penalties of
perjury that, among other things, it is a non-U.S. holder (provided that the payor does not have actual knowledge or reason to know that
such holder is a U.S. person) or otherwise establishes an exemption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Information reporting
and backup withholding generally will apply to the proceeds of a disposition of our common stock by a non-U.S. holder effected by or through
the U.S. office of any broker, U.S. or non-U.S., unless the holder certifies its status as a non-U.S. holder and satisfies certain other
requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment
of disposition proceeds to a non-U.S. holder where the transaction is effected outside the United States through a non-U.S. office of
a broker. However, for information reporting purposes, dispositions effected through a non-U.S. office of a broker with substantial U.S.
ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. Non-U.S.
holders should consult their tax advisors regarding the application of the information reporting and backup withholding rules to them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Backup withholding is
not an additional income tax. Any amounts withheld under the backup withholding rules from a payment to a non-U.S. holder generally can
be credited against the non-U.S. holder&rsquo;s U.S. federal income tax liability, if any, or refunded, provided that the required information
is furnished to the IRS in a timely manner. Non-U.S. holders should consult their tax advisors regarding the application of the information
reporting and backup withholding rules to them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>U.S. Federal Estate Tax</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Shares of our common stock
that are owned or treated as owned by an individual who is not a citizen or resident of the United States (as specially defined for U.S.
federal estate tax purposes) at the time of death are considered U.S. situs assets and will be included in the individual&rsquo;s gross
estate for U.S. federal estate tax purposes. Such shares, therefore, may be subject to U.S. federal estate tax, unless an applicable estate
tax or other treaty provides otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The preceding discussion of material U.S. federal income tax considerations
and certain U.S. federal estate tax considerations is for information only. It is not legal or tax advice. Prospective investors should
consult their tax advisors regarding the particular U.S. federal, state, local and non-U.S. tax consequences of acquiring, owning and
disposing of our common stock, including the consequences of any proposed changes in applicable laws.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 106.9pt 0pt 106.75pt; text-align: center"><B>DESCRIPTION OF SECURITIES
WE ARE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We are offering
shares of our common stock in this offering. See &ldquo;<I>Description of Capital Stock We May Offer</I>&rdquo; in our base prospectus
and &ldquo;<I>Description of Securities</I>&rdquo; filed as Exhibit 4.3 to our Annual Report on 10-K for more information regarding our
shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">We are selling 5,666,667 shares
of our common stock, offered under this prospectus supplement and the accompanying prospectus directly to institutional investors pursuant
a securities purchase agreement dated as of April 9, 2025 (the &ldquo;Securities Purchase Agreement&rdquo;). We have entered into the
Securities Purchase Agreement directly with the investors which will purchase the shares of common stock in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">We
estimate that we will receive net proceeds of approximately $4.6 million, based on the offering price of $0.90 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">Titan Partners Group LLC, a division
of American Capital Partners, LLC (&ldquo;Titan&rdquo;, or the &ldquo;Placement Agent&rdquo;) has agreed to act as our exclusive placement
agent in connection with this offering subject to the terms and conditions of the placement agency agreement dated April 9, 2025 (the
&ldquo;Placement Agency Agreement&rdquo;). The Placement Agent is not purchasing or selling any of the securities offered by this prospectus
supplement, nor is it required to arrange the purchase or sale of any specific number or dollar amount of securities, but has agreed to
use its reasonable best efforts to arrange for the sale of all of the securities offered hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The representations, warranties and covenants contained
in the Securities Purchase Agreement were made solely for the benefit of us and the investors. In addition, such representations, warranties
and covenants (i) are intended as a way of allocating the risk between us and the investors and not as statements of fact, and (ii) may
apply standards of materiality in a way that is different from what may be viewed as material by shareholders of, or other investors in,
our company. Moreover, information concerning the subject matter of the representations and warranties may change after the date of the
Securities Purchase Agreement, which subsequent information may or may not be fully reflected in public disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">A copy of the form of Securities Purchase Agreement
and a copy of the form of Placement Agency Agreement are attached to as Exhibit 1.1 and Exhibit 1.2, respectively, to a Current Report
on Form 8-K as filed on April 9, 2025 and incorporated by reference into the registration statement of which this prospectus supplement
and the accompanying base prospectus form a part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.45pt; text-indent: 0.5in">We expect to deliver the shares of common
stock being offered pursuant to this prospectus supplement on or about April 10, 2025, subject to satisfaction of certain customary closing
conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><B>Fees and Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.42in">We have agreed to pay the Placement Agent a fee based on the aggregate
proceeds as set forth in the table below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Per Share</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="text-align: center; font-size: 10pt; font-weight: bold; border-bottom: Black 1pt solid">Total</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; font-size: 10pt; padding-bottom: 1pt">Offering Price&#9;</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.90</TD><TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,100,000</TD><TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Placement Agent Fees<SUP>(1)</SUP></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.054</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">306,000</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Proceeds, before expenses, to us</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.846</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,794,000</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">(1) Consists of a cash fee of 6.0% of
the aggregate gross proceeds in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; background-color: white">The Placement
Agent may be deemed to be an underwriter within the meaning of Section&nbsp;2(a)(11) of the Securities Act, and any commissions
received by it and any profit realized on the resale of the shares sold by it while acting as principal might be deemed to be
underwriting discounts or commissions under the Securities Act. As an underwriter, the Placement Agent would be required to comply
with the requirements of the Securities Act and the Exchange Act, including, without limitation, Rule&nbsp;415(a)(4) under the
Securities Act and Rule&nbsp;10b-5 and Regulation&nbsp;M under the Exchange Act. These rules and regulations may limit the timing of
purchases and sales of shares by the Placement Agent acting as principal. Under these rules and regulations, the Placement
Agent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>may not engage in any stabilization activity in connection with our securities; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%"></TD><TD STYLE="width: 5%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>may not bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as
permitted under the Exchange Act, until it has completed its participation in the distribution.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">We have also
agreed to reimburse the Placement Agent at closing for reasonable, documented out-of-pocket expenses actually incurred by the Placement
Agent, up to $75,000, including the fees and disbursements of the Placement Agent&rsquo;s legal counsel. We have also paid an advance
of $15,000 to the Placement Agent, which will be applied against the accountable expenses that will be paid by us to the Placement Agent
in connection with this offering. This payment will be returned to us to the extent not actually incurred by the Placement Agent in accordance
with Rule 5110(g)(4)(A) of the Financial Industry Regulatory Authority (&ldquo;FINRA&rdquo;). We estimate that our total offering expenses
for this offering, not including the Placement Agent&rsquo;s fees, will be approximately $175,000.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Placement Agent Warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Upon the closing of this offering, we have agreed to issue to the Placement
Agent, or its respective designees, Placement Agent Warrants to purchase a number of shares of common stock equal to an aggregate of 5%
of the total number of shares of common stock  sold in this offering as partial compensation for the Placement
Agent&rsquo;s services in connection with this offering. The Placement Agent Warrants will be exercisable at a per share exercise price
equal to 125% of the public offering price of the shares of common stock sold in this offering, or $1.125 per share. The Placement Agent
Warrants are exercisable commencing six (6) months after the commencement of sales and will be exercisable for a period of five years
from the commencement of sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">The
Placement Agent Warrants and the shares of common stock underlying the Placement Agent Warrants have been deemed compensation by FINRA
and are therefore subject to a 180-day lock-up pursuant to Rule 5110(e)(1) of FINRA. Neither the Placement Agent nor its respective permitted
assignees under such rule, may sell, transfer, assign, pledge, or hypothecate the Placement Agent Warrants or the securities underlying
the Placement Agent Warrants, nor will the Placement Agent engage in any hedging, short sale, derivative, put, or call transaction that
would result in the effective economic disposition of the Placement Agent warrants or the underlying shares for a period of 180 days
from the date of commencement of sales in this offering. See the form of Placement Agent Warrant to be filed as an exhibit on a Current
Report on Form 8-K for a complete description of the terms of the Placement Agent Warrants. The Placement Agent Warrants and the shares
of common stock underlying the Placement Agent Warrants are being offered pursuant to the exemptions from registration provided in Section
4(a)(2) under the Securities Act and Regulation D promulgated thereunder, and are not being offered pursuant to this prospectus supplement
and the accompanying prospectus.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Tail Financing</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Subject to
the terms and exceptions provided for in that certain Financing Engagement Agreement, dated as of March 19, 2025, as amended, by and between
the Placement Agent and the Company (the &ldquo;Engagement Agreement&rdquo;), the Placement Agent shall be entitled to the compensation
calculated in the manner set forth in the Placement Agency Agreement with respect to any public or private offering or other financing
or capital-raising transaction of any kind (the &ldquo;Tail Financing&rdquo;) to the extent that such financing or capital is provided
to the Company (and actually received by the Company) by investors not already known to the Company and whom the Placement Agent contacted
during the Term (as defined in the Engagement Agreement), if such Tail Financing is consummated at any time prior to the six month anniversary
following the later of (i) the closing of this offering and (ii) the expiration or termination of the Engagement Agreement.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">Indemnification</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Pursuant to
the Placement Agency Agreement, we have agreed to indemnify the Placement Agent against certain liabilities, including liabilities under
the Securities Act, or to contribute to payments that the Placement Agent or such other indemnified parties may be required to make in
respect of those liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Nasdaq Global Select Market Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">Our common stock is listed
                                                                         on The Nasdaq Global Select Market under the symbol &ldquo;IMUX.&rdquo; The last reported sale price of our common stock on April 8,
                                                                         2025 was $0.895 per share. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; color: blue"><FONT STYLE="color: Black">Transfer Agent
and Registrar</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.45pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; color: blue; text-indent: 0.5in"><FONT STYLE="color: Black">The
transfer agent and registrar for our common stock is Equiniti Trust Company, LLC. The transfer agent and registrar&rsquo;s address is
6201 15th Avenue, Brooklyn, New York 11219.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.45pt"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt; color: blue"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LEGAL MATTERS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 24.45pt">The validity of the common stock being offered by this prospectus supplement
will be passed upon for us by Dentons US LLP, New York, New York. Ellenoff Grossman &amp; Schole LLP, New York, New York, is counsel to
the Placement Agent in connection with this offering.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPERTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">The consolidated financial statements of Immunic,
Inc. as of December 31, 2024 and 2023 and for each of the two years in the period ended December 31, 2024 incorporated in this prospectus
supplement by reference to our Annual Report on Form 10-K for the year ended December 31, 2024, have been so incorporated in reliance
on the report of Baker Tilly US, LLP, an independent registered public accounting firm, given on the authority of said firm as experts
in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">This prospectus supplement and the accompanying
prospectus form part of a registration statement on Form S-3 that we filed with the SEC. This prospectus supplement and the accompanying
prospectus do not contain all of the information set forth in the registration statement and the exhibits to the registration statement
or the documents incorporated by reference herein and therein. For further information with respect to us and the securities that we are
offering under this prospectus supplement, we refer you to the registration statement and the exhibits filed as a part of the registration
statement and the documents incorporated by reference herein and therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">You should rely only on the information contained or incorporated by
reference in this prospectus supplement, the accompanying prospectus and any free writing prospectuses we have authorized for use in connection
with this offering. We have not, and the Placement Agent has not, authorized anyone else to provide you with information that is in addition
to or different from that contained or incorporated by reference in this prospectus supplement and the accompanying prospectus, along
with the information contained in any permitted free writing prospectuses we have authorized for use in connection with this offering.
This prospectus supplement and the accompanying prospectus is not an offer to sell or the solicitation of an offer to buy any securities
other than the securities to which it relates, or an offer of solicitation in any jurisdiction where offers or sales are not permitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">The information contained in this prospectus supplement
and the accompanying prospectus is accurate only as of the date of this prospectus supplement or the date of the accompanying prospectus,
and the information in the documents incorporated by reference in this prospectus supplement and the accompanying prospectus is accurate
only as of the date of those respective documents, regardless of the time of delivery of this prospectus supplement and the accompanying
prospectus or of any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed
since those dates. It is important for you to read and consider all information contained or incorporated by reference in this prospectus
supplement and the accompanying prospectus in making your investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">We file annual, quarterly and other reports, proxy
and information statements and other information with the SEC. The SEC maintains a website that contains reports, proxy statements and
other information regarding us. The address of the SEC website is www.sec.gov. We maintain a website at www.imux.com. The information
contained on, or that can be accessed through, our website is not a part of this prospectus supplement. Investors should not rely on any
such information in deciding whether to purchase our common stock. We have included our website address in this prospectus supplement
solely as an inactive textual reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION INCORPORATED BY REFERENCE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">The SEC permits us to &ldquo;incorporate by reference&rdquo;
the information contained in documents we file with the SEC, which means that we can disclose important information to you by referring
you to those documents rather than by including them in this prospectus supplement. Information that is incorporated by reference is considered
to be part of this prospectus supplement and you should read it with the same care that you read this prospectus supplement. Later information
that we file with the SEC will automatically update and supersede the information that is either contained, or incorporated by reference,
in this prospectus supplement, and will be considered to be a part of this prospectus from the date those documents are filed. We have
filed with the SEC, and incorporate by reference in this prospectus supplement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 10pt">our Annual Report on Form 10-K for the fiscal year ended December 31, 2024; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="text-align: left; font-size: 10pt"><FONT STYLE="font-size: 10pt">the description of our common stock contained in our registration statement on Form 8-A12B, filed with the SEC on November 15, 2013 (File No. 001-36201), and all amendments or reports filed for the purpose of updating such description, including Exhibit 4.2 to our Annual Report on Form 10-K filed with the SEC on February 26, 2021.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">In addition, we incorporate by reference all additional
documents that we subsequently file with the SEC pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act that are made after
the initial filing date of the registration statement of which this prospectus supplement is a part and the effectiveness of the registration
statement, as well as between the date of this prospectus supplement and the termination of any offering of securities offered by this
prospectus. We are not, however, incorporating, in each case, any documents or information that we furnish or are deemed to furnish and
not file in accordance with SEC rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">You may request a copy of these filings, at no
cost, by writing or telephoning us at the following address or telephone number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Immunic, Inc.<BR>
Attn: Corporate Secretary<BR>
1200 Avenue of the Americas, Suite 200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">New York, New York 10036</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(333) 255-9818</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, you may obtain a copy of these filings from the SEC, as
described in the section entitled &ldquo;Where You Can Find More Information&rdquo; in this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS</B>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_004.jpg" ALT="">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B><BR>
<B>Preferred Stock<BR>
Debt Securities</B><BR>
<B>Warrants<BR>
Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$412,299,419<BR>
____________________________</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From time to time, we may offer and sell up to $412,299,419 in the
aggregate of the securities identified above in one or more offerings. This prospectus provides you with a general description of the
securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each time we offer and sell securities, we will provide a supplement
to this prospectus that contains specific information about the offering and the amounts, prices and terms of the securities. The supplement
may also add, update or change information contained in this prospectus with respect to that offering. You should carefully read this
prospectus and the applicable prospectus supplement and all documents incorporated by reference herein and therein, before you invest
in any of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may offer and sell the securities described in this prospectus and
any prospectus supplement to or through one or more underwriters, dealers or agents, or directly to purchasers, or through a combination
of these methods. If any underwriters, dealers or agents are involved in the sale of any of the securities, their names and any applicable
purchase price, fee, commission or discount arrangement between or among them will be set forth, or will be calculable from the information
set forth, in the applicable prospectus supplement. See the sections of this prospectus entitled &ldquo;About this Prospectus&rdquo; and
&ldquo;Plan of Distribution&rdquo; for more information. No securities may be sold without delivery of this prospectus and the applicable
prospectus supplement describing the method and terms of the offering of such securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>INVESTING IN OUR SECURITIES INVOLVES RISKS. SEE THE &ldquo;RISK
FACTORS&rdquo; SECTION ON PAGE 7 OF THIS PROSPECTUS AND ANY SIMILAR SECTION CONTAINED IN THE APPLICABLE PROSPECTUS SUPPLEMENT AND IN THE
OTHER DOCUMENTS THAT ARE INCORPORATED BY REFERENCE INTO THIS PROSPECTUS CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR
SECURITIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is quoted on The Nasdaq Global Select Market under
the trading symbol &ldquo;IMUX.&rdquo; Any common stock sold pursuant to this prospectus or any prospectus supplement will be listed on
that exchange, subject to official notice of issuance. Each prospectus supplement to this prospectus will contain information, where applicable,
as to any other listing on any national securities exchange of the securities covered by the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation
to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>_______________________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0.15pt 0pt 0; text-align: center">The date of this prospectus is
<FONT STYLE="text-decoration-style: double">May 31</FONT>, 2024.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: right"><B>Page</B>&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%">
  <TR STYLE="font: 10pt Times New Roman; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">ABOUT THIS PROSPECTUS</TD>
    <TD STYLE="width: 10%; text-align: right; padding-top: 0in; padding-bottom: 5pt">1</TD></TR>
  <TR STYLE="font: 10pt Times New Roman; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">WHERE YOU CAN FIND MORE INFORMATION</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">2</TD></TR>
  <TR STYLE="font: 10pt Times New Roman; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">3</TD></TR>
  <TR STYLE="font: 10pt Times New Roman; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">THE COMPANY</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">4</TD></TR>
  <TR STYLE="font: 10pt Times New Roman; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">RISK FACTORS</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">7</TD></TR>
  <TR STYLE="font: 10pt Times New Roman; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">USE OF PROCEEDS</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">7</TD></TR>
  <TR STYLE="font: 10pt Times New Roman; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">DESCRIPTION OF CAPITAL STOCK WE MAY OFFER</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">8</TD></TR>
  <TR STYLE="font: 10pt Times New Roman; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">DESCRIPTION OF DEBT SECURITIES WE MAY OFFER</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">11</TD></TR>
  <TR STYLE="font: 10pt Times New Roman; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">DESCRIPTION OF WARRANTS WE MAY OFFER</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">19</TD></TR>
  <TR STYLE="font: 10pt Times New Roman; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">DESCRIPTION OF UNITS WE MAY OFFER</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">21</TD></TR>
  <TR STYLE="font: 10pt Times New Roman; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">GLOBAL SECURITIES</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">22</TD></TR>
  <TR STYLE="font: 10pt Times New Roman; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">PLAN OF DISTRIBUTION</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">26</TD></TR>
  <TR STYLE="font: 10pt Times New Roman; text-align: left; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">LEGAL MATTERS</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">27</TD></TR>
  <TR STYLE="font: 10pt Times New Roman; text-align: left; vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-top: 0in; padding-bottom: 5pt; padding-left: 0in">EXPERTS</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 5pt">27</TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>



<P ID="a1" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ABOUT THIS PROSPECTUS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus is part of a registration statement that we filed with
the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;), using a &ldquo;shelf&rdquo; registration process. By using a shelf
registration statement, we may sell securities from time to time and in one or more offerings of securities as described in this prospectus.
Each time that we offer and sell securities, we will provide a prospectus supplement to this prospectus that contains specific information
about the securities being offered and sold and the specific terms of that offering. We may also authorize one or more free writing prospectuses
to be provided to you that may contain material information relating to these offerings. The prospectus supplement or free writing prospectus
may also add, update or change information contained in this prospectus with respect to that offering. If there is any inconsistency between
the information in this prospectus and the applicable prospectus supplement or free writing prospectus, you should rely on the prospectus
supplement or free writing prospectus, as applicable. Before purchasing any securities, you should carefully read both this prospectus
and the applicable prospectus supplement (and any applicable free writing prospectuses), together with the additional information described
under the headings &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation of Certain Documents by Reference.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have not authorized anyone to provide you with any information or
to make any representations other than those contained in this prospectus, any applicable prospectus supplement or any free writing prospectuses
prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the
reliability of, any other information that others may give you. We will not make an offer to sell these securities in any jurisdiction
where the offer or sale is not permitted. You should assume that the information appearing in this prospectus and the applicable prospectus
supplement to this prospectus is accurate only as of the date on its respective cover, that the information appearing in any applicable
free writing prospectuses is accurate only as of the date of that free writing prospectus, and that any information incorporated by reference
is accurate only as of the date of the document incorporated by reference, unless we indicate otherwise. Our business, financial condition,
results of operations and prospects may have changed since those dates. This prospectus, and any prospectus supplement or free writing
prospectus may contain and incorporate by reference, market data and industry statistics and forecasts that are based on independent industry
publications and other publicly available information. Although we believe these sources are reliable, we do not guarantee the accuracy
or completeness of this information and we have not independently verified this information. In addition, the market and industry data
and forecasts that may be included or incorporated by reference in this prospectus, any prospectus supplement or any applicable free writing
prospectuses may involve estimates, assumptions and other risks and uncertainties and are subject to change based on various factors,
including those discussed under the heading &ldquo;Risk Factors&rdquo; contained in this prospectus, the applicable prospectus supplement
and any applicable free writing prospectus, and under similar headings in other documents that are incorporated by reference into this
prospectus. Accordingly, investors should not place undue reliance on this information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">When we refer to &ldquo;we,&rdquo; &ldquo;our,&rdquo; &ldquo;us&rdquo;
and the &ldquo;Company&rdquo; in this prospectus, we mean Immunic, Inc., unless otherwise specified. When we refer to &ldquo;you,&rdquo;
we mean the potential holders of the applicable securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus contains references to our trademarks and to trademarks
belonging to other entities, which are protected under applicable intellectual property laws. Solely for convenience, trademarks and trade
names referred to in this prospectus, including logos, artwork and other visual displays, may appear without the &reg; or &trade; symbols,
but such references are not intended to indicate that we or their respective owners will not assert, to the fullest extent under applicable
law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other
companies&rsquo; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any such companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Options: NewSection -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P ID="a2" STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WHERE YOU CAN FIND MORE INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We file annual, quarterly and other reports, proxy statements and other
information with the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information about
issuers, such as us, who file electronically with the SEC. The address of that website is http://www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our website address is www.imux.com. The information on, or that can
be accessed through, our website, however, is not, and should not be deemed to be, a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus and any prospectus supplement are part of a registration
statement that we filed with the SEC and do not contain all of the information in the registration statement. The full registration statement
may be obtained from the SEC or us, as provided below. Forms of the indenture and other documents establishing the terms of the offered
securities are or may be filed as exhibits to the registration statement or documents incorporated by reference in the registration statement.
Statements in this prospectus or any prospectus supplement about these documents are summaries and each statement is qualified in all
respects by reference to the document to which it refers. You should refer to the actual documents for a more complete description of
the relevant matters. You may obtain a copy of the registration statement through the SEC&rsquo;s website, as provided above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P ID="a3" STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The SEC&rsquo;s rules allow us to &ldquo;incorporate by reference&rdquo;
information into this prospectus, which means that we can disclose important information to you by referring you to another document filed
separately with the SEC. The information incorporated by reference is deemed to be part of this prospectus, and subsequent information
that we file with the SEC will automatically update and supersede that information. Any statement contained in this prospectus or a previously
filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that
a statement contained in this prospectus or a subsequently filed document incorporated by reference modifies or replaces that statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This prospectus and any accompanying prospectus supplement incorporate
by reference the documents set forth below that have previously been filed with the SEC (but excluding any information in such documents
that has been furnished to, rather than filed with, the SEC):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">Our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the SEC on February 22, 2024; </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">Our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, as filed with the SEC on May 8, 2024;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">Our Current Reports on Form 8-K as filed with the SEC on January 5, 2024, February 22, 2024, March 8, 2024 and May 8, 2024; </TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">Our definitive Proxy Statement for our 2024 annual meeting of stockholders, as filed with the SEC on April 23, 2024; and</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the description of our common stock contained in our registration statement on Form 8-A, filed with the SEC on November 15, 2013 (File No. 333-191711), and all amendments or reports filed for the purpose of updating such description.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All reports and other documents we subsequently file pursuant to Section
13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), prior to the termination
of this offering, including all such documents we may file with the SEC after the date of the initial registration statement and prior
to the effectiveness of the registration statement, but excluding any information furnished to, rather than filed with, the SEC, will
also be incorporated by reference into this prospectus and deemed to be part of this prospectus from the date of the filing of such reports
and documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You may request a free copy of any of the documents incorporated by
reference in this prospectus by writing or telephoning us at the following address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center">Immunic, Inc.<BR>
Attn: Corporate Secretary<BR>
1200 Avenue of the Americas, Suite 200<BR>
New York, New York 10036<BR>
(332) 255-9818</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt">Exhibits to the filings will not be sent, however, unless those
exhibits have specifically been incorporated by reference in this prospectus or any accompanying prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P ID="a4" STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">THE COMPANY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a biotechnology company developing a clinical pipeline of selective
oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. We are headquartered in New York City with
our main operations in Gr&auml;felfing near Munich, Germany. We currently have approximately 80 employees.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are pursuing clinical development of orally administered, small
molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory
and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase 3 clinical development for patients
with multiple sclerosis (&ldquo;MS&rdquo;) and which has shown therapeutic activity in Phase 2 clinical trials in patients suffering from
relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis (&ldquo;UC&rdquo;); the IMU-856 program, which is targeted
to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal
diseases, such as celiac disease, inflammatory bowel disease (&ldquo;IBD&rdquo;), short bowel syndrome and irritable bowel syndrome with
diarrhea; and the IMU-381 program, which is a next generation molecule being developed to specifically address the needs of gastrointestinal
diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table summarizes the potential
indications, clinical targets and clinical development status of our three product candidates:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_003.jpg" ALT="A screenshot of a medical report&#10;&#10;Description automatically generated" STYLE="height: 255px; width: 600px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our most advanced drug candidate, vidofludimus calcium (IMU 838), is
being tested in several ongoing MS trials as part of its overall clinical program in order to support a potential approval for patients
with MS in major markets. The Phase 3 ENSURE program of vidofludimus calcium in relapsing multiple sclerosis (&ldquo;RMS&rdquo;), comprising
twin studies evaluating efficacy, safety, and tolerability of vidofludimus calcium versus placebo, and the Phase 2 CALLIPER trial of vidofludimus
calcium in progressive multiple sclerosis (&ldquo;PMS&rdquo;), designed to corroborate vidofludimus calcium&rsquo;s neuroprotective potential,
are ongoing. On October 9, 2023, we announced positive interim data from the CALLIPER trial, showing biomarker evidence that vidofludimus
calcium&rsquo;s activity extends beyond the previously observed anti-inflammatory effects, thereby further reinforcing its neuroprotective
potential. Top-line data from the CALLIPER trial, for which the recruitment of in total 467 patients was completed in August 2023, is
expected to be available in April 2025. Moreover, we currently expect to report an interim futility analysis of the ENSURE program in
late 2024 and to read-out the first of the ENSURE trials in the second quarter of 2026. Although we currently believe that each of these
goals is achievable, they are each dependent on numerous factors, most of which are not under our direct control and can be difficult
to predict. We plan to periodically review this assessment and provide updates of material changes as appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If approved, we believe that vidofludimus calcium, with combined neuroprotective,
anti-inflammatory, and antiviral effects, has the potential to be a unique treatment option targeted to the complex pathophysiology of
MS. Preclinical data showed that vidofludimus calcium activates the neuroprotective transcription factor nuclear receptor related 1, which
is associated with direct neuroprotective properties and may enhance the potential benefit for patients. Additionally, vidofludimus calcium
is a known inhibitor of the enzyme dihydroorotate dehydrogenase, which is a key enzyme in the metabolism of overactive immune cells and
virus-infected cells. This mechanism is associated with the anti-inflammatory and antiviral effects of vidofludimus calcium. We believe
that the combined mechanisms of vidofludimus calcium are unique in the MS space and support the therapeutic performance shown in our Phase
2 EMPhASIS trial in relapsing-remitting MS patients, in particular, via data illustrating the potential to reduce magnetic resonance imaging
lesions, prevent relapses, reduce the rate of disability progression, and reduce levels of serum neurofilament light chain, an important
biomarker of neuronal damage. Vidofludimus calcium has shown in clinical trials reported to date a consistent pharmacokinetic, safety
and tolerability profile and has already been exposed to more than 1,800 human subjects and patients in either of the drug&rsquo;s formulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IMU-856 is an orally available and systemically acting small molecule
modulator that targets Sirtuin 6, a protein which serves as a transcriptional regulator of intestinal barrier function and regeneration
of bowel epithelium. Based on preclinical data, we believe this compound may represent a unique treatment approach, as the mechanism of
action targets the restoration of the intestinal barrier function and bowel wall architecture in patients suffering from gastrointestinal
diseases such as celiac disease, IBD, short bowel syndrome, irritable bowel syndrome with diarrhea and other intestinal barrier function
associated diseases. Based on preclinical investigations demonstrating no suppression of immune cells, IMU-856 may have the potential
to maintain immune surveillance for patients during therapy, which would be an important advantage versus immunosuppressive medications
and may allow the potential for combination with available treatments in gastroenterological diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Data from a Phase 1b clinical trial in celiac disease patients during
periods of gluten-free diet and gluten challenge demonstrated positive effects for IMU-856 over placebo in four key dimensions of celiac
disease pathophysiology: protection of the gut architecture, improvement of patients&rsquo; symptoms, biomarker response, and enhancement
of nutrient absorption. IMU-856 was also observed to be safe and well-tolerated in this trial. We are currently preparing clinical Phase
2 testing of IMU-856 in patients with ongoing active celiac disease despite gluten-free diet, while also considering further potential
clinical applications in other gastrointestinal disorders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Immunic has selected IMU-381 as a development candidate to specifically
address the needs of gastrointestinal diseases. IMU-381 is a next generation molecule with improved overall properties, supported by a
series of chemical derivatives. IMU-381 is currently in preclinical testing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additional research and development activities remain ongoing through
preclinical research examining the potential to treat a broad set of neuroinflammatory, autoimmune and viral diseases with new molecules
leveraging our chemical and pharmacological research platform as well as generated intellectual property in these areas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect to continue to lead most of our research and development
activities from our Gr&auml;felfing, Germany location, where dedicated scientific, regulatory, clinical and medical teams conduct their
activities. Due to these teams' key relationships with local and international service providers, we anticipate that this should result
in more timely and cost-effective execution of our development programs. In addition, we are using our subsidiary in Melbourne, Australia
to perform research and development activities in the Australasia region. We also conduct preclinical work in Halle/Saale, Germany through
a collaboration with the Fraunhofer Institute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our business, operating results, financial condition and growth prospects
are subject to significant risks and uncertainties, including delays in clinical trials, the failure of our clinical trials to meet their
endpoints, failure to obtain regulatory approval and failure to obtain needed additional funding on acceptable terms, if at all, to complete
the development and commercialization of our three development programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt"><B><I>Strategy </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are focused on the development of new molecules that maximize the
therapeutic benefits for patients by uniquely addressing biologically relevant immunological targets. We take advantage of our established
research and development infrastructure and operations in Germany and Australia to more efficiently develop our product candidates in
indications of high unmet need and where the product candidates have the potential to elevate the standard of care for the benefit of
patients. Given the mechanisms of action and the data generated for our product candidates, to date, we continue to execute on the clinical
development of our programs for established indications as well as explore additional indications where patients could potentially benefit
from the unique profiles of each product candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are currently focused on maximizing the potential of our development
programs through the following strategic initiatives:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD>Executing the ongoing Phase 3 ENSURE and Phase 2 CALLIPER clinical trial programs of vidofludimus calcium in RMS and PMS, respectively.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD>Executing the IMU-856 development program, including preparation of a Phase 2 clinical trial.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD>Continuing preclinical research to complement the existing clinical activities, explore additional indications for future development
and generating additional molecules for potential future development.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD>Facilitating readiness for potential commercial launch of our product candidates through targeted and stage-appropriate pre-commercial
activities.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&bull;</FONT></TD><TD>Evaluating potential strategic collaborations for each product candidate in order to complement our existing research and development
capabilities and to facilitate potential commercialization of these product candidates by taking advantage of the resources and capabilities
of strategic collaborators in order to enhance the potential and value of each product candidate.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Prior to April 12, 2019, we were a clinical-stage biotherapeutic company
known as Vital Therapies, Inc. that had historically been focused on the development of a cell-based therapy targeting the treatment of
acute forms of liver failure. Vital Therapies, Inc. was originally incorporated in the State of California in May of 2003 as Vitagen Acquisition
Corp., subsequently changed its name to Vital Therapies, Inc. in June 2003, and reincorporated in Delaware in January 2004. In April 2019,
we completed an exchange transaction with Immunic AG pursuant to which holders of ordinary shares of Immunic AG exchanged all of their
shares for shares of our common stock, resulting in Immunic AG becoming our wholly owned subsidiary. Following the exchange, we changed
our name to Immunic, Inc. and we became a clinical-stage biopharmaceutical company focused on the development of selective oral therapies
in immunology with the goal of becoming a leader in treatments for chronic inflammatory and autoimmune diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our corporate headquarters are located at 1200 Avenue of the Americas,
Suite 200, New York, New York 10036. We also have an office at Lochhamer Schlag 21, 82166 Grafelfing, Germany. Our telephone number is
(332) 255-9818. We maintain a website at www.imux.com. The information contained on, or that can be accessed through, our website is not
a part of this prospectus. Investors should not rely on any such information in deciding whether to purchase our securities. We have included
our website address in this prospectus solely as an inactive textual reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P ID="a7" STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">RISK FACTORS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investment in any securities offered pursuant to this prospectus and
the applicable prospectus supplement involves risks. You should carefully consider the risk factors incorporated by reference from our
most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and any subsequent Annual Reports on Form 10-K, Quarterly Reports
on Form 10-Q or Current Reports on Form 8-K that we file after the date of this prospectus, and all other information contained in or
incorporated by reference into this prospectus, as updated by our subsequent filings under the Exchange Act, and the risk factors and
other information contained in the applicable prospectus supplement and any applicable free writing prospectuses, before acquiring any
of such securities. The occurrence of any of these risks might cause you to lose all or part of your investment in the offered securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">USE OF PROCEEDS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We intend to use the net proceeds from the sale of the securities as
set forth in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P ID="a8" STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">DESCRIPTION OF CAPITAL STOCK WE MAY OFFER</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our authorized capital stock consists of 500,000,000 shares of common
stock, par value $0.0001 per share, and 20,000,000 shares of preferred stock, par value $0.0001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following description of our common stock and preferred stock,
together with the additional information included in any applicable prospectus supplements or related free writing prospectuses, summarizes
the material terms and provisions of these types of securities, but it is not complete. For the complete terms of our common stock and
preferred stock, please refer to our amended and restated certificate of incorporation and our amended and restated bylaws that are incorporated
by reference into the registration statement which includes this prospectus and, with respect to preferred stock, any certificate of designation
that we may file with the SEC for a series of preferred stock we may designate, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will describe, in a prospectus supplement or related free writing
prospectuses, the specific terms of any common stock or preferred stock we may offer pursuant to this prospectus. If indicated in a prospectus
supplement, the terms of such common stock or preferred stock may differ from the terms described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of May 23, 2024, there were 90,079,016 shares of common stock outstanding.
The holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders.
The holders of common stock are not entitled to cumulative voting rights with respect to the election of directors, and as a consequence,
minority stockholders will not be able to elect directors on the basis of their votes alone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to preferences that may be applicable to any then outstanding
shares of preferred stock, holders of common stock are entitled to receive ratably such dividends as may be declared by the board of directors
out of funds legally available therefor. In the event of a liquidation, dissolution or winding up of us, holders of the common stock are
entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preferences of any then outstanding
shares of preferred stock. Holders of common stock have no preemptive rights and no right to convert their common stock into any other
securities. There are no redemption or sinking fund provisions applicable to our common stock. All outstanding shares of common stock
are, and all shares of common stock to be issued under this prospectus will be, fully paid and non-assessable. The rights, preferences
and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of
any of our outstanding preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Listing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our common stock is listed on the Nasdaq Global Select Market under
the symbol &ldquo;IMUX.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Transfer Agent and Registrar</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The transfer agent and registrar for our common stock is Equiniti Trust
Company, LLC. The transfer agent and registrar&rsquo;s address is 6201 15th Avenue, Brooklyn, New York 11219.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Dividends</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have not declared any cash dividends on our common stock since inception
and we do not anticipate paying any cash dividends on our common stock in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are authorized to issue a total of 20,000,000 shares of preferred
stock. As of May 23, 2024, there were no shares of preferred stock issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Preferred stock may be issued from time to time, in one or more series,
as authorized by the board of directors, without stockholder approval. The prospectus supplement relating to any shares of preferred stock
offered thereby will include specific terms of the shares of preferred stock offered, including, if applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the title of the shares of preferred stock;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the number of shares of preferred stock offered, the liquidation preference per share and the offering price of the shares of preferred stock;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the dividend rate(s), period(s) and/or payment date(s) or method(s) of calculation thereof applicable to the shares of preferred stock;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">whether the dividends on shares of preferred stock are cumulative or not and, if cumulative, the date from which dividends on the shares of preferred stock shall accumulate;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the procedures for any auction and remarketing, if any, for the shares of preferred stock;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the provision for a sinking fund, if any, for the shares of preferred stock;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the provision for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights of the shares of preferred stock;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">any listing of the shares of preferred stock on any securities exchange;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the terms and conditions, if applicable, upon which the shares of preferred stock will be convertible into shares of common stock, including the conversion price (or manner of calculation thereof);</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">discussion of federal income tax considerations applicable to the shares of preferred stock;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the relative ranking and preferences of the shares of preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of our affairs;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">any limitations on issuance of any series or class of shares of preferred stock ranking senior to or on a parity with such series or class of shares of preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of our affairs;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">any other specific terms, preferences, rights, limitations or restrictions of the shares of preferred stock; and</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">any voting rights of such preferred stock.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The transfer agent and registrar for any series or class of preferred
stock will be set forth in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Possible Anti-Takeover Effects of Delaware Law and our Charter Documents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Some provisions of Delaware law, our amended and restated certificate
of incorporation and our amended and restated bylaws could make the following transactions more difficult: an acquisition of us by means
of a tender offer, an acquisition of us by means of a proxy contest or otherwise, or the removal of our incumbent officers and directors.
It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise
consider to be in their best interest or in our best interest, including transactions which provide for payment of a premium over the
market price for our shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These provisions, summarized below, are intended to discourage coercive
takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of
us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to
negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging
these proposals because negotiation of these proposals could result in an improvement of their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Delaware Anti-Takeover Statute</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are subject to Section 203 of the Delaware General Corporation Law
(the &ldquo;DGCL&rdquo;), an anti-takeover statute. In general, Section 203 of the DGCL prohibits a publicly held Delaware corporation
from engaging in a &ldquo;business combination&rdquo; with an &ldquo;interested stockholder&rdquo; for a period of three years following
the time the person became an interested stockholder, unless the business combination or the acquisition of shares that resulted in a
stockholder becoming an interested stockholder is approved in a prescribed manner. Generally, a &ldquo;business combination&rdquo; includes
a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. Generally, an &ldquo;interested
stockholder&rdquo; is a person who, together with affiliates and associates, owns (or within three years prior to the determination of
interested stockholder status did own) 15% or more of a corporation&rsquo;s voting stock. The existence of this provision would be expected
to have an anti-takeover effect with respect to transactions not approved in advance by our board of directors, including discouraging
attempts that might result in a premium over the market price for the shares of common stock held by our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Undesignated Preferred Stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The ability of our board of directors, without action by the stockholders,
to issue up to 20,000,000 shares of undesignated preferred stock with voting or other rights or preferences as designated by our board
of directors could impede the success of any attempt to effect a change in control of us. These and other provisions may have the effect
of deterring hostile takeovers or delaying changes in control or management of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Requirements for Advance Notification of Stockholder Nominations
and Proposals.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our amended and restated bylaws establish advance notice procedures
with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors,
other than nominations made by or at the direction of the board of directors or a committee of the board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Elimination of Stockholder Action by Written Consent.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our amended and restated certificate of incorporation eliminates the
right of stockholders to act by written consent without a meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Staggered Board.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our board of directors is divided into three classes. The directors
in each class will serve for a three-year term, one class being elected each year by our stockholders. This system of electing and removing
directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it
generally makes it more difficult for stockholders to replace a majority of the directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Removal of Directors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our amended and restated certificate of incorporation provides that
no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote
required by law, upon the approval of the holders of at least two-thirds in voting power of the outstanding shares of stock entitled to
vote in the election of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Stockholders Not Entitled to Cumulative Voting.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our amended and restated certificate of incorporation does not permit
stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of
our common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other
than any directors that holders of our preferred stock may be entitled to elect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P ID="a11" STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Authorized but Unissued Shares</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our authorized but unissued shares of common stock and preferred stock
will be available for future issuance without stockholder approval. We may use additional shares for a variety of purposes, including
future public offerings to raise additional capital, to fund acquisitions and as employee compensation. The existence of authorized but
unissued shares of undesignated preferred stock may enable our board of directors to render more difficult or to discourage an attempt
to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary
obligations, our board of directors were to determine that a takeover proposal is not in the best interests of us or our stockholders,
our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings
or other transactions that might dilute the voting or other rights of the proposed acquirer, stockholder or stockholder group. The rights
of holders of our common stock described above will be subject to, and may be adversely affected by, the rights of any preferred stock
that we may designate and issue in the future. The issuance of shares of undesignated preferred stock could decrease the amount of earnings
and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers,
including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Director Liability</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our amended and restated bylaws limit the extent to which our directors
are personally liable to us and our stockholders, to the fullest extent permitted by the DGCL. The inclusion of this provision in our
amended and restated bylaws may reduce the likelihood of derivative litigation against directors and may discourage or deter stockholders
or management from bringing a lawsuit against directors for breach of their duty of care.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The provisions of Delaware law, our amended and restated certificate
of incorporation and our amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and,
as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or
rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board of
directors and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders
may otherwise deem to be in their best interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">DESCRIPTION OF DEBT SECURITIES WE MAY OFFER</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following description, together with the additional information
we include in any applicable prospectus supplements or free writing prospectuses, summarizes the material terms and provisions of the
debt securities that we may offer under this prospectus. We may issue debt securities, in one or more series, as either senior or subordinated
debt or as senior or subordinated convertible debt. While the terms we have summarized below will apply generally to any future debt securities
we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the
applicable prospectus supplement or free writing prospectus. The terms of any debt securities we offer under a prospectus supplement may
differ from the terms we describe below. Unless the context requires otherwise, whenever we refer to the &ldquo;indentures,&rdquo; we
also are referring to any supplemental indentures that specify the terms of a particular series of debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will issue any senior debt securities under the senior indenture
that we will enter into with the trustee named in the senior indenture. We will issue any subordinated debt securities under the subordinated
indenture and any supplemental indentures that we will enter into with the trustee named in the subordinated indenture. We have filed
a form of indenture as an exhibit to the registration statement, of which this prospectus is a part, and supplemental indentures and forms
of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of
which this prospectus is a part or will be incorporated by reference to reports that we file with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The indentures will be qualified under the Trust Indenture Act of 1939,
as amended (the &ldquo;Trust Indenture Act&rdquo;). We use the term &ldquo;trustee&rdquo; to refer to either the trustee under the senior
indenture or the trustee under the subordinated indenture, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following summaries of material provisions of the senior debt securities,
the subordinated debt securities and the indentures are subject to, and qualified in their entirety by reference to, all of the provisions
of the indenture and any supplemental indentures applicable to a particular series of debt securities. We urge you to read the applicable
prospectus supplements and any related free writing prospectuses related to the debt securities that we may offer under this prospectus,
as well as the complete indenture that contains the terms of the debt securities. Except as we may otherwise indicate, the terms of the
senior indenture and the subordinated indenture are identical.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The terms of each series of debt securities will be established by
or pursuant to a resolution of our board of directors and set forth or determined in the manner provided in an officers&rsquo; certificate
or by a supplemental indenture. Debt securities may be issued in separate series without limitation as to aggregate principal amount.
We may specify a maximum aggregate principal amount for the debt securities of any series. We will describe in the applicable prospectus
supplement the terms of the series of debt securities being offered, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the title;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the principal amount being offered and, if a series, the total amount authorized and the total amount outstanding;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">any limit on the amount that may be issued;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">whether or not we will issue the series of debt securities in global form, and, if so, the terms and who the depositary will be;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the maturity date;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">whether and under what circumstances, if any, we will pay additional amounts on any debt securities held by a person who is not a U.S. person for tax purposes, and whether we can redeem the debt securities if we have to pay such additional amounts;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the annual interest rate, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the terms of the subordination of any series of subordinated debt;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the place where payments will be payable;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">restrictions on transfer, sale or other assignment, if any;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">our right, if any, to defer payment of interest and the maximum length of any such deferral period;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the date, if any, after which, and the price at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">provisions for a sinking fund, purchase or other analogous fund, if any, including the date, if any, on which, and the price at which we are obligated, pursuant thereto or otherwise, to redeem, or at the holder&rsquo;s option, to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">provisions relating to modification of the terms of the security or the rights of the security holder;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">whether the indenture will restrict our ability or the ability of our subsidiaries to:</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">incur additional indebtedness;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">issue additional securities;</TD></TR>
  </TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">create liens;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">pay dividends or make distributions in respect of our capital stock or the capital stock of our subsidiaries;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">redeem capital stock;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">place restrictions on our subsidiaries&rsquo; ability to pay dividends, make distributions or transfer assets;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">make investments or other restricted payments;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">sell, transfer or otherwise dispose of assets;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">enter into sale-leaseback transactions;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">engage in transactions with stockholders or affiliates;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">issue or sell stock of our subsidiaries; or</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">effect a consolidation or merger;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">whether the indenture will require us to maintain any interest coverage, fixed charge, cash flow-based, asset-based or other financial ratios;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">information describing any book-entry features;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the applicability of the provisions in the indenture on discharge;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">whether the debt securities are to be offered at a price such that they will be deemed to be offered at an &ldquo;original issue discount&rdquo; as defined in paragraph (a) of Section 1273 of the Internal Revenue Code of 1986, as amended;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the currency of payment of debt securities, if other than U.S. dollars, and the manner of determining the equivalent amount in U.S. dollars; and</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, including any additional events of default or covenants provided with respect to the debt securities, and any terms that may be required by us or advisable under applicable laws or regulations.</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">U.S. federal income tax consequences applicable to debt securities
sold at an original issue discount will be described in the applicable prospectus supplement. In addition, U.S. federal income tax or
other consequences applicable to any debt securities which are denominated in a currency or currency unit other than U.S. dollars may
be described in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Conversion or Exchange Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will set forth in the applicable prospectus supplement the terms
under which a series of debt securities may be convertible into or exchangeable for our common stock, our preferred stock or other securities
(including securities of a third party). We will include provisions as to whether conversion or exchange is mandatory, at the option of
the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock, our preferred stock
or other securities (including securities of a third party) that the holders of the series of debt securities receive would be subject
to adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Consolidation, Merger or Sale</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless we provide otherwise in the prospectus supplement applicable
to a particular series of debt securities, the indentures will not contain any covenant that restricts our ability to merge or consolidate,
or sell, convey, transfer or otherwise dispose of all or substantially all of our assets. However, any successor to or acquirer of such
assets must assume all of our obligations under the indentures or the debt securities, as appropriate. If the debt securities are convertible
into or exchangeable for our other securities or securities of other entities, the person with whom we consolidate or merge, or to whom
we sell all of our assets, must make provisions for the conversion of the debt securities into securities that the holders of the debt
securities would have received if they had converted the debt securities before the consolidation, merger or sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Events of Default under the Indenture</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless we provide otherwise in the prospectus supplement applicable
to a particular series of debt securities, the following are events of default under the indentures with respect to any series of debt
securities that we may issue:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">if we fail to pay interest when due and payable and our failure continues for 90 days and the time for payment has not been extended;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">if we fail to pay the principal, premium or sinking fund payment, if any, when due and payable and the time for payment has not been extended;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">if we fail to observe or perform any other covenant contained in the debt securities or the indentures, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90 days after we receive notice from the trustee or we and the trustee receive notice from the holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">if specified events of bankruptcy, insolvency or reorganization occur.</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will describe in each applicable prospectus supplement any additional
events of default relating to the relevant series of debt securities. If an event of default with respect to debt securities of any series
occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least
25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if
notice is given by such holders, may declare the unpaid principal, premium, if any, and accrued interest, if any, due and payable immediately.
If an event of default arises due to the occurrence of certain specified bankruptcy, insolvency or reorganization events, the unpaid principal,
premium, if any, and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any
notice or other action on the part of the trustee or any holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The holders of a majority in principal amount of the outstanding debt
securities of an affected series may waive any default or event of default with respect to the series and its consequences, except defaults
or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default
in accordance with the indenture. Any such waiver shall cure the default or event of default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to the terms of the applicable indenture, if an event of default
under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under
such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have
offered the trustee reasonable indemnity or security satisfactory to it against any loss, liability or expense. The holders of a majority
in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting
any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the
debt securities of that series, provided that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the direction so given by the holders is not in conflict with any law or the applicable indenture; and</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might subject it to personal liability or might be unduly prejudicial to the holders not involved in the proceeding.</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The indentures provide that, if an event of default has occurred and
is continuing, the trustee will be required in the exercise of its powers to use the degree of care that a prudent person would use in
the conduct of its own affairs. The trustee, however, may refuse to follow any direction that conflicts with law or the indenture, or
that the trustee determines is unduly prejudicial to the rights of any other holder of the relevant series of debt securities, or that
would subject the trustee to personal liability. Prior to taking any action under the indentures, the trustee will be entitled to indemnification
against all costs, expenses and liabilities that would be incurred by taking or not taking such action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A holder of the debt securities of any series will have the right to
institute a proceeding under the indentures or to appoint a receiver or trustee, or to seek other remedies only if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the holder has given written notice to the trustee of a continuing event of default with respect to that series;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made a written request and such holders have offered reasonable indemnity to the trustee or security satisfactory to it against any loss, liability or expense to be incurred in compliance with instituting the proceeding as trustee; and</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions within 60 days after the notice, request and offer.</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These limitations do not apply to a proceeding instituted by a holder
of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will periodically file statements with the trustee regarding our
compliance with specified covenants in the indentures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The indentures provide that if a default occurs and is continuing and
is actually known to a responsible officer of the trustee, the trustee must mail to each holder notice of the default within 45 days after
it occurs, unless such default has been cured. Except in the case of a default in the payment of principal or premium of, or interest
on, any debt security or certain other defaults specified in an indenture, the trustee shall be protected in withholding such notice if
and so long as the board of directors, the executive committee or a trust committee of directors, or responsible officers of the trustee,
in good faith determine that withholding notice is in the best interests of holders of the relevant series of debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Modification of Indenture; Waiver</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to the terms of the indenture for any series of debt securities
that we may issue, we and the trustee may change an indenture without the consent of any holders with respect to the following specific
matters:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">to fix any ambiguity, defect or inconsistency in the indenture;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">to comply with the provisions described above under &ldquo;-Consolidation, Merger or Sale&rdquo;;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">to add to, delete from or revise the conditions, limitations and restrictions on the authorized amount, terms or purposes of issue, authentication and delivery of debt securities, as set forth in such indenture;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">to provide for the issuance of, and establish the form and terms and conditions of, the debt securities of any series as provided above under &ldquo;-General,&rdquo; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">to evidence and provide for the acceptance of appointment hereunder by a successor trustee;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">to provide for uncertificated debt securities in addition to or in place of certificated debt securities and to make all appropriate changes for such purpose;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">to add such new covenants, restrictions, conditions or provisions for the protection of the holders, and to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default, or to surrender any right or power conferred to us in the indenture; or</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">to change anything that does not materially adversely affect the interests of any holder of debt securities of any series in any material respect; provided that any amendment made solely to conform the provisions of the indenture to the corresponding description of the debt securities contained in the applicable prospectus or prospectus supplement shall be deemed not to adversely affect the interests of the holders of such debt securities; provided further, that in connection with any such amendment we will provide the trustee with an officers&rsquo; certificate certifying that such amendment will not adversely affect the rights or interests of the holders of such debt securities.</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, under the indentures, the rights of holders of a series
of debt securities may be changed by us and the trustee with the written consent of the holders of at least a majority in aggregate principal
amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise in the prospectus supplement
applicable to a particular series of debt securities, we and the trustee may only make the following changes with the consent of each
holder of any outstanding debt securities affected:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">extending the fixed maturity of the series of debt securities;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption of any debt securities;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">changing any of our obligations to pay additional amounts;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">reducing the amount of principal of an original issue discount security or any other note payable upon acceleration of the maturity thereof;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">changing the currency in which any note or any premium or interest is payable;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">impairing the right to enforce any payment on or with respect to any note;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">adversely changing the right to convert or exchange, including decreasing the conversion rate or increasing the conversion price of, such series of debt securities, if applicable;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">in the case of the subordinated indenture, modifying the subordination provisions in a manner adverse to the holders of the subordinated debt securities;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">if the debt securities are secured, changing the terms and conditions pursuant to which the debt securities are secured in a manner adverse to the holders of the secured debt securities;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">reducing the requirements contained in the applicable indenture for quorum or voting;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">changing any of our obligations to maintain an office or agency in the places and for the purposes required by the indentures; or</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">modifying any of the above provisions set forth in this paragraph.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Discharge</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each indenture provides that, subject to the terms of the indenture
and any limitation otherwise provided in the prospectus supplement applicable to a particular series of debt securities, we may elect
to be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations, including
obligations to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">register the transfer or exchange of debt securities of the series;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">replace stolen, lost or mutilated debt securities of the series;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">maintain paying agencies;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">hold monies for payment in trust;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">recover excess money held by the trustee;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">compensate and indemnify the trustee; and</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">appoint any successor trustee.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order to exercise our rights to be discharged, we must deposit with
the trustee money or government obligations sufficient to pay all the principal of, and any premium and interest on, the debt securities
of the series on the dates payments are due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Form, Exchange and Transfer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will issue the debt securities of each series only in fully registered
form without coupons and, unless we otherwise specify in the applicable prospectus supplement, in denominations of $1,000 and any integral
multiple thereof. The indentures provide that we may issue debt securities of a series in temporary or permanent global form and as book-entry
securities that will be deposited with, or on behalf of, The Depository Trust Company or another depositary named by us and identified
in a prospectus supplement with respect to that series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At the option of the holder, subject to the terms of the indentures
and the limitations applicable to global securities described in the applicable prospectus supplement, the holder of the debt securities
of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like
tenor and aggregate principal amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject to the terms of the indentures and the limitations applicable
to global securities set forth in the applicable prospectus supplement, holders of the debt securities may present the debt securities
for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required
by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this
purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose no service
charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will name in the applicable prospectus supplement the security registrar,
and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time
designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which
any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities
of each series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we elect to redeem the debt securities of any series, we will not
be required to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">issue, register the transfer of, or exchange, any debt securities of that series during a period beginning at the opening of business 15 days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Information Concerning the Trustee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The trustee, other than during the occurrence and continuance of an
event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture
and is under no obligation to exercise any of the powers given it by the indentures at the request of any holder of debt securities unless
it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur. However, upon an event
of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of
his or her own affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Payment and Paying Agents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless we otherwise indicate in the applicable prospectus supplement,
we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities,
or one or more predecessor securities, are registered at the close of business on the regular record date for the interest payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will pay principal of, and any premium and interest on, the debt
securities of a particular series at the office of the paying agents designated by us, except that, unless we otherwise indicate in the
applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain
holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate the corporate trust office of the trustee
in the City of New York as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable
prospectus supplement any other paying agents that we initially designate for the debt securities of a particular series. We will maintain
a paying agent in each place of payment for the debt securities of a particular series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All money we pay to a paying agent or the trustee for the payment of
the principal of, or any premium or interest on, any debt securities that remains unclaimed at the end of two years after such principal,
premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us
for payment thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Governing Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The indentures and the debt securities will be governed by and construed
in accordance with the laws of the State of New York, except to the extent that the Trust Indenture Act is applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P ID="a19" STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Ranking Debt Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The subordinated debt securities will be unsecured and will be subordinate
and junior in priority of payment to certain of our other indebtedness to the extent described in a prospectus supplement. The subordinated
indenture does not limit the amount of subordinated debt securities that we may issue. It also does not limit us from issuing any other
secured or unsecured debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The senior debt securities will be unsecured and will rank equally
in right of payment to all of our other senior unsecured debt. The senior indenture does not limit the amount of senior debt securities
that we may issue. It also does not limit us from issuing any other secured or unsecured debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">DESCRIPTION OF WARRANTS WE MAY OFFER</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may issue warrants to purchase debt securities, preferred stock,
common stock or any combination of the foregoing. We may issue warrants independently or together with any other securities we offer under
a prospectus supplement. The warrants may be attached to or separate from the securities. We will issue each series of warrants under
a separate warrant agreement to be entered into between a warrant agent and us. The warrant agent will act solely as our agent in connection
with the warrants and will not have any obligations or relationship of agency or trust for or with holders or beneficial owners of warrants.
The following outlines some of the general terms and provisions of the warrants that we may issue from time to time. When we issue warrants,
we will provide the specific terms of the warrants and the applicable warrant agreement in a prospectus supplement and any related free
writing prospectuses and such terms may differ from those described below. To the extent the information contained in the prospectus supplement
or free writing prospectuses differs from this summary description, you should rely on the information in the prospectus supplement or
free writing prospectuses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following description, and any description of the warrants included
in a prospectus supplement, may not be complete and is subject to and qualified in its entirety by reference to the terms and provisions
of the applicable warrant agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Equity Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will describe in the applicable prospectus supplement and any related
free writing prospectuses the terms of the preferred stock warrants or common stock warrants being offered, the warrant agreement relating
to the preferred stock warrants or common stock warrants and the warrant certificates representing the preferred stock warrants or common
stock warrants, including, as applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the title of the warrants;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the securities for which the warrants are exercisable;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the price or prices at which the warrants will be issued;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">if applicable, the number of warrants issued with each share of preferred stock or share of common stock;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">if applicable, the date on and after which the warrants and the related preferred stock or common stock will be separately transferable;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the date on which the right to exercise the warrants will commence, and the date on which the right will expire;<BR>
</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the maximum or minimum number of warrants which may be exercised at any time;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">information with respect to book-entry procedures, if any;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">a discussion of the material U.S. federal income tax considerations applicable to exercise of the warrants; and</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">any other terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless otherwise provided in the applicable warrant agreement and corresponding
prospectus supplement or any related free writing prospectuses, holders of equity warrants will not be entitled, by virtue of being such
holders, to vote, consent, receive dividends, receive notice as stockholders with respect to any meeting of stockholders for the election
of our directors or any other matter, or to exercise any rights whatsoever as stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except as provided in the applicable warrant agreement and corresponding
prospectus supplement or any related free writing prospectuses, the exercise price payable and the number of shares of common stock or
preferred stock purchasable upon the exercise of each warrant will be subject to adjustment in certain events, including the issuance
of a stock dividend to holders of common stock or preferred stock or a stock split, reverse stock split, combination, subdivision or reclassification
of common stock or preferred stock. In lieu of adjusting the number of shares of common stock or preferred stock purchasable upon exercise
of each warrant, we may elect to adjust the number of warrants. Unless otherwise provided in the applicable warrant agreement and corresponding
prospectus supplement or any related free writing prospectuses, no adjustments in the number of shares purchasable upon exercise of the
warrants will be required until all cumulative adjustments require an adjustment of at least 1% thereof. No fractional shares will be
issued upon exercise of warrants, but we will pay the cash value of any fractional shares otherwise issuable. Notwithstanding the foregoing,
except as otherwise provided in the applicable warrant agreement and corresponding prospectus supplement or any related free writing prospectuses,
in the event of any consolidation, merger, or sale or conveyance of our assets as an entirety or substantially as an entirety, the holder
of each outstanding warrant will have the right to the kind and amount of shares of stock and other securities and property, including
cash, receivable by a holder of the number of shares of common stock or preferred stock into which each warrant was exercisable immediately
prior to the particular triggering event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Debt Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will describe in the applicable prospectus supplement and any related
free writing prospectuses the terms of the debt warrants being offered, the warrant agreement relating to the debt warrants and the debt
warrant certificates representing the debt warrants, including, as applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the title of the debt warrants;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the aggregate number of the debt warrants;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the price or prices at which the debt warrants will be issued;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the designation, aggregate principal amount and terms of the debt securities purchasable upon exercise of the debt warrants, and the procedures and conditions relating to the exercise of the debt warrants;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the designation and terms of any related debt securities with which the debt warrants are issued, and the number of the debt warrants issued with each security;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the date, if any, on and after which the debt warrants and the related debt securities will be separately transferable;<BR>
</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the principal amount of debt securities purchasable upon exercise of each debt warrant, and the price at which the principal amount of the debt securities may be purchased upon exercise;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the date on which the right to exercise the debt warrants will commence, and the date on which the right will expire;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the maximum or minimum number of the debt warrants that may be exercised at any time;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">information with respect to book-entry procedures, if any;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P ID="a21" STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">changes to or adjustments in the exercise price of the debt warrants;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">a discussion of the material U.S. federal income tax considerations applicable to the exercise of the debt warrants; and</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">any other terms of the debt warrants and terms, procedures and limitations relating to the exercise of the debt warrants.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As may be permitted under the warrant agreement, holders may exchange
debt warrant certificates for new debt warrant certificates of different denominations, and may exercise debt warrants at the corporate
trust office of the warrant agent or any other office indicated in the applicable prospectus supplement and any related free writing prospectuses.
Prior to the exercise of their debt warrants, holders of debt warrants will not have any of the rights of holders of the securities purchasable
upon the exercise and will not be entitled to payments of principal, premium or interest on the securities purchasable upon the exercise
of debt warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exercise of Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each warrant will entitle the holder of the warrant to purchase for
cash at the exercise price provided in the applicable warrant agreement and corresponding prospectus supplement or any related free writing
prospectuses the principal amount of debt securities or shares of preferred stock or shares of common stock being offered. Holders may
exercise warrants at any time up to the close of business on the expiration date provided in the applicable warrant agreement and corresponding
prospectus supplement or any related free writing prospectuses. After the close of business on the expiration date, unexercised warrants
will be void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Holders may exercise warrants as described in the applicable warrant
agreement and corresponding prospectus supplement or any free writing prospectuses relating to the warrants being offered. Upon receipt
of payment and the warrant certificate properly completed and duly executed at the corporate trust office of the warrant agent or any
other office indicated in the applicable warrant agreement and corresponding prospectus supplement or any related free writing prospectuses,
we will, as soon as practicable, forward the debt securities, shares of preferred stock or shares of common stock purchasable upon the
exercise of the warrant. If less than all of the warrants represented by the warrant certificate are exercised, we will issue a new warrant
certificate for the remaining warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">DESCRIPTION OF UNITS WE MAY OFFER</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following description, together with the additional information
we may include in any applicable prospectus supplements and free writing prospectuses, summarizes the material terms and provisions of
the units that we may offer under this prospectus. While the terms we have summarized below will apply generally to any units that we
may offer under this prospectus, we will describe the particular terms of any series of units in more detail in the applicable prospectus
supplement. The terms of any units offered under a prospectus supplement may differ from the terms described below. However, no prospectus
supplement will fundamentally change the terms that are set forth in this prospectus or offer a security that is not registered and described
in this prospectus at the time of its effectiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will file as exhibits to the registration statement of which this
prospectus is a part, or will incorporate by reference from a current report on Form 8-K that we file with the SEC before the issuance
of the related series of units, the form of unit agreement that describes the terms of the series of units we are offering, and any supplemental
agreements. The following summaries of material terms and provisions of the units are subject to, and qualified in their entirety by reference
to, all the provisions of the unit agreement and any supplemental agreements applicable to a particular series of units. We urge you to
read the applicable prospectus supplements related to the particular series of units that we sell under this prospectus, as well as the
complete unit agreement and any supplemental agreements that contain the terms of the units.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P ID="a22" STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may issue units comprised of one or more shares of common stock,
shares of preferred stock, debt securities and warrants in any combination. Each unit will be issued so that the holder of the unit is
also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of
each included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be
held or transferred separately, at any time or at any time before a specified date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will describe in the applicable prospectus supplement the terms
of the series of units, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">any provisions of the governing unit agreement that differ from those described below; and</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The provisions described in this section, as well as those described
under &ldquo;Description of Capital Stock We May Offer,&rdquo; &ldquo;Description of Debt Securities We May Offer&rdquo; and &ldquo;Description
of Warrants We May Offer&rdquo; will apply to each unit and to any common stock, preferred stock, debt security or warrant included in
each unit, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Issuance in Series</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may issue units in such amounts and in numerous distinct series
as we determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Enforceability of Rights by Holders of Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each unit agent will act solely as our agent under the applicable unit
agreement and will not assume any obligation or relationship of agency or trust with any holder of any unit. A single bank or trust company
may act as unit agent for more than one series of units. A unit agent will have no duty or responsibility in the event of any default
by us under the applicable unit agreement or unit, including any duty or responsibility to initiate any proceedings at law or otherwise,
or to make any demand upon us. Any holder of a unit may, without the consent of the related unit agent or the holder of any other unit,
enforce by appropriate legal action its rights as holder under any security included in the unit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We, the unit agents and any of their agents may treat the registered
holder of any unit certificate as an absolute owner of the units evidenced by that certificate for any purpose and as the person entitled
to exercise the rights attaching to the units so registered, despite any notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">GLOBAL SECURITIES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Book-Entry, Delivery and Form</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Unless we indicate differently in any applicable prospectus supplement
or free writing prospectus, the securities initially will be issued in book-entry form and represented by one or more global notes or
global securities, or, collectively, global securities. The global securities will be deposited with, or on behalf of, The Depository
Trust Company, New York, New York, as depositary (&ldquo;DTC&rdquo;), and registered in the name of Cede &amp; Co., the partnership nominee
of DTC. Unless and until it is exchanged for individual certificates evidencing securities under the limited circumstances described below,
a global security may not be transferred except as a whole by the depositary to its nominee or by the nominee to the depositary, or by
the depositary or its nominee to a successor depositary or to a nominee of the successor depositary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">DTC has advised us that it is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">a limited-purpose trust company organized under the New York Banking Law;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">a &ldquo;banking organization&rdquo; within the meaning of the New York Banking Law;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">a member of the Federal Reserve System;<BR>
</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">a &ldquo;clearing corporation&rdquo; within the meaning of the New York Uniform Commercial Code; and</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">a &ldquo;clearing agency&rdquo; registered pursuant to the provisions of Section 17A of the Exchange Act.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">DTC holds securities that its participants deposit with DTC. DTC also
facilitates the settlement among its participants of securities transactions, such as transfers and pledges, in deposited securities through
electronic computerized book-entry changes in participants&rsquo; accounts, thereby eliminating the need for physical movement of securities
certificates. &ldquo;Direct participants&rdquo; in DTC include securities brokers and dealers, including underwriters, banks, trust companies,
clearing corporations and other organizations. DTC is a wholly-owned subsidiary of The Depository Trust &amp; Clearing Corporation (&ldquo;DTCC&rdquo;).
DTCC is the holding company for DTC, National Securities Clearing Corporation and Fixed Income Clearing Corporation, all of which are
registered clearing agencies. DTCC is owned by the users of its regulated subsidiaries. Access to the DTC system is also available to
others, which we sometimes refer to as indirect participants, that clear through or maintain a custodial relationship with a direct participant,
either directly or indirectly. The rules applicable to DTC and its participants are on file with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Purchases of securities under the DTC system must be made by or through
direct participants, which will receive a credit for the securities on DTC&rsquo;s records. The ownership interest of the actual purchaser
of a security, which we sometimes refer to as a beneficial owner, is in turn recorded on the direct and indirect participants&rsquo; records.
Beneficial owners of securities will not receive written confirmation from DTC of their purchases. However, beneficial owners are expected
to receive written confirmations providing details of their transactions, as well as periodic statements of their holdings, from the direct
or indirect participants through which they purchased securities. Transfers of ownership interests in global securities are to be accomplished
by entries made on the books of participants acting on behalf of beneficial owners. Beneficial owners will not receive certificates representing
their ownership interests in the global securities, except under the limited circumstances described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To facilitate subsequent transfers, all global securities deposited
by direct participants with DTC will be registered in the name of DTC&rsquo;s partnership nominee, Cede &amp; Co., or such other name
as may be requested by an authorized representative of DTC. The deposit of securities with DTC and their registration in the name of Cede
&amp; Co. or such other nominee will not change the beneficial ownership of the securities. DTC has no knowledge of the actual beneficial
owners of the securities. DTC&rsquo;s records reflect only the identity of the direct participants to whose accounts the securities are
credited, which may or may not be the beneficial owners. The participants are responsible for keeping account of their holdings on behalf
of their customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">So long as the securities are in book-entry form, you will receive
payments and may transfer securities only through the facilities of the depositary and its direct and indirect participants. We will maintain
an office or agency in the location specified in the prospectus supplement for the applicable securities, where notices and demands in
respect of the securities and the indenture may be delivered to us and where certificated securities may be surrendered for payment, registration
of transfer or exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Conveyance of notices and other communications by DTC to direct participants,
by direct participants to indirect participants, and by direct participants and indirect participants to beneficial owners will be governed
by arrangements among them, subject to any legal requirements in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Redemption notices will be sent to DTC. If less than all of the securities
of a particular series are being redeemed, DTC&rsquo;s practice is to determine by lot the amount of the interest of each direct participant
in the securities of such series to be redeemed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Neither DTC nor Cede &amp; Co. (or such other DTC nominee) will consent
or vote with respect to the securities. Under its usual procedures, DTC will mail an omnibus proxy to us as soon as possible after the
record date. The omnibus proxy assigns the consenting or voting rights of Cede &amp; Co. to those direct participants to whose accounts
the securities of such series are credited on the record date, identified in a listing attached to the omnibus proxy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">So long as securities are in book-entry form, we will make payments
on those securities to the depositary or its nominee, as the registered owner of such securities, by wire transfer of immediately available
funds. If securities are issued in definitive certificated form under the limited circumstances described below, and unless otherwise
provided in the description of the applicable securities herein or in the applicable prospectus supplement, we will have the option of
making payments by check mailed to the addresses of the persons entitled to payment or by wire transfer to bank accounts in the United
States designated in writing to the applicable trustee or other designated party at least 15 days before the applicable payment date by
the persons entitled to payment, unless a shorter period is satisfactory to the applicable trustee or other designated party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Redemption proceeds, distributions and dividend payments on the securities
will be made to Cede &amp; Co., or such other nominee as may be requested by an authorized representative of DTC. DTC&rsquo;s practice
is to credit direct participants&rsquo; accounts upon DTC&rsquo;s receipt of funds and corresponding detail information from us on the
payment date in accordance with their respective holdings shown on DTC records. Payments by participants to beneficial owners will be
governed by standing instructions and customary practices, as is the case with securities held for the account of customers in bearer
form or registered in &ldquo;street name.&rdquo; Those payments will be the responsibility of participants and not of DTC or us, subject
to any statutory or regulatory requirements in effect from time to time. Payment of redemption proceeds, distributions and dividend payments
to Cede &amp; Co., or such other nominee as may be requested by an authorized representative of DTC, is our responsibility, disbursement
of payments to direct participants is the responsibility of DTC, and disbursement of payments to the beneficial owners is the responsibility
of direct and indirect participants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except under the limited circumstances described below, purchasers
of securities will not be entitled to have securities registered in their names and will not receive physical delivery of securities.
Accordingly, each beneficial owner must rely on the procedures of DTC and its participants to exercise any rights under the securities
and the indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The laws of some jurisdictions may require that some purchasers of
securities take physical delivery of securities in definitive form. Those laws may impair the ability to transfer or pledge beneficial
interests in securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">DTC may discontinue providing its services as securities depositary
with respect to the securities at any time by giving reasonable notice to us. Under such circumstances, in the event that a successor
depositary is not obtained, securities certificates are required to be printed and delivered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As noted above, beneficial owners of a particular series of securities
generally will not receive certificates representing their ownership interests in those securities. However, if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">DTC notifies us that it is unwilling or unable to continue as a depositary for the global security or securities representing such series of securities or if DTC ceases to be a clearing agency registered under the Exchange Act at a time when it is required to be registered and a successor depositary is not appointed within 90 days of the notification to us or of our becoming aware of DTC&rsquo;s ceasing to be so registered, as the case may be;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">we determine, in our sole discretion, not to have such securities represented by one or more global securities; or</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">an event of default has occurred and is continuing with respect to such series of securities,</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">then we will prepare and deliver certificates for such securities in
exchange for beneficial interests in the global securities. Any beneficial interest in a global security that is exchangeable under the
circumstances described in the preceding sentence will be exchangeable for securities in definitive certificated form registered in the
names that the depositary directs. It is expected that these directions will be based upon directions received by the depositary from
its participants with respect to ownership of beneficial interests in the global securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Euroclear and Clearstream</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If so provided in the applicable prospectus supplement, you may hold
interests in a global security through Clearstream Banking S.A. (&ldquo;Clearstream&rdquo;), or Euroclear Bank S.A./N.V., as operator
of the Euroclear System (&ldquo;Euroclear&rdquo;), either directly if you are a participant in Clearstream or Euroclear or indirectly
through organizations which are participants in Clearstream or Euroclear. Clearstream and Euroclear will hold interests on behalf of their
respective participants through customers&rsquo; securities accounts in the names of Clearstream and Euroclear, respectively, on the books
of their respective U.S. depositaries, which in turn will hold such interests in customers&rsquo; securities accounts in such depositaries&rsquo;
names on DTC&rsquo;s books.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Clearstream and Euroclear are securities clearance systems in Europe.
Clearstream and Euroclear hold securities for their respective participating organizations and facilitate the clearance and settlement
of securities transactions between those participants through electronic book-entry changes in their accounts, thereby eliminating the
need for physical movement of certificates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payments, deliveries, transfers, exchanges, notices and other matters
relating to beneficial interests in global securities owned through Euroclear or Clearstream must comply with the rules and procedures
of those systems. Transactions between participants in Euroclear or Clearstream, on the one hand, and other participants in DTC, on the
other hand, are also subject to DTC&rsquo;s rules and procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investors will be able to make and receive through Euroclear and Clearstream
payments, deliveries, transfers and other transactions involving any beneficial interests in global securities held through those systems
only on days when those systems are open for business. Those systems may not be open for business on days when banks, brokers and other
institutions are open for business in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cross-market transfers between participants in DTC, on the one hand,
and participants in Euroclear or Clearstream, on the other hand, will be effected through DTC in accordance with DTC&rsquo;s rules on
behalf of Euroclear or Clearstream, as the case may be, by their respective U.S. depositaries; however, such cross-market transactions
will require delivery of instructions to Euroclear or Clearstream, as the case may be, by the counterparty in such system in accordance
with the rules and procedures and within the established deadlines (European time) of such system. Euroclear or Clearstream, as the case
may be, will, if the transaction meets its settlement requirements, deliver instructions to its U.S. depositary to take action to effect
final settlement on its behalf by delivering or receiving interests in the global securities through DTC, and making or receiving payment
in accordance with normal procedures for same-day fund settlement. Participants in Euroclear or Clearstream may not deliver instructions
directly to their respective U.S. depositaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Due to time zone differences, the securities accounts of a participant
in Euroclear or Clearstream purchasing an interest in a global security from a direct participant in DTC will be credited, and any such
crediting will be reported to the relevant participant in Euroclear or Clearstream, during the securities settlement processing day (which
must be a business day for Euroclear or Clearstream) immediately following the settlement date of DTC. Cash received in Euroclear or Clearstream
as a result of sales of interests in a global security by or through a participant in Euroclear or Clearstream to a direct participant
in DTC will be received with value on the settlement date of DTC but will be available in the relevant Euroclear or Clearstream cash account
only as of the business day for Euroclear or Clearstream following DTC&rsquo;s settlement date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Other</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information in this section of this prospectus concerning DTC,
Clearstream, Euroclear and their respective book-entry systems has been obtained from sources that we believe to be reliable, but we do
not take responsibility for this information. This information has been provided solely as a matter of convenience. The rules and procedures
of DTC, Clearstream and Euroclear are solely within the control of those organizations and could change at any time. Neither we nor the
trustee nor any agent of ours or of the trustee has any control over those entities and none of us takes any responsibility for their
activities. You are urged to contact DTC, Clearstream and Euroclear or their respective participants directly to discuss those matters.
In addition, although we expect that DTC, Clearstream and Euroclear will perform the foregoing procedures, none of them is under any obligation
to perform or continue to perform such procedures and such procedures may be discontinued at any time. Neither we nor any agent of ours
will have any responsibility for the performance or nonperformance by DTC, Clearstream and Euroclear or their respective participants
of these or any other rules or procedures governing their respective operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P ID="a26" STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PLAN OF DISTRIBUTION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may sell the securities from time to time pursuant to underwritten
public offerings, negotiated transactions, block trades or a combination of these methods or through underwriters or dealers, through
agents and/or directly to one or more purchasers. The securities may be distributed from time to time in one or more transactions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">at a fixed price or prices, which may be changed;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">at market prices prevailing at the time of sale;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">at prices related to such prevailing market prices; or</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD>
    <TD STYLE="font-size: 10pt">at negotiated prices.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each time that we sell securities covered by this prospectus, we will
provide a prospectus supplement or supplements that will describe the method of distribution and set forth the terms and conditions of
the offering of such securities, including the offering price of the securities and the proceeds to us, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Offers to purchase the securities being offered by this prospectus
may be solicited directly. Agents may also be designated to solicit offers to purchase the securities from time to time. Any agent involved
in the offer or sale of our securities will be identified in a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If a dealer is utilized in the sale of the securities being offered
by this prospectus, the securities will be sold to the dealer, as principal. The dealer may then resell the securities to the public at
varying prices to be determined by the dealer at the time of resale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an underwriter is utilized in the sale of the securities being offered
by this prospectus, an underwriting agreement will be executed with the underwriter at the time of sale and the name of any underwriter
will be provided in the prospectus supplement that the underwriter will use to make resales of the securities to the public. In connection
with the sale of the securities, we or the purchasers of securities for whom the underwriter may act as agent, may compensate the underwriter
in the form of underwriting discounts or commissions. The underwriter may sell the securities to or through dealers, and those dealers
may receive compensation in the form of discounts, concessions or commissions from the underwriters and/or commissions from the purchasers
for which they may act as agent. Unless otherwise indicated in a prospectus supplement, an agent will be acting on a best efforts basis
and a dealer will purchase securities as a principal, and may then resell the securities at varying prices to be determined by the dealer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any compensation paid to underwriters, dealers or agents in connection
with the offering of the securities, and any discounts, concessions or commissions allowed by underwriters to participating dealers will
be provided in the applicable prospectus supplement. Underwriters, dealers and agents participating in the distribution of the securities
may be deemed to be underwriters within the meaning of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), and
any discounts and commissions received by them and any profit realized by them on resale of the securities may be deemed to be underwriting
discounts and commissions. We may enter into agreements to indemnify underwriters, dealers and agents against civil liabilities, including
liabilities under the Securities Act, or to contribute to payments they may be required to make in respect thereof and to reimburse those
persons for certain expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any common stock will be listed on the Nasdaq Global Select Market,
but any other securities may or may not be listed on a national securities exchange. To facilitate the offering of securities, certain
persons participating in the offering may engage in transactions that stabilize, maintain or otherwise affect the price of the securities.
This may include over-allotments or short sales of the securities, which involve the sale by persons participating in the offering of
more securities than were sold to them. In these circumstances, these persons would cover such over-allotments or short positions by making
purchases in the open market or by exercising their over-allotment option, if any. In addition, these persons may stabilize or maintain
the price of the securities by bidding for or purchasing securities in the open market or by imposing penalty bids, whereby selling concessions
allowed to dealers participating in the offering may be reclaimed if securities sold by them are repurchased in connection with stabilization
transactions. The effect of these transactions may be to stabilize or maintain the market price of the securities at a level above that
which might otherwise prevail in the open market. These transactions may be discontinued at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P ID="a27" STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may engage in at the market offerings into an existing trading market
in accordance with Rule 415(a)(4) under the Securities Act. In addition, we may enter into derivative transactions with third parties,
or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus
supplement so indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the
applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by us or borrowed
from us or others to settle those sales or to close out any related open borrowings of stock, and may use securities received from us
in settlement of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be
an underwriter and, if not identified in this prospectus, will be named in the applicable prospectus supplement (or a post-effective amendment).
In addition, we may otherwise loan or pledge securities to a financial institution or other third party that in turn may sell the securities
short using this prospectus and an applicable prospectus supplement. Such financial institution or other third party may transfer its
economic short position to investors in our securities or in connection with a concurrent offering of other securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The specific terms of any lock-up provisions in respect of any given
offering will be described in the applicable prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The underwriters, dealers and agents may engage in transactions with
us, or perform other services for us, in the ordinary course of business for which they receive compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">LEGAL MATTERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The validity of the securities being offered hereby will be passed
on by Dentons US LLP. Any underwriters, dealers or agents will also be advised about the validity of the securities and other legal matters
by their own counsel, which will be named in the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXPERTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The consolidated financial statements of Immunic, Inc. as of December
31, 2023 and 2022 and for each of the two years in the period ended December 31, 2023 incorporated in this prospectus by reference to
our Annual Report on Form 10-K for the year ended December 31, 2023, have been so incorporated in reliance on the report of Baker Tilly
US, LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; text-align: right; font-size: 8pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 106.9pt 0pt 106.75pt; text-align: center">5,666,667 Shares of Common
Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 70px; width: 241px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Immunic, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 100%; border-top: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>PROSPECTUS SUPPLEMENT</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Titan Partners Group</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>a division of American Capital Partners</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">April 9, 2025</P>

















































</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" !& .0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V3M7-^*/%
MEOH4!CCQ->./DBSP/=O:JOBWQE'I"M969$EZ1SSQ%[GW]J\QFEDGF:>9V>60
MY9F/6NNAAW/WI;'F8O&JG[L=S1LO&VLZ9K#WDD[74<IS+"Q^4_[O]W%=G?\
MC^";3D;3$8SS+SO&/*_Q-</9Z!<W42WBQB2-ONJ#S4SVMQ <202*1ZCBO0^K
MT9239Y4L96A'ECU.U\!ZK+<27-I=2M)(3YJLQY.>M=J*\?T34/[-UFVN<D*&
MVO\ 0\&O7D8%01R#T]Z\_%TN2>FQZN6UG4I6ENA],D<1H78X"C)/M3ZAO/\
MCSF_ZYM_*N5'I-V10TGQ#IFN-*NG70G:'&\ 'Y:U17F/PD'^E:K_ ,!_F:]-
M!XJZD.27*9TI\\;CJ*;NI<UF:BT4F:,T %+3=WL:-WM0 ZDI-U&Z@!:6DS1F
M@!:*3-&: %HI,T;A0 UCCD]!3(IXIL^6ZMCK@TYP'4KG&1BJ6G::M@\C"0N7
M[D8IJQ+;N: I::*7-(844FX#K10,\M^(VG066LPW47RM=J3(/4KCG\C7(Y.#
MZBNT^+)Q=:61V5_YBN-MQ]HEB4=78+^M>SAF_8IGS6.@E6=COM+B\C2[6/IM
MC%6OK_*D"[0%_N\4M0]RTE9$$MG:RJ3+;QL "2<#-;/@O7EUC36C<@3VS%&
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M9FB3A5Y4]T<G;>(O$<FN:CI=A<27$]Q,T<)<\0J&.2*=JVC^+O#<"ZLVL23
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M,^"T9P2,&M"6\N%^'YNQ,_VC[#N\W/.[;UK%^+1 \/6HXR;C^AK5F_Y)H?\
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M"O6_#FA6_A[28K* 98#=))W=NY-<E>:I0Y5N>GA*/MY<[V-&WA2WA2&)0J(
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MQ;NG2@#28W$MDCV[(DKJ#EAD>]4[:;5)[B:,RV^()-K80\\9K1MU*6\:-U5
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MR8&))A0GN2HHHH D "KP,#T J-8(1-YHB02'JVT9HHH EI H4D@ 9Z^]%%
M5#$$@''3-!&>#W]J** (X[>"-BT4*(QZD+BG211S+LDC5U]&&:** %1%C7:B
+A5'0 8HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +P!=L# 2(  A$! Q$!_\0
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MZZK\?TH_']*/JZ#ZP^QRO_#97@+_ )\O%7_A.7G_ ,;H_P"&RO 7_/EXJ_\
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M^7BK_P )R\_^-T?\-E> O^?+Q5_X3EY_\;KJOQ_2C\?TH^KH/K#['*_\-E>
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M (3EY_\ &ZZK\?TH_']*/JZ#ZP^QRO\ PV5X"_Y\O%7_ (3EY_\ &Z/^&RO
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M/^&RO 7_ #Y>*O\ PG+S_P"-UU7X_I1^/Z4?5T'UA]CE?^&RO 7_ #Y>*O\
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M']*/Q_2CZN@^L/L<K_PV5X"_Y\O%7_A.7G_QNC_ALKP%_P ^7BK_ ,)R\_\
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MZZK\?TH_']*/JZ#ZP^QRO_#97@+_ )\O%7_A.7G_ ,;H_P"&RO 7_/EXJ_\
M"<O/_C==5^/Z4?C^E'U=!]8?8Y7_ (;*\!?\^7BK_P )R\_^-T?\-E> O^?+
MQ5_X3EY_\;KJOQ_2C\?TH^KH/K#['*_\-E> O^?+Q5_X3EY_\;H_X;*\!?\
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M (3EY_\ &ZZK\?TH_']*/JZ#ZP^QRO\ PV5X"_Y\O%7_ (3EY_\ &Z/^&RO
M7_/EXJ_\)R\_^-UU7X_I1^/Z4?5T'UA]CE?^&RO 7_/EXJ_\)R\_^-T?\-E>
M O\ GR\5?^$Y>?\ QNNJ_']*/Q_2CZN@^L/L<K_PV5X"_P"?+Q5_X3EY_P#&
MZ/\ ALKP%_SY>*O_  G+S_XW75?C^E'X_I1]70?6'V.5_P"&RO 7_/EXJ_\
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M4J1IJ\F>V\^E'/I7FGPO^/WACXJZE=Z38B\TO7[12\VDZI"8IPO=@.XKTO\
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M?%*^^+7P;U#5M5MXK;5[5+RQO%@&(VDC1AN ]#6!^Q'_ ,F_Z?\ ]?\ =_\
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M&W]CIY#_ -LSQQX6U[X5GPY9:A9:WXAU&]A&GVMC,L\J,'&7^7)'''OFL_\
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M/I1SZ4 '%4=<Q_8.J8_Y\YO_ $6U7N?2J6N_\@'5/^O.;_T6U"#J>;_LN?\
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M_14E>M\5Y)\.<?\ "_OBU]-,_P#14E'8?1GK?/K1SZT<4<4"#GUHY]:.*.*
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MM> __ 6Z_P#BJZ+]KW_DENE?]C+I'_I9'7MR_=J8SE%:%RA&6K/F_P#X0/\
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M_&OI#CUHX]:/:S[A[.'8^;_^$#_:#_Z#?@/_ ,!;K_&C_A _V@_^@WX#_P#
M6Z_QKZ0X]:./6CVL^X>SAV/F_P#X0/\ :#_Z#?@/_P !;K_&C_A _P!H/_H-
M^ __  %NO\:^D./6CCUH]K/N'LX=CYO_ .$#_:#_ .@WX#_\!;K_ !H_X0/]
MH/\ Z#?@/_P%NO\ &OI#CUHX]:/:S[A[.'8^;_\ A _V@_\ H-^ _P#P%NO\
M:/\ A _V@_\ H-^ _P#P%NO\:^D./6CCUH]K/N'LX=CYO_X0/]H/_H-^ _\
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M_P ('^T'_P!!OP'_ . MU_C7TAQZT<>M'M9]P]G#L?-__"!_M!_]!OP'_P"
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MNO\ &OI#CUHX]:/:S[A[.'8^;_\ A _V@_\ H-^ _P#P%NO\:/\ A _V@_\
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MV@_^@WX#_P# 6Z_QH_X0/]H/_H-^ _\ P%NO\:^D./6CCUH]K/N'LX=CYO\
M^$#_ &@_^@WX#_\  6Z_QH_X0/\ :#_Z#?@/_P !;K_&OI#CUHX]:/:S[A[.
M'8^;_P#A _V@_P#H-^ __ 6Z_P :/^$#_:#_ .@WX#_\!;K_ !KZ0X]:./6C
MVL^X>SAV/F__ (0/]H+_ *#7@/\ \!;K_&N<\7? GXX^-+K09K[7O!*/HVH+
MJ5OY-M<@&5590&R3E<,>F*^L^*.*7M9]Q^SCV/F__A!/V@VR3K?@/_P%N?\
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MI#CUHX]:/:S[A[.'8^;_ /A _P!H/_H-^ __  %NO\:/^$#_ &@_^@WX#_\
M 6Z_QKZ0X]:./6CVL^X>SAV/F_\ X0/]H/\ Z#?@/_P%NO\ &C_A _V@_P#H
M-^ __ 6Z_P :^D./6CCUH]K/N'LX=CYO_P"$#_:#_P"@WX#_ / 6Z_QH_P"$
M#_:#_P"@WX#_ / 6Z_QKZ0X]:./6CVL^X>SAV/F__A _V@_^@WX#_P# 6Z_Q
MH_X0/]H/_H-^ _\ P%NO\:^D./6CCUH]K/N'LX=CYO\ ^$#_ &@_^@WX#_\
M 6Z_QH_X0/\ :#_Z#?@/_P !;K_&OI#CUHX]:/:S[A[.'8^;_P#A _V@_P#H
M-^ __ 6Z_P :/^$#_:#_ .@WX#_\!;K_ !KZ0X]:./6CVL^X>SAV/F__ (0/
M]H/_ *#?@/\ \!;K_&H[KX>_M 75K/;R:WX#"31M$V+6YSAE(..?0U]*;:45
M/M9]Q^SCV/E#P+\$/CK\/?".F>'--U[P.]CI\9BB::VN2Y!8MR0>O)K?_P"$
M#_:"_P"@WX#_ / 6Z_\ BJ^CS]:./6G[6?<7LX=CYO\ ^$#_ &@_^@WX#_\
M 6Z_QH_X0/\ :#_Z#?@/_P !;K_&OI#CUHX]:?M9]P]G#L?-_P#P@?[0?_0;
M\!_^ MU_C1_P@?[0?_0;\!_^ MU_C7TAQZT<>M'M9]P]G#L?-_\ P@?[0?\
MT&_ ?_@+=?XT?\('^T'_ -!OP'_X"W7^-?2''K1QZT>UGW#V<.Q\W_\ "!_M
M!_\ 0;\!_P#@+=?XT?\ "!_M!_\ 0;\!_P#@+=?XU](<>M''K1[6?</9P['S
M?_P@?[0?_0;\!_\ @+=?XT?\('^T'_T&_ ?_ ("W7^-?2''K1QZT>UGW#V<.
MQ\W_ /"!_M!_]!OP'_X"W7^-'_"!_M!_]!OP'_X"W7^-?2''K1QZT>UGW#V<
M.Q\W_P#"!_M!_P#0;\!_^ MU_C1_P@?[073^V_ ?7G_1;G_XJOI#CUHXH]K/
MN'LX=CYDTWPK\?\ 5(I9(]9\"*(Y7B^:UN>=IQG[U6_^$#_:#_Z#?@/_ ,!;
MK_XJO<_"'_'E>?\ 7Y-_Z%6[S1[6?</90['S?_P@?[0?_0;\!_\ @+=?XT?\
M('^T'_T&_ ?_ ("W7^-?2'U-''K1[6?</9P['S?_ ,('^T'_ -!OP'_X"W7^
M-'_"!_M!_P#0;\!_^ MU_C7TAQZT<>M'M9]P]G#L?-__  @?[0?_ $&_ ?\
MX"W7^-'_  @?[0?_ $&_ ?\ X"W7^-?2''K1QZT>UGW#V<.Q\W_\('^T'_T&
M_ ?_ ("W7^-'_"!_M!_]!OP'_P" MU_C7TAQZT<>M'M9]P]G#L?-_P#P@?[0
M?_0;\!_^ MU_C1_P@?[0?_0;\!_^ MU_C7TAQZT<>M'M9]P]G#L?-_\ P@?[
M0?\ T&_ ?_@+=?XT?\('^T'_ -!OP'_X"W7^-?2''K1QZT>UGW#V<.Q\W_\
M"!_M!_\ 0;\!_P#@+=?XT?\ "!_M!_\ 0;\!_P#@+=?XU](<>M''K1[6?</9
MP['S?_P@?[0?_0;\!_\ @+=?XT?\('^T'_T&_ ?_ ("W7^-?2''K1QZT>UGW
M#V<.Q\W_ /"!_M!_]!OP'_X"W7^-'_"!_M!_]!OP'_X"W7^-?2''K1QZT>UG
MW#V<.Q\W_P#"!_M!_P#0;\!_^ MU_C1_P@?[0?\ T&_ ?_@+=?XU](<>M''K
M1[6?</9P['S?_P ('^T'_P!!OP'_ . MU_C1_P ('^T'_P!!OP'_ . MU_\
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MLDCZSHKPG_AM[X-?]#A#_P" TO\ \31_PV]\&O\ H<(?_ :7_P")K?ZGB?\
MGV_N.;^T,)_S\7WGNU%>$_\ #;WP:_Z'"'_P&E_^)H_X;>^#7_0X0_\ @-+_
M /$T?4\3_P ^W]P?VAA/^?B^\]VHKPG_ (;>^#7_ $.$/_@-+_\ $T?\-O?!
MK_H<(?\ P&E_^)H^IXG_ )]O[A?VAA/^?B^\]VHKPG_AM[X-?]#A#_X#2_\
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M $.$/_@-+_\ $T?4\3_S[?W!_:&$_P"?B^\]VHKPG_AM[X-?]#A#_P" TO\
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MCZGB?^?;^X/[0PG_ #\7WGNU%>$_\-O?!K_H<(?_  &E_P#B:/\ AM[X-?\
M0X0_^ TO_P 31]3Q/_/M_<']H83_ )^+[SW:BO"?^&WO@U_T.$/_ (#2_P#Q
M-'_#;WP:_P"APA_\!I?_ (FCZGB?^?;^X/[0PG_/Q?>>[45X3_PV]\&O^APA
M_P# :7_XFC_AM[X-?]#A#_X#2_\ Q-'U/$_\^W]P_P"T,)_S\7WGNU%>$_\
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M+$_\^W]P?VAA/^?B^\^DJ*\('[;WP:_Z'"+_ ,!I?_B:7_AM[X-?]#A#_P"
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MC_AM[X-?]#A#_P" TO\ \31]2Q/_ #[?W!_:&$_Y^+[SW:BO"?\ AM[X-?\
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M'U/$_P#/M_</^T,)_P _%]Y[M7.?$#_D69_^ND7_ *,%>6?\-O?!K_H<(?\
MP'E_^)K%\7?MF_"'5-#FM[?Q;%)*SQD+]GE'1P3U7VI_4\3_ ,^W]PO[0PG_
M #\7WGT='_JU^@IU>$+^V[\&E4 ^,(<@?\^TO_Q-+_PV]\&O^APA_P# :7_X
MFE]3Q/\ S[?W!_:&$_Y^+[SW:BO"?^&WO@U_T.$/_@-+_P#$T?\ #;WP:_Z'
M"'_P&E_^)H^IXG_GV_N'_:&$_P"?B^\]VHKPG_AM[X-?]#A#_P" TO\ \31_
MPV]\&O\ H<(?_ :7_P")H^IXG_GV_N#^T,)_S\7WGNU%>$_\-O?!K_H<(?\
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M:_Z'"'_P&E_^)H^IXG_GV_N#^T,)_P _%]Y[M17A/_#;WP:_Z'"'_P !I?\
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MB@ HHHH **** "BBB@ HHHH Y7XK?\DO\8_]@:\_]$/7X@3#YE_W%_E7[?\
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M<[M<Z*5&I6O[-7MN>9[<=>:"M-R-N>W7/->F>(OV=O&OA3X6V?C_ %2QAMM
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M5V6CW&GZS^WUXIU"UN/.6*PFEL]1MV\RVMY!  )9BIP8QSD=*J>)-/\ %/Q
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M>VYSCWZ5WWP%\,_$CP'?:,]AXK\.ZI\-KSRYM1CO-1BELTA8 R*T4GS(XY'
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MJ=F E3^N)T]O/T//_B!\#[CX?>'QJDGC/PMKB>8L?V71]46XFY_BV#L*]_\
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M_94Z<H2TO=K:W0YOX3_#GPS:? 35/B+JWAF\\=WT.HBQ&DVMRT,=I'C)EEV
MM@_ETKR7Q[J7AO5_$!NO"ND7.AZ8\2EM/N9_.,4N/G"M@97/3/->E? CPO\
M$NSTF'Q)\.?$^G6L[2-%=Z8^H1Q.NT\&6&3"LA'.>:E_:\OO#E]\1-+DT4Z<
MVL?V9&->DT@#[*U[_%LQQG'4CO7JT)N.*Y6[W_#RL>/B:<983GBN6WEOZ,\-
MY]*3GTH_&CGUKWCY@.?2CGTHY]:.?6@ Y]*.?2CGUHY]: #GTHY]*.?6CGUH
M .?2CGTHY]:.?6@ Y]*.?2CGUHY]: #GTHY]*.?6CGUH .?2CGTHY]:.?6@
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M_KW_ $/%A_X!/_\ %4?VQ@?YP_L7,?\ GV_O/B$[2V>]+ZC<=IZKS@U]O?\
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MM!_>?$05<C/*DY/J1WKT+XQ?%9?B==>'H;33_P"R=&T/38].LK+?O(V_?<G
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M*VA^)\0G&[.>G;%''KDU]O?\.O\ 7O\ H>+#_P  G_\ BJ/^'7^O?]#Q8?\
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ML?\ P";_ .*I?VQ@?Y_P#^Q<Q_D?WGQ%Q_D4F,*0"0IZJ"<5]O?\.O\ 7O\
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M ,52?\.O]>_Z'BP_\ G_ /BJ2SC QVG^ WDF8RWIO[SXB(#48&,5]O?\.O\
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M;_XJC^VL%_/^8?V%C_\ GW^*/B+BCBOMW_AU_KW_ $/%C_X!-_\ %4?\.O\
M7O\ H>+'_P  F_\ BJ/[:P7\_P"8?V%C_P#GW^*/B+BCBOMW_AU_KW_0\6/_
M (!-_P#%4?\ #K_7O^AXL?\ P";_ .*H_MK!?S_F']A8_P#Y]_BCXBXHXK[=
M_P"'7^O?]#Q8_P#@$W_Q5'_#K_7O^AXL?_ )O_BJ/[:P7\_YA_86/_Y]_BCX
MBXHXK[=_X=?Z]_T/%C_X!-_\51_PZ_U[_H>+'_P";_XJC^VL%_/^8?V%C_\
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M)/\ =_6OL,8K\ZS"K"MB9U(.Z9^IY;1G0PM.G/=(\1_:]_Y);I7_ &,ND?\
MI9'7MR_=%>(_M>_\DMTK_L9=(_\ 2R.O;E^Z*X#TQU%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!R?Q9_P"25^,_^P+>?^B'
MKG/V8?\ DWGX>_\ 8&M__0!71_%K_DE?C/\ [ MY_P"B'KG/V8?^3>?A[_V!
MK?\ ] % 'I]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %<VW_)0D_[!S?^C!725S;?\E"3
M_L'-_P"C!0!TE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?$#_ +%W2O\ T9<U['7CGA1#_P -3>/WP0I\/:4,_P#;2YKV(=* /$/VO?\
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MHI,T9H 6BDS2T %%%% ')_%G_DE?C/\ [ M[_P"B'KF_V7_^3>?A[_V!K?\
M]!%=)\6O^25^,_\ L"WG_HAZYS]F'_DWGX>_]@:W_P#0!0!Z?1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7-M_P E"3_L'-_Z,%=)7-M_R4)/^P<W_HP4 =)1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5S?Q _Y%F?\ ZZ1?^ABNDKF_B!_R
M+,__ %TB_P#0Q0!T4?\ JU^@IU-C_P!6OT%.H **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** ,'P?_ ,>=Y_U^3?\ H5;M87@__CSO/^OR;_T*MV@!
M:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q
MOPF/^,JOB!_V+NE?^C+FO9*\<\*_\G4?$#_L7=*_]&7->QT >'_M>_\ )+=*
M_P"QETC_ -+(Z]N7[HKQ']KW_DENE?\ 8RZ1_P"ED=>W+]T4 ?#/[<EA-\+_
M (S?#GXKV<1$4-PEK>,@QDHVX ^[(7'_  &NE_;X\=/K7PQ\)>$]$F\R;Q?>
MP[=A_P!9"-I'X%F0_A7J_P"U]\._^%E? 7Q-81PF>]M8?MULJC+;XOFX]R-P
M_&OCW]E:;5/VA/C1X%;5X&72_ 6DA K [9'1B(R>.I++_P!\5]-AG&K0A7EO
M3O\ \ ^-QBG1Q$\/%:5;?\$]@^+/B+_A07B;X%^!M,T31]0M)7@LGNM1LUEG
MC_>1HSQM_"26)X[UT7[0_P"T9XTT?XL:/\,/AG86ESXDNXA-/<7HW+'D$A<9
MP %&XD^M<?\ MMQLW[0OP+VHS#^TX^0/^GF*L3X[:U-\ _VT-)^(VL:?=3>&
M=0M$A:Z@3?M(B\M@/<8!QZ&BE3A54)25Y.,G;N[BK5*E#VD(NT4XJZZ*QS&O
M^(O'NL?M??"RT^(NCV^F:[I[I")K-LPW<99V$B_B2/J.U>Z_&K]H_P 9M\8+
M?X5_"W2[2Z\1>5YMW?WY_=P9&[ 'L,$DYZX KQ'Q/\5C\:?VN/A;XCL-$O\
M3O#R3BTL+R\B*?;0K,7<#' !;%;_ (^UR?\ 9K_;/OO'7B+3;V7PGKEOY:ZA
M;Q&14W*H(^JLO(ZX]:WG34Y04H*ZB[+I>YS4ZDZ<9\LWRN:O+K:QV_@7]HWX
MD^!OC5IWPX^*]AIKS:NF;'4M.!5=YSL]BI(V]B#7A-C-\69OVT-8FMM.T:;Q
M^+;+P2MFU6'RU 8<_>V;?S-=W=>)/^&LOVLO!NM>$M.O6\+>&-DEQJDT!C4E
M6,G?U.  >>IQ6_X91A_P4I\1$(P!TL$$CC_41=ZJ$HT>9J*4G#5#G&>(Y4YM
MQ4U9^0NC@K_P4=NPP"N-(!8#IN\A<_K7H?[.O[07B;XI?&7XD^&-7CLUTW0)
MF2S-O&5? E9/F.>>!7 6"-_P\BO_ )6 .E=<<?ZE:\\\#?%"W_95_:A^)_\
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M_/M_<']HX3_GXOO/H;%&*^>O^&\O@W_T,DG_ (!3?_$TG_#>?P;_ .ADD_\
M *;_ .)H^HXK_GV_N#^T<)_S\7WGT-BC%?//_#>?P;_Z&23_ , IO_B:/^&\
M_@W_ -#))_X!3?\ Q-'U'%?\^W]P?VCA/^?J^\^AL48KYY_X;S^#?_0R2?\
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M!2__ !-'_#>?P;_Z&23_ , I?_B:/J.*_P"?;^X/[1PG_/Q?>?0V*,5\\_\
M#>?P;_Z&23_P"E_^)H_X;S^#?_0R2?\ @%+_ /$T?4<5_P ^W]P?VCA/^?B^
M\^AL48KYY_X;S^#?_0R2?^ 4O_Q-'_#>?P;_ .ADD_\  *7_ .)H^HXK_GV_
MN#^T<)_S\7WGT-BC%?//_#>?P;_Z&23_ , I?_B:/^&\_@W_ -#))_X!2_\
MQ-'U'%?\^W]P?VCA/^?B^\^AL48KYY_X;S^#?_0R2?\ @%+_ /$T?\-Y_!O_
M *&23_P"E_\ B:/J.*_Y]O[@_M'"?\_%]Y]"G]::&Y/%?/G_  WI\&O^ADE_
M\ I?_B:0_MY?!MF 'B28DG _T*7_ .)J?J.)7_+M_<']H83_ )^K[SZ'I:K:
M=>1:C86UW V^&>-94;&,JPR#^1JS7&>@M4%%%% PHHHH **** "BBB@ HHHH
M **** "BBB@#!\'_ /'G>?\ 7Y-_Z%6[6%X/_P"/.\_Z_)O_ $*MV@!:***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QSPK_R
M=1\0/^Q=TK_T9<U['7CGA7_DZCX@?]B[I7_HRYKV.@#P_P#:]_Y);I7_ &,N
MD?\ I9'7MR_=%>(_M>_\DMTK_L9=(_\ 2R.O;E^Z* $*[N",@U!;Z?:V>XP6
MT4!8_-Y:!<_7 J<MCO3?.1C@."WH#3UZ$/EO=D<UE!<-&\D,<CH<JSJ"5^A/
M2HM0TNSU: P7EI#=PYR8YXPZ_D15Q6W"CA:.9]&/EB]T5$TVTA\D):PJ(1B+
M:@&P>W'%+?:;::I;M!=VL-U"W6.9 RG\#531?$^D^)$F;2=4M-22!_+E:UF6
M41L.JM@G!]JU3TH;DGJ2HPDM%H5+'2[+2X/(LK2&UA'/EPQA%_("I?LD'V@S
M"&/SB,&3:-V/3/6FOJ%M'<+;O/$L[#*Q%P&/N!UJP*+RW8TH[+H0_8X/M'G>
M3'Y^,>9M&['UZU6O-#L-0N(9[FQMKF>(YCDEB5F3Z$CBM&DHYGNF-QB]T0+:
M0QRM*L*+(PPSA &./4U6NM$T^^NHKFXL;::YB_U<TD2LZ?0D<5HTF!1S-:W#
MDBU:Q EG;QR/(L,:O)]YE4 M]3WI([&WAC:*.WBCC;JB( #GU&*LT47?<.5=
MBO'9P0P^5'!&D6,>6J@+^72B.S@AA\J."..+&/+50!^0JQ11=ARKL5X;2&VC
M\N&)(X_[J* /R%5;;0=-L9II;>PM8)9_]:\<*JS_ .\0.:T*.M',^XN6/8J2
M:59S6IMGM(6M2,&%HP4Q_NXQ2:;H]CH\/DV-G!90YSY=O&J+GUP!5WFCFCF=
MK7'RQO>PM%%%(HY7XK?\DO\ &/\ V!KS_P!$/7X>1C]U%@?\LU_E7[A_%7_D
ME_C#_L#7G_HAZ_#Q?]3%_P!<U_E7U_#?\:?H?$\4_P"[P]1>1VHQ7HWP'^$:
M?&CQP^@RZL-%@ALYKV6[\GS=J1C)^7(KM[3]F?P_XZCOX/AQ\1[/Q9K5G UP
M='N+-[2>95^]Y9.03[5]G4QE&C/DD]4?!4L!7K4U4@M&> [?:C;[4Z6-X)7B
ME4QR(Q5E88((."#28]\5V<R.'EEV$Q[48]J4G:,G=BDS[FCF6XK2VL&/:C'M
M2YQUS^5'/K3YEW"TMK";?:C'M1[9HS\V.12N@Y9;AM]J-OM2\>II.^,T^9!:
M787IQBC\*DM5CDNX4FD,,32*LDFW)121EL=\#M73_$WP_P"&O#/B?[%X5\1-
MXHTD0QR?;S 8?WA'S+M/H:R]I%24>YJJ4G!S[')[?:C;[4OYTF?<UK=(RM)[
M!CVI?PHZ\9IT<9DDCC!Y=@N?J<4G))7&HMOEZC?RH_"O=OCU^RS/\%O"NFZ]
M:^((O$-I*\=O?+'#Y;6<TD8=%;DY!!X->1>#/"E_XZ\6:3X?TQ#)?ZE<+;Q+
MC@$]S[ 9/X5STL52JT_:Q=T==7!UJ-54IK5F-CVHVX/2O6OVA/@/'\#+S0([
M?Q#'XCMM6MGG6XBA\M0RMM8#DY&<\^U>3=.E71K0K04X.Z9G7H5</-TYJS0A
M^E&WVKJOA3X<M/&7Q.\+:#?F066I:A%;3>6=K;&.#@]C75S?#KP?:_&CQAX9
MUSQ))X9T/2IKF.UNWA,[.Z?<C./7UJ)XB%.7*^BN:4\+4J0YULW8\I_"E_"A
ML+(X4[E!(#8QD9X-)^F>E=',CD<9(7OTH_"O6F^%^C#]F&/Q\?M']N-KQT[[
M_P"Z\H#/W?7WKR7V[^U8TZT*G,UT=CHJT)TN6_57 "@XH!!KK?A;\-=6^+GC
M:Q\,Z,8DN[C<[33MMCAC499V([ 5I.I&$7.6R,:=.52:A'<Y(?=H_"O:]?\
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MO_)U'Q _[%W2O_1ES7L=>.>%?^3J/B!_V+NE?^C+FO8Z /#_ -KW_DENE?\
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M@P"A!&,CBF+XP\/_  =_9P^%?B:V\)Z9K'C'4(KF&&ZU" 211H'R[NO&]SP
M3T&:YSX@>'[+XY> O$7C71OB%KWB6[\*1+)=V'B.W6,K"[ 9A*$J#D]*X_XF
M>.M#U_X"_"?P_87OGZOHHN_MUOL8&'>05R2,'/L36E&DJBC#^]JM=--C+$5G
M1<Y_W5RO377<]1^"_A&XU[X=^,?BQIWA'2]>\67>J_8]+TZ=46SL<C,DH1R%
M..P.:D^(O@W6O&?P&\4:WX]\.Z+X<\7>'WCGT_4=.\B)KZ%CAXG2-L$C.1Q7
MG_P=^(/A34OA/KWPM\::G<>'[*^O4U+3M;@B,J6MPHP1(J\E3[5SGC[P'X&\
M*>'))--^)7_"7:TTB+%8V%G*D03/S,[OQG'0#O5^QG[=J3:=]'9[>HE6I/#Q
M<4GIKJM_0]^U2/6O#/P[\)ZG\(_"/A[Q;X)735;6-UC'>7;W6,RK.#\ZX[8Z
M"N%_9>L=/US3_B!<Z/IVB7/Q-(5]"TO6%4PJA8F00H_!<= #TQ4_PA7X<_"O
MQ;I7C;2_C!<VNG6P6>YT(6,JWDYV_- P'R,">,GBN"TW3_ OQ4\5>)]:O_%_
M_"O=1N-2DN["*>U>2W,+'.-T?*.#^%1&$N2I#6VFMG??9]RI5%STYZ7[77WE
M+XR:WXFU7QAH]IXR\)V?AG7K,K'/]FL1:F[5I 0[J/E;T!'%?07B!?"OA7]M
M2TT'4M(TZ/P]KFC6VG2Q-;H(XI)8!MD QPV[N.>:\J_:&^*6@^)='^'OAG3=
M<N/%]SX:&+SQ-<1,AN,L#L7=\Q50.IK$_:D^(6D>./C,OB+POJ'VVTBLK)8K
MA49,2Q(N>& /##TK54ZE90BXN*M)?E9F$JM*@YR4E)WC]W4Z;X&?"N#PO\=O
M&$_B6R2;0O ,5U>7D5RH9)&7(@0@]=QQ78?#3P1JEI\&W^)?AOPGI>O^,?%&
MJSK;C4$B-OI5LK'E(W(4L3^51?'S]H3P5XE^$MT?"L[-XP\8K9KXBC$3(8%@
MCPP)*@,6/H37#^ O''A'QY\%;;X9^,=>F\)7>D7SWVD:TL+2PE7^_%*J\CV-
M82CB*L/:S36J37DO+U_ ZHRPM&I[*#3NFT_-^?H=7\;?!=UKGP%'BWQ=H&D^
M&_'FF:FEJS::8HQJ%LX^\T<;$;E/<5\N6?%Y;?\ 75/_ $(5Z%\1O!O@OPGH
MT:Z-\0#XQUIYAF&TM)([>).Y9WZGZ"O/+=UCN(6;@(Z,?H&%>WA(.-"2O=-O
MIL>#C*D98F+M:UKZW/O?Q9<VWC+XS_$+X4WY79XH\,6%QIV_^&^AMPR;?1B.
M*\$_9ZL7^%OAKX@?$_5;?RKG0;>31M,248)U"7*' ]5&?I53XV?&+3[G]H[2
M_'7A*_\ M]MIMOIY29%:/<\4861/F /J.E;W[7WQO\*>/[/1M \ A$T-I)-8
MU+RXV0/?2@;@00.GY9KQ*6'K1C&DE[LTK^5M_OV/<J8BA.4JTG[T&[?/;[B+
M]HAFN_!G[/[S'S7FT:-I"W\1:<%L_7)KF/VP-(LM#_: UFSTZT@L;1;>S*P0
M1A$!,8R0!QS2?&OXA:)XE\&_""VT:\%Y>^'M'6"^AV.OE3+(&"$D 'IU%=]\
M4K[X/_&#7K7XD:CXTNM-N'M(%U+PM'9,UU+-$H79%)]T!L=2<"M<.IX=4W).
MUI+;ST,J[IXJ4TI*]XO\-2]\1-'L-"_;.^&-OIUG!8VYCTB0Q6\8C4L8\DX'
M&3W-'PST6PU[]L3XHV^I65O?P+%JLBQW$0=0X0D, 1U%<_\ $KXO>$_$7[5/
M@CQCIU]L\.6":?\ :)2CDVXC7#J>,MMZ9 Y[4SX:_%CPMH/[3?C_ ,4WVJ"#
M0M3@U%+2[,3D2F5"(_E R,GU%9.G6]C\+OR6^=S7VM#VK7,K<_Z#_P!G&U\-
M6WP,^*NO^(O#\'B :3<6MQ!;RX4LP)VH6ZA">H'4"NA^'?BBS_:C\&^.O#/B
M#PQH>F:II6F/JNC:AH]F+=H"G_+,XZKC\ZH?LO\ ]@?\,^_&5/%/VI-#E>U2
MXDLQF6+=D!U'?:><54T3Q)\//V=_!'BR7PMXR_X3GQ7XCL3IMK]GLWMX[*%O
MO/(6_B]A4R3E.:2;G=6\MKEJT84Y-I0L[_B9K$_\,&0G'/\ PEC?C\HKTZ\^
M&OBKX.^"?"%A\.O"&CZMJ.HZ?'J.K:YJZ0322R. 1"BR-\J 'L/QKQ!O'F@M
M^R-%X+%^/^$C7Q";TV?EMGR=N-^[&W\,YKL/$'B;P+^T3X4\*2ZWXR_X0+Q=
MH6GIIEREY;R26UY$GW71DZ$8Z&M*E.JOB3MS.^E_33J33K4'I'?E5M4O4S?V
MKO =CHEIX*\3II=EX>UO7;1_[8T6PD5H8;A#C>BJ3M##MTKSCX'?%>?X+_$:
MP\3Q6:ZC#$KV]S:,<>;"XPX![''2J7Q*T/PMX>OK&T\,>*9_%W[LF[O&MFAB
M5\\+&&^8C'4D4WX9V/@W5->EM/&^I7VCZ9- 5@U"QC\TP3=F=.K)Z@<UZ]*"
M6$Y)WDK/UL>%6J-XWFIVB_PN>T^)/@'X(^,6EZOXF^#WB!I[^%'OKOPCJ:A+
MF)>K>4?X@#GU^M4_AW'I?P7_ &>T^)3:-8:[XLUS5)--TY=4A\V&RCC'SOL/
M!<^]:?@.^^%_[-VH7OB[3?'C>._$364UKING:?9201J9$*EYF?L!VK"^'/CG
MPA\0O@W<?#3QWK;>%;BVU-]6TG6Q;M-$'?F2*15Y )Z?6O);K./+JZ::Z:VZ
MKS/9_<*7,VE4:?72_1D'A'XJ1_%+XU?"Z>Z\-:5H^M6NLPK<7VEPB!+M2WR[
MXQP&'J.M=OX/^%=G\2OVKOBO>:CIXUBR\.S76I_V8SA%NY<@11L<CY2W7->=
MV-O\-OAA\3_A_<:+XLG\2-8:JEUJ^K_96BM(H@?E6-"-S$=2?RK9\,_'30/#
M'[0GQ#U.Z>>_\$>+6N;*ZFM5(D\B0C;*@.#D'G'6KJTYN[P\6ERZ??\ U8FC
M4A&RQ,DWS?H>M^$?#?BOXF76K>'_ (F>!?#.C^&;JRG>SOM/6V@DTR94+1['
M1MQ!(QSFO-_V>+?POH/P1^*GB#Q+H%OXD_L*_M6MH74?O)06"*7ZB,L 2!U%
M<EJWPM^&&CV5W=Q_&3^T[58V-K9VNG3?:I3CY4;.%7MDYJI\//'FA:+^SK\3
MO#-[>"'6]8N;-[&UV,3,J$[CG&!CW-1[&3IOD;LW'2S774TE7A&JN9*Z3UNF
M=O\ "Z_T_P#:(^)VI^*/&'A[2[;2/".AR:E<Z;I,/D17>P_NU8 \\D ^PJ[\
M*_C_ &GQ>^(6G^#/%G@GPT/"OB"7['#%8V"0RV!<$(T<@YR#BO,?V</BMIOP
MK\9:@=?MY;CPUKNGR:5J0MQF1(G_ (U'?:><5WW@O2?@_P#!'Q7;^-X_B"WC
M,Z8QGTG1+.QDCFDEYV><S !0O&?7%:8BDJ<YQ<6]%RVZ?\&YAAZWM(0FI):O
MFOV_X8TO@?X!LO#/B[XK:!IT.CZI\0])E-KX<M]="F*95<[V16X,FW&,UYQ\
M1]1\4:M\3O"EAXW\)6?AW6;>ZACG$%B+87B-*OS.J_*WID<53\-V?A?XL:WX
MBUKQ5XV_X0OQ+=Z@UY!));/);2!R6(W)\RL#C';%=G\9OBEX?U*/X7^'K/Q'
M-XQF\+SB2^\37$+)YRF13Y:[OF*J!W]*7+4C5;LY-K71Z:=RN>E*ENDD]-M=
M3K=2\.^#+;]NK7M,URVTVRT>-G^Q6ERHBLS=>2/)60#@*6_"N&_:%U'XAV6F
M_P!C>._!6CZ2K7/F66K:;IZ1#:/^6<<J?*R$8X.34?Q2U7P!\7OVB_%NHW_B
MF;2?#NH8>PUF&U>1/,"*!O3&[;D$<#-:_CKQKX:\'_L_ZA\/+/QP_P 1-0U"
M_ANK=UAD6WTR.,Y(1I.<MZ"E",XU*3LV[):IZ>:?YA4E3G3JI-)7=FK?D>"^
M%=.75_%>BV+<I<7T,;<X&"Z@UZO^V7?&[_:.\3P+N$%BUO90+V5$C4 #\Z\=
MTV^;2]4LKY?O6T\<P_X"P/\ 2O<OVTM/63XP0>*+<^98>)],M-4A=>G*!67\
M"OZUZ5:_UR%_Y6OF>7AVG@YI;J2;]#T7]HOX'R^/_'OAW5)_%GAOP_II\.:;
M',=4OQ'/&JQ?,WEXR>O'K7&_&[XD:%X]^-7P[T[PU=MJ.C^&8[+2HM0="OVE
ME==SC/..!C\:XO\ :<\:Z)\0/B!I.HZ%>#4+.#0;"RDD",N)HXR'7Y@#P:\\
M\(7T&E^+M#O;E_+MK:]AEE?&=JAP2<"N2CA)N@IS=VHNR.ROC8+$.G36C:NS
M[,\;+%\4/%/[0'PQG DU.WNQXAT5&Z^='$GFJGN5QQZ9KQKX1%_A-\!?&OQ$
ME3R]5UK_ (IS1=W##=S<2#_=7^M0^(OC3I^B_M?ZA\1-#NOMVBMJRR>:BLOG
M6[1JD@P1GIGJ*D_:X^+7AOQYX@TC0? >Q?!.BQ/);^4C(LEQ,Y>5MK 'C.!^
M-<L,/67+02]V23?RW7S.VIB*+OB&_>BVEYWZ_(ZK]I+QK>?#CXS?"OQ/IZ)+
M>:7X<TRY2.3[KX3E3[$9%2:U\-?AU^U)J6H:W\/=;;PYX[OMUW<>%=8X2XFQ
ME_)?IR>>_P!!7-?&+QU\//B-\3/ \NHZE>7'ABV\/6NGW]QIL966WF6/!P''
M.UL$\<UJ^ M&^#WP9\76'CI?B=)XK;2G-S8Z-8Z=)#//)CY5=F^51ZT^7V=&
M#BFJB6EEOY,'-5:TU)Q=-N[N]O-'(?LJK>^%?VGO#&G7D+VUT+R73KJW<<C<
MC1NI_6O,_B)IB:)\0/%&GQ@"*UU.YB3;R HE8 ?E7MW[-.I2>/\ ]J&_\<WD
M*VMI8B]U^["GY81M8HN?]XBO _$6K-KWB+5M38?->W<UR?\ @;EL?K7J8?FE
MB9-[\JOZGBXCECA(I;<SMZ'JNB?LQWFMZ/9:@OCOP7:+=0K,+>YU4++'N&=K
M#'##TIVK_LPWVDZ7=WA\>^"KE;>)I?)@U4-(^!G"C')->+;1Z T!!Z"NKV6(
MO?VFGH<WM\-:WLOQ-WP'90ZGX[\.VER1]FN-1MXY=P&-ID&:]<_;@U*YO/VC
M/$-I/D6VGQ6]M:1_PI$(E;CT&2:\+M[B6SN89X&\N:)Q)&P[,#D']*^H/&7B
MGX5_M-P:;KWB/Q/+\//'%K:I:W[36C7%K?!1@2*5'!^O]*Y,2G2Q,*S3<;-:
M:V.K"VK86I0BTI-IZNUT?,%K9RZA=P6ENA>>XD6*-1W9C@#\Z^T/$M[XH^"_
MQ6^$_AS1M!U.]T#PC:1Q:E);6<CQ3RW(_P!*.0,'"G KS/P3#\%O /Q4\*3P
M^)[_ %>UT>22^U#5[JT9+>YD1<PPPQ %A\_5FKD?$W[4WQ,UWQ%JNH6WB[4[
M"WNKF26*UAF*I"A8E5 ]A@?A7+7C4QL[0C[J7735G9AI4\O@W4E[S:VUT1<^
M-/PW;X6_M+3:1&I6QFU6&^LF((S#*X=1_P !)*_A4?[8?_)ROCC_ *^8O_1*
M5T?Q8^+6@?%'PS\*_$U]JF[QOH\BV6MVK1MNEA1PRSEL8/ Z ]6-=)\8/#_P
M7^+'Q+UOQ;_PN9--_M.19?LO]C7#F/"*N,XY^[44:LZ=2$JT7HFGH^YI7HPK
M4ZD:,EJTUJNIQWP1'_&.GQV_ZX:=_P"CFKQ?PSC_ (271\=?MD/_ *&*]S^"
MFL^ -*\,?%KP7K_C0:/IVMO;0Z?K!L99!.D4C'?L4$C(V\''6N7\5^"?AOX-
MCTS4_#?Q,7Q7?1WT)DLAIDMOMC#99]S#MCI[UO&HHU*L6G[VVC['-*BY0HR3
M7N[ZKN>H_$/_ )2$VG_89L/_ $5'5_Q5\&=,TG]H_6_&7BGQWX<T;0;;7)-1
M:"&]$MZVV3<(Q$!D,2,>U<-XP^)_AG5/VRK?QK::D)?#$>J6EP;_ ,IP!&B(
M&.W&[@@]NU>7?&;7=/\ %7Q:\7ZSI4PNM.OM3GN+>?:5WHSDAL'GFL:>'JSE
M"/PKEU_KN=%3%4J<)S^)\VA]"?!+XA0_%;]N2Z\40Q&WLK\77DJ1AA$L!121
MZ[1FO+_'GA/X-VMGK5QH_CK6;[6U>1H+.?2MD;R9^Z6SP/>J_P"RKXWT/X=_
M&K2=;\1WW]G:3%!/'+<F-GVEHV4<*"3R?2M36?A;\))6OKR'XUVTTS&29(?[
M$N06;)(7)'KQ0Z?L,39-J-ELK[=]"8U'B,)>T7)MMW>WH=7\!-"T'Q)^R[\1
M['Q+XA'A?2VU>R9]0-NTX0CHNT<G)K4\?:5I/P+_ &:[O3_!M]-XQTKQQ<(M
MUXF50EO#Y9R(!'DLKGGKBO*O"?CC1-._9H\=>%[B\\O7-1U6SN+6T,;$R1H?
MF;.-HQ[G-:?PA^(OA^3X,^/_ (=>+=0^P6=Y$NI:/<-&T@CO4_@PH.-_'/ '
M-9SHU.>51IM<U[?J;PQ%)4XTM$^6U_T/#RHZ9KZ0_8M7_3/B?_V*5U_2OF]2
M2!ZU[;^S#\0M ^']UX\?7]0%@NI>';BQM<QL_F3-C"?*#C/J>*]C'1<L.U%7
M?_!/"R^2IXE.3TU-3]C'1=!UGQCXO7Q'I\>I:5;^'+J>6)D#-M7!)3/W6QD9
M]ZQM9^+\?Q:\;>#--_X170]!TFQU6%+:'3[;:S0LZKY<IS\_ []R:9^S)X\T
M+P!K'C*?7KX6$=]X<O+&W9HV??,ZC:GR@]?4UYIX'O[?2/&.@WUW)Y5M;7\$
MTKX)VHL@+'CT KC]BYU:DVMDK?<>A[=0HTZ::U;OZ7/9_BS]G\(_M>>((]*\
M(6?B(0W8CL]!,!,,DAB&W]VO7!.['0U[7X9\&^-OB3X3\8:;\3_ASI&D:5'H
MT][IU_9V<5M-:3QKN11L.[!]".WO7GFC_'7P;I'[7'C#Q7->/)X=UJWDLK76
M[>$E[-GC51.JD;N"".F<$U8^&6O_  X^#NK^*KJ\^)]QXNU'6-&O+6WEAM9A
M C.GR^:7Y+L< 8&!SDUY5:-7EBN5W271_P!(]BBZ/-*7,K-O33^F<Q\*\_\
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MN_MS _S?@SX?_5[,/Y/Q1^?VWWHQ[U^@/_#KO3?^A[NO_ !?_BZ/^'7>F_\
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M?ZO9A_)^*/S^V^]&/>OT!_X==Z;_ -#W=?\ @ O_ ,71_P .N]-_Z'NZ_P#
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M?!?ASQ+HVE-#;P^((%MKRXV9F\H')16[!N_K7+>G-?H#_P .N]-_Z'RZ_P#
M!?\ XNC_ (==Z;_T/=W_ . "_P#Q=1'.<!%N2EOY,N61YC)*+CMYH_/['O1C
MWK] ?^'7>F_]#W=_^ "__%T?\.N]-_Z'N[_\ %_^+J_[<P/\WX,R_P!7\?\
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MC_U>S#^3\4?G]M]Z-OO7Z _\.N]-_P"A[NO_   7_P"+H_X==Z;_ -#W=?\
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MO_0]W7_@ O\ \71_;F!_F?W,/]7LP_D_%'Y_8]Z,>]?H#_PZ[TW_ *'NZ_\
M !?_ (NC_AUWIO\ T/=U_P" "_\ Q=']N8'^9_<P_P!7LP_D_%'Y_8]Z,>]?
MH#_PZ[TW_H>[K_P 7_XNC_AUWIO_ $/=U_X +_\ %T?VY@?YG]S#_5[,/Y/Q
M1^?V/>C'O7Z _P##KO3?^A[NO_ !?_BZ/^'7>F_]#W=?^ "__%T?VY@?YG]S
M#_5[,/Y/Q1^?V/>C'O7Z _\ #KO3?^A[NO\ P 7_ .+H_P"'7>F_]#W=?^ "
M_P#Q=']N8'^9_<P_U>S#^3\4?G]CWHQ[U^@/_#KO3?\ H>[K_P  %_\ BZ/^
M'7>F_P#0]W7_ ( +_P#%T?VY@?YG]S#_ %>S#^3\4?G]CWHQ[U^@/_#KO3?^
MA[NO_ !?_BZ/^'7>F_\ 0]W7_@ O_P 71_;F!_F?W,/]7LP_D_%'Y_8]Z,>]
M?H#_ ,.N]-_Z'NZ_\ %_^+H_X==Z;_T/=U_X +_\71_;F!_F?W,/]7LP_D_%
M'Y_8]Z,>]?H#_P .N]-_Z'NZ_P# !?\ XNC_ (==Z;_T/=W_ . "_P#Q=+^W
M,#_,_N8O]7L?_)^*/S^Q[TZ+_71>SK_,5]__ /#KO3?^A[N__ !?_BZ%_P""
M7^G(P(\>70P0?^/!?7/]^IEGF"E%I2_ J&08]23Y/Q1]H>"?^1-T+_KQ@_\
M1:UMU1T/3QI.C6-B'\T6T"0[\8W;5"Y_2KU?F<M6V?K<%:*3"BBBI+"BBB@
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MHH 3:*-HI:* $VBC:*6B@!-HHVBEHH 3:*-HI:* $VBC:*6B@!-HKG/B /\
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M@ HHHH \<\*_\G4?$#_L7=*_]&7->QUXYX5_Y.H^('_8NZ5_Z,N:]CH \/\
MVO?^26Z5_P!C+I'_ *61U[>O2O$/VOO^27Z5_P!C)I'_ *61U[>O2@#XP_;X
MTFZ\)>*OAM\3[6(R0:)J*0W>T=%WATS['#C\J]%_: ^ ,G[3$?@76=*UZWTZ
MTTUQ>AI(C()T?8PQ@C' _6O<_$?AG2O%VDSZ7K6GV^IZ=-CS+>Y0.C8.1P?>
MK&E:7::+I]O865O':V=N@CBAB7"HHZ #L*]%8R480Y?BC?[F>2\#&52HYZQG
M;3S1XG\?OV<;SXR^+OAYK-MK4.FIX7NO/ECEA+F<;XVPN",?ZO\ 6L;]JS]D
MD_M$W^A7]AK,.AW^GHT$LDL!D$T9(('!'(.?SKZ2X]*3:OI65/&5J;BXOX=O
MF:SP%"HI*<?BW^1X1\9OV:A\1/@3I/PYT;4X](BTYK?R[F:$N"L2D8(!')SF
MM7QI^SGI/Q&^!^E?#W7+IR^G6L$4.HVZX:.:) HD"GL>>#V->Q;<"C;4+%5=
M+/9W^97U*@[W6ZM\CXH7]CCXPMH'_"&S?%[/@G_5F'RW,OD_W,?W<?P[L5]-
M_!?X/Z-\$? MEX9T0/)#"6DEN9,;YY6^\[>_8#L !7>D>U+Q5UL95K1Y9/3R
MT)P^ H8>7/!:^;N8WBKPW9>+O#NIZ)?KOLM0MY+68#KM=2#C\Z^2]%_9'^+G
MPXTO4/#'@CXIV]AX1O'8^7<6G[^(-PVTX)!QW##\*^S<4W;4T<54HQ<8O1E8
MC TL0U*>C7;0^;?#?['Z^"?@M>>#_#OB[4-(\075XFH2>((,H[3+T7:&'R8X
MQGWK@M?_ &.?BK\6+JPLOB1\4DU3P_9/N2"SM]K/VR1A1NQ_$<D9K[/_  I=
MHK:..KQ;DGJ^MM3&66X><5%K1=+Z'SA\:OV/=,^(7A_PE%X9U23PMK/A2)(=
M,NE7>NQ""H;&#D,,AAW)X-<A<?LB?$/XJ>(-$N/BU\0H-=T?2)/,BT_3[81^
M:<@G<0%'.,$X)Q7U[M%+M]JF&.KPC9/_ #'++</.7-;Y=#XS_P""@5S_ ,)!
M;_#SX;:;\]]K&I(P@7J(U(0''IRWY&OKSP]I4>@Z#IVFQ*%CM+>.!0/]E0/Z
M5GWW@/P_J/BBS\17>CV=SKMFGEVU_+$&EB7GA6/(ZG\ZZ#IUJ:N(52E"DNGY
MLTHX9TZTZTG\5E\D/HHHKC/0"BBB@ HHHH Y/XM?\DK\9_\ 8%O/_1#USG[,
M/_)O/P]_[ UO_P"@"NC^+7_)*_&?_8%O/_1#USG[,/\ R;S\/?\ L#6__H H
M ]/HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KFV_Y*$G_ &#F_P#1@KI*YMO^2A)_V#F_
M]&"@#I**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N;^('_(LS_\
M72+_ -#%=)7-_$#_ )%F?_KI%_Z&* .BC_U:_04ZFQ_ZM?H*=0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 8/@__CSO/^OR;_T*MVL+P?\ \>=Y
M_P!?DW_H5;M "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% 'CGA7_DZCX@?]B[I7_HRYKV.O'/"O_)U'Q _[%W2O_1ES7L=
M'B'[79Q\+]+X!_XJ32.O_7Y'7MJUXC^U[_R2W2O^QETC_P!+(Z]O7I0 M%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R?Q8.
MWX6>,B1G_B2WAYZ?ZAZYS]F([OV>_A\<;?\ B36_ _W:Z/XM?\DK\9_]@6\_
M]$/7.?LP_P#)O/P]_P"P-;_^@"@#T^BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N;;_DH
M2?\ 8.;_ -&"NDKFV_Y*$G_8.;_T8* .DHHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *YOX@?\BS/_P!=(O\ T,5TE<W\0/\ D69_^ND7_H8H Z*/
M_5K]!3J;'_JU^@IU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!@
M^#_^/.\_Z_)O_0JW:PO!_P#QYWG_ %^3?^A5NT +1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4E+10!XYX3/_&4WQ &!_P B]I7/
M?_67->Q"O'?"O_)U'Q _[%W2O_1ES7L= 'A_[7O_ "2W2O\ L9=(_P#2R.O;
ME^Z*\1_:]_Y);I7_ &,ND?\ I9'7MZ]* %HHHH **** "BBB@ HHHH ****
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M7-%O/#FK7&F7Z"*\MVVR(&W8/UJ(TL,VHJ*NRO:5TFVW8U/^%B^*O^A@U/\
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M^X/K%7^9G0_\+&\5?]##J?\ X$M_C1_PL;Q5_P!##J?_ ($M_C7/44?5J/\
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MSD>@ _6M?2_AY9W4>M:G=ZQ]A\,:;<FV74&BW27#=@B#J:]3\0V]MX47Q/\
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M_9]LXM.LKB_F&M.Q2WC+D#;UX[5S0J?NH0GIRRM_D;3I_O)2CKS1N<_\&?\
MDJ7AL=_M']*N:Y\5O%FC>,-5:WUNZ:."]E"P2-OCVASA2#VI?A;H.IZ'\5/#
M U+3[G3S)<907$3(6XYQFJ>L_#WQ-KOC35HK/0KYO.OI=LLD+)%@N<-N8 8]
MZZJCH3Q#E4LURK\SGBJL:*4--3H_B)X7L_%6K>"=7TJW6P3Q0%CFAC&U5F#
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MI-X@@;=%I\<)*E-W&Y^@8CG%,^(7AR^MO$7A^RU+7#>&\L8'2ZO.%MT;L?\
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MYKV1M0N#+?+MN6,AS,/1_7\:MZ3XTU_0;7[+IVL7EG;?\\HI2%'T';\*L?\
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M*/\ A7?B?_H :A_X#M_A1]8H_P R#V-7^5G/45T/_"O/$_\ T =0_P# =O\
M"HKCP)XBM8S)-HE]%&/XG@8#FCZQ2_F0O8U?Y68=%="/AYXGQ_R -0_\!V_P
MH_X5WXG_ .@!J'_@.W^%'UBC_,A^QJ_RLYZBNA_X5WXG_P"@!J'_ (#M_A1_
MPKOQ/_T -0_\!V_PH^L4?YD'L:O\K.>HKH?^%=^)_P#H :A_X#M_A1_PKOQ/
M_P! #4/_  ';_"CZQ1_F0>QJ_P K.>HKH?\ A7?B?_H :A_X#M_A1_PKOQ/_
M - #4/\ P';_  H^L4?YD'L:O\K.>HKH?^%=^)_^@!J'_@.W^%'_  KOQ/\
M] #4/_ =O\*/K%'^9![&K_*SGJ*Z'_A7?B?_ * &H?\ @.W^%'_"N_$__0 U
M#_P';_"CZQ1_F0>QJ_RLYZBNA_X5WXG_ .@!J'_@.W^%'_"N_$__ $ -0_\
M =O\*/K%'^9![&K_ "LYZBNA_P"%=^)_^@!J'_@.W^%'_"N_$_\ T -0_P#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YMO^2A)_P!@
MYO\ T8*Z2N;;_DH2?]@YO_1@H Z2BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ KF_B!_R+,__ %TB_P#0Q725S?Q _P"19G_ZZ1?^AB@#HH_]6OT%
M.IL?^K7Z"G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[\6O_P ?H_X7WK?_ $2'QS_WXM?_ (_7L%% 'C__  OO6_\ HD/CG_OQ:_\
MQ^C_ (7WK?\ T2'QS_WXM?\ X_7L%% 'C_\ POO6_P#HD/CG_OQ:_P#Q^C_A
M?>M_]$A\<_\ ?BU_^/U[!10!X_\ \+[UO_HD/CG_ +\6O_Q^C_A?>M_]$A\<
M_P#?BU_^/U[!10!X_P#\+[UO_HD/CG_OQ:__ !^C_A?>M_\ 1(?'/_?BU_\
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M?_C]>P44 >/_ /"^];_Z)#XY_P"_%K_\?H_X7WK?_1(?'/\ WXM?_C]>P44
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M[UO_ *)#XY_[\6O_ ,?H_P"%]ZW_ -$A\<_]^+7_ ./U[!10!X__ ,+[UO\
MZ)#XY_[\6O\ \?H_X7WK?_1(?'/_ 'XM?_C]>P44 >/_ /"^];_Z)#XY_P"_
M%K_\?H_X7WK?_1(?'/\ WXM?_C]>P44 >/\ _"^];_Z)#XY_[\6O_P ?H_X7
MWK?_ $2'QS_WXM?_ (_7L%% 'C__  OO6_\ HD/CG_OQ:_\ Q^C_ (7WK?\
MT2'QS_WXM?\ X_7L%% 'C_\ POO6_P#HD/CG_OQ:_P#Q^C_A?>M_]$A\<_\
M?BU_^/U[!10!X_\ \+[UO_HD/CG_ +\6O_Q^C_A?>M_]$A\<_P#?BU_^/U[!
M10!X_P#\+[UO_HD/CG_OQ:__ !^C_A?>M_\ 1(?'/_?BU_\ C]>P44 >/_\
M"^];_P"B0^.?^_%K_P#'Z/\ A?>M_P#1(?'/_?BU_P#C]>P44 >/_P#"^];_
M .B0^.?^_%K_ /'Z/^%]ZW_T2'QS_P!^+7_X_7L%% 'C_P#POO6_^B0^.?\
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M]@HH \?_ .%]ZW_T2'QS_P!^+7_X_1_POO6_^B0^.?\ OQ:__'Z]@HH \?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<W\0/\ D69_^ND7_H8KI*YOX@?\BS/_ -=(O_0Q0!T4
M?^K7Z"G4V/\ U:_04Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M P?!_P#QYWG_ %^3?^A5NUA>#_\ CSO/^OR;_P!"K=H 6BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "N;;_DH2?\ 8.;_ -&"NDKFV_Y*$G_8.;_T8* .
MDHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YOX@?\BS/_P!=(O\
MT,5TE<W\0/\ D69_^ND7_H8H Z*/_5K]!3J;'_JU^@IU !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGA_PDFK?]!2\_P"_[?XT?\))JW_04O/^_P"W^-'^K]3_ )^?@']O1_D/T/\
M,7^^*/,7^^*_/#_A)-6_Z"EW_P!_V_QH_P"$DU;_ *"EY_W_ &_QH_U?J?\
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M7G_?]O\ &E_J_/\ Y^?@']O1_D/T/\Q?[XH\Q?[XK\\/^$DU;_H*7G_?]O\
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MT2_\]6_[Z-'VB7_GJW_?1H^KON'UA=CT;(HR*\Y^T2_\]7_[Z-'VB7_GJ_\
MWT:/J_F'UA=CT;(HR*\Y^T2_\]7_ .^C1]HE_P">K_\ ?1H^K^8?6%V/1LBC
M(KSG[1+_ ,]7_P"^C1]HE_YZO_WT:/J_F'UA=CT;(KG/B 1_PB]S_P!=(O\
MT8M<Y]HE_P">K_\ ?1IDKO,FUW+KW5CD?E1]7?</K"['I$9'EK]!2Y%><?:)
M1_RU8?\  C2_:)?^>K_]]&CZOYB^L+L>C9%&17G/VB7_ )ZO_P!]&C[1+_SU
M?_OHT?5_,?UA=CT;(HR*\Y^T2_\ /5_^^C1]HE_YZO\ ]]&CZOYA]878]&R*
M,BO.?M$O_/5_^^C1]HE_YZO_ -]&CZOYA]878]&R*,BO.?M$O_/5_P#OHT?:
M)?\ GJ__ 'T:/J_F'UA=CT;(HR*\Y^T2_P#/5_\ OHT?:)?^>K_]]&CZOYA]
M878]&R*,BO.?M$O_ #U?_OHT?:)?^>K_ /?1H^K^8?6%V/1LBC(KSG[1+_SU
M?_OHT?:)?^>K_P#?1H^K^8?6%V/1LBC(KSG[1+_SU?\ [Z-'VB7_ )ZO_P!]
M&CZOYA]878]&R*,BO.?M$O\ SU?_ +Z-'VB7_GJ__?1H^K^8?6%V/1LBC(KS
MG[1+_P ]7_[Z-'VB7_GJ_P#WT:/J_F'UA=CT?</6C</45YQ]HE_YZM_WT::U
MQ-_SU?T^\:7U=VW%]8UV/2J*@L3NLH#_ + Z_2IZY3K6JN%%%%(84444 %%%
M% !1110 4444 %%%% !1110!@^#_ /CSO/\ K\F_]"K=K"\'_P#'G>?]?DW_
M *%6[0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@V74/!.J>(UN(UAL+A+=H"OS-N'7/M7.\>E>UW'_  CLOP-\27/AT7,$,U]
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M:2&?[%&MUAX?F.=QQ\W-<[HOA3PAIOPWT;Q3KYN9IIIY8C96[X-T0?E /\(
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MI>*]7L+K71;W"VRZ=9R&,KD9,CL,D#G]*TCCHI.;U6EEZ^8?59-I+S_ \_\
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MX1^"?B73[N_M9M5DOH))[6WD#^1Z*2.K8Y([5Y#9W)L[RWN N_R94EVCJ=K
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MA657X'Z%T_C7J?8WX]J/QH_#M1^%?G#W/OUL'XT?C1^%'X4AA^-'XT?A1^%
M!^-'XT?A1^% !^-'XT?A1^% !^-'XT?A1^% !^-'XT?A1^% !^-'XT?A1^%
M!^-'XT?A1^% !^-'XT?A1^% !^-'XT?A1^% !^-'XT?A1^% !^-'XT?A1^%
M!^-'XT?A1^% !^-'XT?A1^% !^-'XT?A1^% !^-'XT?A1^% !^-'XT?A1^%
M!^-'XT?A1^% !^-(U+^%(W?B@.IZ-8_\>4'^XO\ *IZ@L?\ CR@_W%_E4]>0
M]SUH[(****104444 %%%% !1110 4444 %%%% !1110!@^#_ /CSO/\ K\F_
M]"K=K"\'_P#'G>?]?DW_ *%6[0 M%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!XYX5_Y.H^('_8NZ5_Z,N:]CKQSPK_R=1\0
M/^Q=TK_T9<U['0!X?^U[_P DMTK_ +&72/\ TLCKV]?NBO$/VO?^26Z5_P!C
M+I'_ *61U[<OW10 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH Y/XL?\DK\9?\ 8%O?_1#U\#_!OX3^+[[X4^%+B#0+R6"7
M3XG1U3(*D<$?A7WQ\6?^25^,_P#L"WO_ *(>N:_9A_Y-Z^'O_8&M_P#T&O1P
M>.G@FW!7N>?C,%#&)*;M8^7?^%.^-?\ H6[W_OW1_P *=\:_]"W>_P#?NOO'
MBCBO6_M_$?RH\O\ L.C_ #,^#O\ A3OC7_H6[W_OW1_PIWQK_P!"W>_]^Z^\
M>*.*/[?Q'\J#^PZ/\S/@[_A3OC7_ *%N]_[]T?\ "G?&O_0MWO\ W[K[QXHX
MI_ZP8C^5!_8='^9GP=_PIWQK_P!"W>_]^Z/^%.^-?^A;O?\ OW7WCQ1Q2_M_
M$?RH?]AT?YF?!W_"G?&O_0MWO_?NC_A3OC7_ *%N]_[]U]X\4<4?V_B/Y4']
MAT?YF?!W_"G?&O\ T+=[_P!^Z/\ A3OC7_H6[W_OW7WCQ1Q1_;^(_E0?V'1_
MF9\'?\*=\:_]"W>_]^Z/^%.^-?\ H6[W_OW7WCQ1Q1_;^(_E0?V'1_F9\'?\
M*=\:_P#0MWO_ '[H_P"%.^-?^A;O?^_=?>/%'%']OXC^5!_8='^9GP=_PIWQ
MK_T+=[_W[H_X4[XU_P"A;O?^_=?>/%'%']OXC^5!_8='^9GP=_PIWQK_ -"W
M>_\ ?NC_ (4[XU_Z%N]_[]U]X\4<4?V_B/Y4']AT?YF?!W_"G?&O_0MWO_?N
MC_A3OC7_ *%N]_[]U]X\4<4?V_B/Y4']AT?YF?!W_"G?&O\ T+=[_P!^Z/\
MA3OC7_H6[W_OW7WCQ1Q1_;^(_E0O[#H_S,^#O^%.^-?^A;O?^_='_"G?&O\
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MNC_A3OC7_H6[W_OW7WCQ1Q1_K!B/Y4']AT?YF?!W_"G?&O\ T+=[_P!^Z/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7-M_P E"3_L'-_Z,%=)7-M_R4)/^P<W_HP4 =)1110 4444 %%%% !1110
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<W\0/\
MD69_^ND7_H8KI*YOX@?\BS/_ -=(O_0Q0!T4?^K7Z"G4V/\ U:_04Z@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH P?!_P#QYWG_ %^3?^A5NUA>
M#_\ CSO/^OR;_P!"K=H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH \<\*_\G4?$#_L7=*_]&7->QUXYX5_Y.H^('_8NZ5_
MZ,N:]CH \/\ VO?^26Z5_P!C+I'_ *61U[<OW17A'[9EY_9WP=MKLP37/V?7
M]+E\FW3?))MNXSM5>['L*L?\-30#_FFGQ#_\)^3_ !H ]QHKP[_AJB#_ *)I
M\0__  GY/\:/^&J(/^B:?$/_ ,)^3_&@#W&BO#O^&J(/^B:?$/\ \)^3_&C_
M (:H@_Z)I\0__"?D_P : /<:*\._X:H@_P"B:?$/_P )^3_&C_AJB#_HFGQ#
M_P#"?D_QH ]QHKP[_AJB#_HFGQ#_ /"?D_QH_P"&J(/^B:?$/_PGY/\ &@#W
M&BO#O^&J(/\ HFGQ#_\ "?D_QH_X:H@_Z)I\0_\ PGY/\: /<:*\._X:H@_Z
M)I\0_P#PGY/\:/\ AJB#_HFGQ#_\)^3_ !H ]QHKP[_AJB#_ *)I\0__  GY
M/\:/^&J(/^B:?$/_ ,)^3_&@#W&BO#O^&J(/^B:?$/\ \)^3_&C_ (:H@_Z)
MI\0__"?D_P : /<:*\._X:H@_P"B:?$/_P )^3_&C_AJB#_HFGQ#_P#"?D_Q
MH ]QHKP[_AJB#_HFGQ#_ /"?D_QH_P"&J(/^B:?$/_PGY/\ &@#W&BO#O^&J
M(/\ HFGQ#_\ "?D_QH_X:H@_Z)I\0_\ PGY/\: /1?BU_P DK\9?]@6]_P#1
M#US?[+__ ";S\/?^P-;_ /H KSSXA_M+0:K\/_$]D/AWX^MC<Z7=1":XT%UC
MCW1,-S'/"C.2>PS6)\!_VBH?#7P9\&:4W@#QSJ#6FF0PFZL=$>6"7"_>1L_,
MI[&@?0^KJ*\._P"&J(/^B:?$/_PGY/\ &C_AJB#_ *)I\0__  GY/\:!'N-%
M>'?\-40?]$T^(?\ X3\G^-'_  U1!_T33XA_^$_)_C0![C17AW_#5$'_ $33
MXA_^$_)_C1_PU1!_T33XA_\ A/R?XT >XT5X=_PU1!_T33XA_P#A/R?XT?\
M#5$'_1-/B'_X3\G^- 'N-%>'?\-40?\ 1-/B'_X3\G^-'_#5$'_1-/B'_P"$
M_)_C0![C17AW_#5$'_1-/B'_ .$_)_C1_P -40?]$T^(?_A/R?XT >XT5X=_
MPU1!_P!$T^(?_A/R?XT?\-40?]$T^(?_ (3\G^- 'N-%>'?\-40?]$T^(?\
MX3\G^-'_  U1!_T33XA_^$_)_C0![C17AW_#5$'_ $33XA_^$_)_C1_PU1!_
MT33XA_\ A/R?XT >XT5X=_PU1!_T33XA_P#A/R?XT?\ #5$'_1-/B'_X3\G^
M- 'N-%>'?\-40?\ 1-/B'_X3\G^-'_#5$'_1-/B'_P"$_)_C0![C17AW_#5$
M'_1-/B'_ .$_)_C1_P -40?]$T^(?_A/R?XT >XT5X=_PU1!_P!$T^(?_A/R
M?XT?\-40?]$T^(?_ (3\G^- 'N-%>'?\-40?]$T^(?\ X3\G^-'_  U1!_T3
M3XA_^$_)_C0![C17AW_#5$'_ $33XA_^$_)_C1_PU1!_T33XA_\ A/R?XT >
MXT5X=_PU1!_T33XA_P#A/R?XT?\ #5$'_1-/B'_X3\G^- 'N-%>'?\-40?\
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M#_HFGQ#_ /"?D_QH_P"&J(/^B:?$/_PGY/\ &@#W&BO#O^&J(/\ HFGQ#_\
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MFGQ#_P#"?D_QH ]QHKP[_AJB#_HFGQ#_ /"?D_QH_P"&J(/^B:?$/_PGY/\
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MMTK_ +&72/\ TLCKV]?NB@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#D_BS_R2OQG_P!@6]_]$/7-_LP?\F\_#W_L#6__
M * *Z3XM?\DK\9_]@6\_]$/7.?LP_P#)O/P]_P"P-;_^@"@#T^BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ I,>]+10 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4E+10!@^$2?L5YDY_TR;_T*MZL'P?_ ,>=Y_U^3?\
MH5;M "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'CGA/_DZGX@?]B[I/_HRYKV.O'/"?_)U/Q!_[%[2?_1ES7L= 'A_[7O_
M "2W2O\ L9=(_P#2R.O;E^Z*\1_:]_Y);I7_ &,ND?\ I9'7MR_=% #J***
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M %%%% !1110 4444 %%%% !7-M_R4)/^P<W_ *,%=)7-M_R4)/\ L'-_Z,%
M'24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<W\0/^19G_ZZ1?\
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M_P"#&7_XJN5HK3ZO2_E1G]8K?S,ZK_A:WC?_ *&_7?\ P8R__%4?\+6\;_\
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M#)_V%)_Y+7@\0?[I\T?1<-?[]\F?5E%%%?FI^L!1110 4444 %%%% !1110
M4444 %%%% !7-M_R4)/^P<W_ *,%=)7-M_R4)/\ L'-_Z,% '24444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %<W\0/^19G_ZZ1?\ H8KI*YOX@?\
M(LS_ /72+_T,4 =%'_JU^@IU-C_U:_04Z@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=6!6"('J"$%3YI:,T7;W*45'86BBBD,**** "BBB@ HHHH Y3XK?\DO\8?\
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M,H4LS*.@8\#Z>E+)(\K N[.1P"QR:[W_ (9_^)/_ $(NO_\ @#)_A1_PS_\
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MGO) L/BEJHLX K^/KFIY+^[F@$,EU.\2](VE8K^6:[?_ (9_^)7_ $(NO?\
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MF_\ 0JW:PO!__'G>?]?DW_H5;M "T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'CGA/_ ).I^(/_ &+VD_\ HRYKV.O'/"O_
M "=1\0/^Q=TK_P!&7->QT >'_M>_\DMTK_L9=(_]+(Z]N7[HKQ']KW_DENE?
M]C+I'_I9'7MZ_=% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% ')_%K_DE?C/\ [ M[_P"B'KF_V80#^SS\/<C_ )@UO_Z
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M "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M')_%K_DE?C/_ + MY_Z(>N<_9A_Y-Y^'O_8&M_\ T 5T?Q:_Y)7XS_[ MY_Z
M(>N<_9A_Y-Y^'O\ V!K?_P! % 'I]%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<VW_)0D
M_P"P<W_HP5TE<VW_ "4)/^P<W_HP4 =)1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5S?Q _Y%F?_ *Z1?^ABNDKF_B!_R+,__72+_P!#% '11_ZM
M?H*=38_]6OT%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,'P?
M_P >=Y_U^3?^A5NUA>#_ /CSO/\ K\F_]"K=H 6BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH \<\)_\ )U/Q!_[%[2?_ $9<
MU['7CGA7_DZCX@?]B[I7_HRYKV.@#PO]L)I8?A!!=);75W'9Z[IEU-'9P/-(
M(DNHV8A%!8X )X%1_P##:'P[7_EW\5?^$S??_&J]V^6C:OH/RH \)_X;2^'?
M_/OXJ_\ "9OO_C5'_#:'P\_Y]_%7_A,WW_QJO=OE]J7:/04 >$?\-I?#O_GW
M\5?^$S??_&J/^&TOAW_S[^*O_"9OO_C5>[87T_2C:/3]* /"?^&TOAW_ ,^_
MBK_PF;[_ .-4?\-H?#S_ )]_%7_A,WW_ ,:KW;Y>V*7:/04 >$?\-H?#S_GW
M\5?^$S??_&J/^&T/AY_S[^*O_"9OO_C5>[[1Z"C:/04 >$?\-H?#S_GW\5?^
M$S??_&J/^&T/AY_S[^*O_"9OO_C5>[[1Z"C:/04 >$?\-I?#O_GW\5?^$S??
M_&J/^&T/AY_S[^*O_"9OO_C5>[87T%+M'H* /"/^&T/AY_S[^*O_  F;[_XU
M1_PVA\//^??Q5_X3-]_\:KW?:/04;1Z"@#PC_AM#X>?\^_BK_P )F^_^-4?\
M-H?#S_GW\5?^$S??_&J]WVCT%&T>@H \(_X;0^'G_/OXJ_\ "9OO_C5'_#:'
MP\_Y]_%7_A,WW_QJO=]H]!1M'H* /"/^&T/AY_S[^*O_  F;[_XU1_PVA\//
M^??Q5_X3-]_\:KW?:/04;1Z"@#PC_AM#X>?\^_BK_P )F^_^-4?\-H?#S_GW
M\5?^$S??_&J]WVCT%&T>@H ^:?'O[7'@3Q!X%\1Z796GBF2\OM-N;6%&\-7H
M#.\3*HSY6!R16-\$?VI/!G@?X0^$?#VKV7BB'5--TV&VN8T\.7KA9%7!&X1X
M-?5^T>@I-J^@H \)_P"&T?AW_P ^_BK_ ,)F^_\ C5'_  VE\._^??Q5_P"$
MS??_ !JO=MJ^@H&T]A0!X3_PVA\//^??Q5_X3-]_\:H_X;2^'?\ S[^*O_"9
MOO\ XU7N^T>@I/E]/TH \)_X;2^'?_/OXJ_\)F^_^-4?\-H_#O\ Y]_%7_A,
MWW_QJO=MH]!^5 "GL* /"?\ AM#X>?\ /OXJ_P#"9OO_ (U1_P -H?#S_GW\
M5?\ A,WW_P :KW?:/04;1Z"@#PC_ (;0^'G_ #[^*O\ PF;[_P"-4?\ #:'P
M\_Y]_%7_ (3-]_\ &J]WVCT%&T>@H \(_P"&T/AY_P ^_BK_ ,)F^_\ C5'_
M  VC\._^??Q5_P"$S??_ !JO=]H]!3&9(U+,54 9);@ 4 >%_P##:/P[_P"?
M?Q5_X3-]_P#&J/\ AM'X=_\ /OXJ_P#"9OO_ (U7NJ['4,NU@>012[1Z#\J
M/"?^&TOAW_S[^*O_  F;[_XU1_PVC\//^??Q5_X3-]_\:KW;Y?04NT>@H \(
M_P"&T/AY_P ^_BK_ ,)F^_\ C5'_  VA\//^??Q5_P"$S??_ !JO=]H]!1M'
MH* /"/\ AM'X=_\ /OXJ_P#"9OO_ (U1_P -H?#S_GW\5?\ A,WW_P :KW0M
M'OV97=UV\9^M/VCT% 'A'_#:'P\_Y]_%7_A,WW_QJC_AM#X>?\^_BK_PF;[_
M .-5[OM'H*-H]!0!X1_PVA\//^??Q5_X3-]_\:H_X;0^'G_/OXJ_\)F^_P#C
M5>[[1Z"C:/04 >$?\-H?#S_GW\5?^$S??_&J/^&T/AY_S[^*O_"9OO\ XU7N
M^T>@HVCT% 'A'_#:7P[_ .??Q5_X3-]_\:H_X;2^'?\ S[^*O_"9OO\ XU7N
MVT>@_*C"^@H \)_X;2^'?_/OXJ_\)F^_^-4?\-I?#O\ Y]_%7_A,WW_QJO=M
MJ^@HVKZ"@#PG_AM#X>?\^_BK_P )F^_^-4?\-I?#O_GW\5?^$S??_&J]WVCT
M%)\N<8_2@#PG_AM#X>?\^_BK_P )F^_^-4?\-H?#S_GW\5?^$S??_&J]WVCT
M%&T>@H \(_X;0^'G_/OXJ_\ "9OO_C5'_#:'P\_Y]_%7_A,WW_QJO=]H]!1M
M'H* /"/^&T/AY_S[^*O_  F;[_XU1_PVA\//^??Q5_X3-]_\:KW?:/04;1Z"
M@#PC_AM#X>?\^_BK_P )F^_^-4I_;0^'@4$V_BK!_P"I9OO_ (U7NVT>@HVC
MT% 'A'_#:'P\_P"??Q5_X3-]_P#&J/\ AM#X>?\ /OXJ_P#"9OO_ (U7N^T>
M@HVCT% 'A'_#:'P\_P"??Q5_X3-]_P#&J/\ AM#X>?\ /OXJ_P#"9OO_ (U7
MN^T>@HVCT% 'A'_#:'P\_P"??Q5_X3-]_P#&J/\ AM+X=_\ /OXJ_P#"9OO_
M (U7N^T>@I/E]!0!X3_PVE\._P#GW\5?^$S??_&J/^&TOAW_ ,^_BK_PF;[_
M .-5[MA?3]* %/8?E0!X3_PVA\//^??Q5_X3-]_\:H_X;0^'G_/OXJ_\)F^_
M^-5[OM'H*-H]!0!X1_PVA\//^??Q5_X3-]_\:H_X;0^'G_/OXJ_\)F^_^-5[
MOM'H*-H]!0!X1_PVA\//^??Q5_X3-]_\:H_X;0^'G_/OXJ_\)F^_^-5[OM'H
M*-H]!0!X1_PVA\._^??Q5_X3-]_\:K&/[7?@(^+5U#[-XI^S_8S"3_PC5]D-
MN!_YY>U?2&T>@HVCT% 'A'_#:'P\_P"?;Q5_X3%]_P#&J/\ AM'X=_\ /OXJ
M_P#"9OO_ (U7N^T>@J-Y(X^794&<?,0* /#/^&T/AY_S[^*O_"9OO_C5'_#:
M'P\_Y]_%7_A,WW_QJO=]H]!1M'H* /"/^&T/AY_S[^*O_"9OO_C5'_#:'P\_
MY]_%7_A,WW_QJO=]H]!1M'H* /"/^&T/AY_S[^*O_"9OO_C5'_#:'P\_Y]_%
M7_A,WW_QJO=]H]!1M'H* /"/^&T/AY_S[^*O_"9OO_C5'_#:'P\_Y]_%7_A,
MWW_QJO=]H]!1M'H* /"/^&TOAW_S[^*O_"9OO_C5'_#:'P\_Y]_%7_A,WW_Q
MJO='>./[Q5><#-/VCT'Y4 >$?\-H?#S_ )]_%7_A,WW_ ,:H_P"&T/AY_P ^
M_BK_ ,)F^_\ C5>[[1Z"C:/04 >$?\-H?#S_ )]_%7_A,WW_ ,:H_P"&T/AY
M_P ^_BK_ ,)F^_\ C5>[[1Z"C:/04 >$?\-H?#S_ )]_%7_A,WW_ ,:H_P"&
MT/AY_P ^_BK_ ,)F^_\ C5>[[1Z"C:/04 >$?\-H?#S_ )]_%7_A,WW_ ,:H
M_P"&T/AY_P ^_BK_ ,)F^_\ C5>[[1Z"C:/04 >$?\-H?#S_ )]_%7_A,WW_
M ,:H_P"&T/AY_P ^_BK_ ,)F^_\ C5>[[1Z"C:/04 >$?\-H?#S_ )]_%7_A
M,WW_ ,:H_P"&T/AY_P ^WBK_ ,)F^_\ C5>[[1Z"C:/2@#PC_AM#X>?\^_BK
M_P )F^_^-4?\-H?#S_GW\5?^$S??_&J]WVCT%&T>@H \(_X;0^'G_/OXJ_\
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MC)_Z%7J993C6Q4835TSR\RJ2IX:4H.S.;_X:D\:^MC_WX/\ C7J/P!^+VO\
MQ&UW4[35S;&*WMUD3R8]IW$D'/-?*->\?LC_ /(V:W_UZ)_Z$:^LS' X>EA9
MSA!)H^7P&,KU,3"$Y.S/JH=*\&^-'CKQ-XB^)NB?"7P+JJZ#JM_9OJ>LZ\(A
M+)I]DK;0(E/'FNV0"1P.:]ZKYHTN3_A'?V^->34&\L>(O"5NVFM)P',$A$J*
M>YYSBOS\^\-BQ_9Q\5>"]2L=4\,?%WQ1<7D<L9N[/Q)*E]:7D>[,BE=H*$C.
M"I&#BO2?B%\7O"7PLCM&\2ZQ'82WC;;:U5&EN)R.NR- 6;\!792L$7<Q"J.I
M8XKYV\ Q1:]^V=\4;G5(TGO-$TG3;;2?.7)@MY4+RM'GIN?J1UQB@#T_X>_&
MSP;\5+F]M?#>L+=W]E@W-C-$\%Q"#T9HY%# >^,54\3?M > O"&H:A8:EK\:
M:E83I:S:?#$\MSYC)O55C52S_*0?E! [UY_\8K.+2_VH/@MJFEQ1QZU?O?V%
M^T8P\MB(0YWXZJKX(SW-,^#?A32+C]I[XW>(YK"&76[>YL+."\=<O%";5695
M],GKZT#.Y7]ICX;2>&;?78_$T,]I<7+6<4$,4CW3SK]Z(0!?,W#N-O%=-X$^
M)_AGXE:#-J_AW5([^R@D:*X^5DD@D499)$8!D8>A%>*?!OP+H-K^UK\;-8BT
MNW74HSIXCN/+&Z/S8 TA7T+'&2.34'PMQ8?M4?M V%NBPVTECIUXT:<*96@8
M,Y'J0!S0!WMU^UE\+;>UM[F/Q-]MCFC,N+&TFN&C0,5+.J(2@R#RV.E2?&7Q
M7IGC#]F7QMKF@ZC%J.FW7A^[EM[RUDRKCRFY!'0BN*_8'\.:1I?[.VE75E8V
M\5UJ5W=S7TR*"TTGGN/G/TXQVKS3X>HNG_ /]J+2;'"Z!I^L:PFG(A^1%:+<
MZKV W$\"@-3Z.^$?B"Q\-_L\^#M7UF_BLM.M= M9KF\NG"HBB)<LQ-0^%OVF
M/AUXPUZST?3M>9+Z^.VR%Y:36R79QG$3R(JN<<X!YKYW^,\^I3?L^?LY:19V
M]O>6>IZGI45U:WLIBMKC;!NCCE8 G86'3!Z"N^^,GPY^+WQE\&IX=NO#WA#1
MO)O+:\M=1M=2F>6T>*16#QCRAS@$=>] %CXD?M=Z7X$_:*\.>"I;M%T)K.\;
M6)&L)WFBN$"^6$(7YE.3DJ"/>O9-6^+?A+P]X(M_%NJ:S%IV@W 7R;FZ5HVD
M+?=54(W%CV4#->-?$*.1/VU_@RDIWR?\(]J@D;'#-A,FJ7[0AUS4?VHOA+IN
MF:9I>L?9=-U'4K.SUFX:"V^UIM42 JK9=5)P,=S0(]?\!_'[P/\ $C6GT;1-
M88ZNL1G^P7MM+:SO&#@NJ2*I9<]QFK?Q$^-7@[X6W%G:^(M7%K?7@9K>QMX7
MN+B51U811JS8'KC%>5Z_\/?BG\0OB-\/=>UC1_"^@CPSJGVR6^TZ_EFN)+=D
M*R0 &->&R,Y/:IOA+##K'[5_QHU/4HD;5M-BTW3[(R %H[,Q%R5] SYSCKB@
M>AE>$_B1HGQ(_; TS4O#>LIJFE-X-F5UB8CRY!=#*R(<%7'H0#7T]7S3:^'=
M(T7]O5[K3;.VL[O4O!K37K6ZA6FD%P '?'?'<\FOI:@0M%%% !1110 4444
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MD525]P*\W\<>%]%\2?MI>!I-7L;>^ET_PO=W5DMP WES"=!O4'JP&<>E2_M
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;VX^,/B#1=4@M%:XL[/Q%<6TUO<8RT<=GGY=K94(%QP*^]]O.:QG\&:!)?\
MVYM#TUKW=N^T&TC,F?7=C.:!G"?LQ:OXJUSX*>'[WQG]J;6I5D/F7T7E7$D
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MM<\3ZOHM]!>V,TBQ00P>6X8JL**%R^ "QR<=#7T'2T4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
L !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" #_ E@# 2(  A$! Q$!_\0
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M *"EU^4?_P 11Y=W_P!!2Z_*/_XBI:*.5!S,IWK7UO8SS)J=SOC0L,B/&?\
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M#14MW9:5D%G_ ,A/4/\ ?C_] %7JHV?_ "$]0_WX_P#T 5>I#"BBB@ HHHH
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MUD_[[-.^RW/_ #[3?]^S_A1]EN?^?:;_ +]G_"C0/>&^;+_SUD_[[-'FR_\
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M_P"^S1YLO_/63_OLT[[+<_\ /M-_W[/^%'V6Y_Y]IO\ OV?\*/=#WAOFR_\
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MJ06DDR.L@9B;=PY. 3M'N<8'UJ_JM*U[LCZY6O:R/7?^%C>%_P#H(G_OR_\
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M]\+_ /%4?\+8T3_GSOO^^%_^*H]A5_E#ZS1_F.ZHKA?^%L:)_P ^=]_WPO\
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M37]O*D+\HBL"<@C^M14Q%-P:3-*6&JQJ)M'HE%%%>0>V%%%% !1110 4444
M%%%% !1110 4444 4;O_ )"=A_O2?^@T47?_ "$[#_>D_P#0:* "S_Y">H?[
M\?\ Z *O5DQV:7&JW[-+.F&C&(YF0?<'8&K/]EQ_\_%Y_P"!+_XT 7:*I?V7
M'_S\7G_@2_\ C1_9<?\ S\7G_@2_^- %VBJ7]EQ_\_%Y_P"!+_XT?V7'_P _
M%Y_X$O\ XT 7:*I?V7'_ ,_%Y_X$O_C1_9<?_/Q>?^!+_P"- %VBJ7]EQ_\
M/Q>?^!+_ .-']EQ_\_%Y_P"!+_XT 7:*I?V7'_S\7G_@2_\ C1_9<?\ S\7G
M_@2_^- %VBJ7]EQ_\_%Y_P"!+_XT?V7'_P _%Y_X$O\ XT 7:HZ5_JKC_KZE
M_P#0S2_V7%_S\7G_ ($O_C5+3--C:*?_ $B[&+F4<7#C^(^] &U15+^RX_\
MGYO/_ E_\:/[+C_Y^+S_ ,"7_P : +M%4O[+C_Y^+S_P)?\ QH_LN/\ Y^+S
M_P "7_QH NT52_LN/_GXO/\ P)?_ !H_LN/_ )^+S_P)?_&@"[15+^RX_P#G
MXO/_  )?_&C^RX_^?B\_\"7_ ,: +M%4O[+C_P"?B\_\"7_QH_LN/_GXO/\
MP)?_ !H NT52_LN/_GXO/_ E_P#&C^RX_P#GXO/_  )?_&@"[253_LN/_GXO
M/_ E_P#&C^RXO^?B\_\  E_\: +,'^HC_P!T5)6?#ID9A0_:+O[H_P"7E_\
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MEQ_\_%Y_X$O_ (T?V7'_ ,_%Y_X$O_C0!=HJE_9<?_/Q>?\ @2_^-']EQ_\
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M$4;E'M[-6'56B8$?K3?^%JZ__P \K+_OVW_Q5/ZI5#Z[2/8**\?_ .%JZ_\
M\\K+_OVW_P 51_PM3Q!_SQLO^_;?_%4?5*HOKM$]@HKQ_P#X6IX@_P">-E_W
M[;_XJC_A:GB#_GC9?]^V_P#BJ/JE4/KM$]@HKQ__ (6IX@_YXV7_ '[;_P"*
MH_X6IX@_YXV7_?MO_BJ/JE4/KM$]@HKQ_P#X6IX@_P">-E_W[;_XJC_A:GB#
M_GC9?]^V_P#BJ/JE4/KM$]<@_P!1'_NBI*\>7XIZ^JA1#98 Q_JV_P :7_A:
MGB#_ )XV7_?MO_BJ/JE4/KM$]@HKQ_\ X6IX@_YXV7_?MO\ XJC_ (6IX@_Y
MXV7_ '[;_P"*H^J50^NT3V"BO'_^%J>(/^>-E_W[;_XJC_A:GB#_ )XV7_?M
MO_BJ/JE4/KM$]@HKQ_\ X6IX@_YXV7_?MO\ XJC_ (6IX@_YXV7_ '[;_P"*
MH^J50^NT3V"BO'_^%J>(/^>-E_W[;_XJC_A:GB#_ )XV7_?MO_BJ/JE4/KM$
M]@HKQ_\ X6IX@_YXV7_?MO\ XJC_ (6IX@_YXV7_ '[;_P"*H^J50^NT3V"B
MO'_^%J>(/^>-E_W[;_XJC_A:GB#_ )XV7_?MO_BJ/JE4/KM$]<G_ -0_^Z:D
MKR&/XH:]/*D+0V6V1PIQ&W0G'K7IYO)02,+P?2LIT)PW-J>(A4^$OT50^VS>
MB_E1]MF]%_*L^1FO,B_15#[;-Z+^5'VV;T7\J.5AS(OT50^VS>B_E1]MF]%_
M*CE8<R+]%4/MLWHOY4?;9O1?RHY&',B_15#[;-Z+^5'VV;T7\J.1ASHOT50^
MVS>B_E1]MF]%_*CE8<R+]13]$_WU_G57[;-Z+^5(+F25XU8+@N.E'*PYD:%%
M%%24%%%% !1110 4444 %%%% !1110 4444 4;O_ )"=A_O2?^@T47?_ "$[
M#_>D_P#0:* *[PM</K,*8WR(%7/J8\5SH\*:M&Z36[0Q3-!!:R-O_P"67EA9
M,>X(!%=59_\ (3U#_?C_ /0!5ZKC-QV,YTU+<XV#P[J6F1@6EK#*IM[BV$?F
M[=BO(61LXY&.HJS?^']2;1+2RCN%G%MY&(U 1DV#!9&.03_O#%=313]I*]Q*
ME%*QQ]CX?U2TETPQPQ0RPHB7$H=60Q@L=H4C.[YNH(&:M^%M(U32GDCNV46Z
MQA0-P8N^XDN" " 01P<\UTE+0ZC:L"I13N@HHHK,U"BBB@ HHHH **** "O#
M-4NH[+Q_J5Q+NV+=R@LHRR9! 8>XSG\*]SKCAX#T+6+J\OKN*<S2W4NXK,0/
MO$=*Z*%2,)/F.;$TI5(I1[GFUC=Z=9B5995O)#MV231,5V\[DP<GG(]*D&IZ
M=(8MY9&0)AO+SC;#MQR#QN]O>O1_^%8^&?\ GC<?]_VH_P"%8^&?^>-Q_P!_
MVKJ^L4O,X_JU;R/--1OM.GAN!8[(-\C,4-N"9 0N,'^'!#>G6B#4K:&SMR9Y
M&>*TE@:V"':Y8MC)Z8^8'UXKTO\ X5AX9_YXW'_?]J/^%8>&?^>-S_W_ &H^
ML4K6U#ZK6O?0\Z&I:.7S+$&C%R)!&L."Z\9W$]AC@ ^U+%J6D^=*\ZHVY A"
M0<2#:W/(R&R5]!Q7HG_"L?#/_/&X_P"_[4?\*P\,_P#/&X_[_M2]O2\Q_5JW
MD><PZCI2B)G5/.$ 0$0_NXV!7G&,Y(#9Z]>.M8MRZ27,LD:*B,Y*J@( &>@S
MVKV'_A6/AG_GC<?]_P!J3_A6/AK_ )XW'_?]JJ.*I1[D2PE:2Z'C5%>R_P#"
ML?#7_/&X_P"_YH_X5CX:_P">-Q_W_-7]<I^9'U&KY'C5%>R_\*Q\-?\ /&X_
M[_FC_A6/AK_GC<?]_P T?7*?F'U&KY'C5%>R_P#"L?#7_/&X_P"_YH_X5CX9
M_P">-Q_W_:CZY3\P^HU?(\:HKV./X9^&GB5C#<9(S_KS3O\ A6/AK_GC<?\
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M^<?\M4]?K0!H452^UWG_ $#)?^_J?XT?:[S_ *!DO_?U/\: +M%4OM=Y_P!
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M4X89TNI=R,3D98FFDWL)R2W9TE%8/_"<>&?^@S;_ )G_  H_X3CPS_T&;?\
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M(P(1%)P!@>_4\U>H I?V18_\\/\ Q]O\:/[(L?\ GA_X^W^-7:* *7]D6/\
MSP_\?;_&C^R+'_GA_P"/M_C5VB@"E_9%C_SP_P#'V_QH_LBQ_P">'_C[?XU=
MHH I?V18_P#/#_Q]O\:/[(L?^>'_ (^W^-7:* *7]D6/_/#_ ,?;_&C^R+'_
M )X?^/M_C5VB@"E_9%C_ ,\/_'V_QH_LBQ_YX?\ C[?XU=HH I'2+ \&W_\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" !. ,$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V4TPN .E.
M8<5RGB[Q>FC1&TM&$E](.!VC']XU4(2F[(SJ5(TX\TC8DURPBU=-+:XC%PZ[
M@N>?I5N[O(;*VDN)F"H@R<FO!;IIKJY$QE=KEVW>;GG=['M6]=:KJ6IV<%M?
MW)E6)<8'\7^]ZUW+!2;7XGERS.*BV_D>NV5TEY:Q7$?W9%!%6*Y3P%?_ &G1
MS;,V7MFV\^G:NJ%<52#A-Q/2H5/:4U,"<4@8'BHKIVAM9I5ZHA8?7%<[X$UZ
M]\0:5/<WP021SE%V#L*E1;CS&CDE+E.I[44F:,TBA:*,TF: %HHR*,T %%)F
MC- "TM-I<T@%IM+FD-, )Q2UGM>S#5%M?)/ED9WU?!YQ0).XHI:2B@8M%)10
M!5U 7+:?.+1E6<H?++#(!KPR8RO<2O<LSW)<B0L<DG/->]N/E/TKP.XDSJ=Z
MOI._\Z[\%\3/)S--Q5CHO#%C!/97$DT0<-)@9[8K2E\/V4APC-$3Z<BD\-1>
M5HL6?^6A9OUK5KJ=22>AYZI1E'4J^'H_[ U57EN08+HB+![-VKOL_P Z\K\7
M2E(+6-&VL9-X/H1T-=SX3UH:UHD4S<3(-DJ]\BN+$P?\3N>C@:L5^Y-6_P#^
M0?<?]<F_E7&?"@_\4]=D=?M+5V5^<Z=<?]<F_E7&?"C_ )%Z['_3RU8Q_AL[
MI?Q$++\2[=4N42QEDNHYS%% O)?'\7TI=+^)5K/]HCU2T>PGA0OL;^+V^M4O
MAU802ZYKEX\:F6*X,:$C.T$G.*9XQTZVF^(6AQO&"L_^L&/O8-:\D.=P,.>I
MR*1/'\462Z0WFC3V]G(V$F8<X]376ZSK<>DZ!+JZKY\:(&51_$#C'\ZR_B!:
M0/X+OMT:GRE!3C[O/:LO4'9OA CL2Q^S)U^HJ%&$N5^9HY3AS)B7GQ, 6,Z9
MI<UYA \Q4<1Y[5.WQ+L6T>*ZMK>2>[F.T6JC+ CN?:M/P3I]O;>$;$)&N9HM
MTAQ]XGUKF_ .GVP\7:[)Y2Y@E*Q\?=!/:JM#7R)O4T\S7\.>/5UC4_[,O;)[
M&Z890-T:M/6_$Z:-K6FZ:UNTC7[85@?NUSGC2&.W\;^';B-0DLDNUW48)&:D
M\;$_\)OX;'_37^M)0BY+T*YYQB_4[2^N_L-A/=,NX0QE]H[X%8^F>*5U+PJ^
MO+:LBHKMY6>3MJ_XA_Y %_Z?9W_E7(>&,_\ "I[D]/W4M9P@G'7N7.<E+0>_
MQ.26SA>PTN>YN7&Z2)!GRQ[G\JV/"?C*W\3"6%H6M[N'[\1[#VJC\,[&WC\)
MQ7*1J);B1B[8Y.#C%4;6WCM?C!*D*^6KVQ9@O )Q6CC!N45T,XRFN63ZG2-X
MD1?&*^'_ +.2YA\P2_TI?$OBNR\,VZ/<9>:7(BB09+FN?D_Y+''[655/(76?
MBY-'> 21V,68T;H#C-)4U>[[ ZCLTNY/!\42EQ&-3T>XLX)2 DA4GK7?12"6
M-9%^ZZAAQZU!<6-K=JJ7-O'(JL&4,H.".AJRH X'%8R<7L=$%);CJ***@L:W
MW3]*^>[P.VL72Q@L[3N !WYKZ!N9X[>W>:5MJ*.37DEKIL$%Y<70(DFFE9@W
M]T$YKOP;M)G!C8\T4D;6F7=I'8P0"959$"E6]>]7U8,,H0WT-<;>0A+I^.#\
MP_QIB331_<F=0/0UZ/L;ZH\!XCDDXLL>,)]M]%&>?*CZ>I)KN? >A2:3I)N+
MC(N;PAW0_P (["N4\'Z)+XCU]M7OCYMM:-B/=TD<=/P%>IJ/08KS<55M[B/:
MP-'_ )>O<AO@?[/G &3Y;=/I7&_"M)(M NA)$\9^TM@,,9KNB.*:L:H,*H'T
M&*Y5*T;'H.%Y7.%^'$<B7FOEXW0-=_+N7&>O2D\4Q2/\0_#S+&[*"<L%X'6N
MZ"!2<  GDX&*4HK$,5!(Z$CI5>T?-S$^Q7+RW.?\>*S^#=25%9F\OHHR3R*Q
M+Z.0_!]$$;E_LR?)MYZCM7>,H888 @]B*38NS;M&W'3''Y4HSLDAN',VV9'A
M,,GA734*E2(!D,,$5S?@..1/%'B(O&ZAI^"RXSR>E=Y@ 8   [#M2!%4DA0"
M?04O:;^8_9[:['"^.8Y'\5^'&2-V"S_,57('UI/B39WJ2Z=KEG"9?L,F7"C)
M S7=LBM@E0<="1TH8!A@C(/8TU4Y6GV)=+FNNYYMJ?CBX\1Z3-I^DZ;<":6(
M^<[K\L8[U<\,QR)\*KF-D<-Y<H"LO/?M7=1VL$.?+A1-W7:H&:>$4+M"@#TQ
MQ5.JK6BB52E>[9S'PY1X_!EH)(V1LM\K#!^\:S%CD/QB9_+?9]DQOV\=/6N[
M4*HPJX [ 4FQ=V[:-WKCFI]H[M]R_9I)+L<-*C_\+?C?RW*?8\;MO'YU6\6V
M6HZ#XHA\4Z9 T\;+MN449R*]"*+N#;0#ZXYH*JP(8 @]013]K9HETKIGGK_$
MV2[,$.CZ1/+<NPWJZ\ =Z]!A8O&KLI4E02I[>U,2TMXG+QP1JY[J@!J8=34S
ME%[(NG&2W8M%%%0:#)(UD0JZAE/4'I5"XT+3KG/F6J@G^[Q6G28IIM;":3W.
M%\0^$[:(Q202NFX[<'I6$GA6_GN5@A=7#'#-_=7UKT+7TW6 <#)1@:71[#[-
M!YC_ .LD&3GM[5VPQ,HT['E5<%"I6N2Z5ID.DZ=#96Z[8XEQ]?4U>'%*!BC%
M<3=W=GJQ2BDD(W*D9QD5D16DAU)X3>3%40/@GU-;&*K) ZZC+<?PM&JC\,_X
MTAE6YO5M=45)92L1ASTSSFGZ?<FZ:[=9"R+)A.V.*E>V+:DMPVTQB(K@COFD
MMK=H9;H\!9'W+VQQ0!G:9-',T3/?3-,6.4YQG)I^I3JFH^7+>-;J(@5V]SFI
M;*&^MMD+V\!1&(\P'G'7-2W-@+JYE:3:4>'8,CH<]: 'V4TG]FI/=9#!,OGC
MCUJOIEQ<232I<-_K1YL0/9?2I9;:YGTQ;=V D8!9"#U ZU&=+$%S;SVK-F,X
M8,V05Q0!7U"?;J,JM=R1;8@8U4=34MY<3+H4<LCF*1MF]@.1D\U;6U(U&6=M
MI1HU501G!%&I6\ES:!(@I<.K ,< XH CTUH29##<R3 '!W]JBCGE.C3R;R74
MN WIS5FV:ZRWVB&.,#H8SG-4Y+*^5);.)8S!(W$A/*@GD8H L74;S6"R"XDC
M9(MV5[\46$3I:>:9Y)#)&&RQZ<59DBW6C0IUV;1GZ8I((FCL4B)&X1!?QQ0!
M2^US1Z)%,"6FD&U2?4G%2V]C+!,DINY7)&)%;D,:3^SV?2$LY& =1PWH0<BE
M@.IO,BS)$B+]]P<[Z *MY(7U,Q7%U);1A5\IEX5O7)K83A0,EL#J>]9VHPWE
MQO@2&*2)Q@,3RI[FKUNGEPHA;<54 GUH EHI:* "BBB@".2-)%VLN13@,4N*
M* "EHHH *2EHH 3%&**6@!,48I:* $Q1BEHH 3%%+10 F*,4M% "8HQ2T4 )
1BBEHH 2@#%+10 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
